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Novel acridine ligands were synthesized and converted to the corresponding cationic 
gold(I) complexes to provide new fluorescent tools for the study of their mechanism of 
action using confocal microscopy. These complexes were characterized by X-ray 
crystallography and their activity was evaluated against liver hepatocellular carcinoma 
HepG2 cells. A new series of cationic gold(I) pyrazole complexes were also prepared in 
excellent yields as their perchlorate salts. Results of cell viability assays show that these 
novel complexes have good cytotoxic properties against the human HepG2 cancer cell 
line. These complexes showed promising anti-cancer activities and pyrazoles have never 
been tested against this cell line in prior art. The regioselectivity of the complexation is 
also discussed in regards to the substitution pattern of the pyrazoles. The investigation of 
the reactivity of gold(I) with triphenyl phosphine and trihexyl phosphine provided an 
insight into the behaviour of cationic gold(I) in solution. The exchange of ligands could 
be observed at low temperature (-80 oC) with higher coordination numbers. The 
photophysical properties of substituted acridine ligands and their complexes have 
also been investigated. The substituted acridine functionalised by small 
electronically active groups showed a hypsochromic shift to shorter wavelengths 
when the conjugated π-system is electron deficient and bathochromic shift to 
longer wavelengths when the delocalised ring bore electron donating group and 
electron withdrawing group. Investigations into the effect of halogen substituents 
indicated a similar trend in the excitation and emission wavelengths. The position of the 
substitution and the nature of the substituent(s) has been shown to have a great impact on 
the Stokes shift and the quantum yield of the compounds. For instance, the addition of 
one or more methoxy groups lead to bathochromic shift which also reflects in the Stokes 
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CHAPTER I. INTRODUCTION 
I.1 Metals in Medicine 
Herbal medicine and traditional remedies have been used for the treatment of various 
ailments throughout  the generations.1,2 However, treatment of a disease requires deeper 
knowledge of effect of a drug on its target as well as origin of a disease. The use of 
bioactive drugs from the basic component of pharmaceutical development, through 
modern scientific discovery have allowed for deeper knowledge of drug administration 
and their efficacies. It is reported that metals have been used in a modern way in tackling 
the various medicinal problems.3,4 Although the use of metals in medicine could be dated 
back to antiquity.5  
 
Figure 1: Schematic diagram of the basic applications of metals in medicine 
For the past few decades, the synthesis of different organometallic complexes has 
recorded great advancement due to their wide applications in many areas such as materials 
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and medicinal chemistry, as well as their potential usage as reaction intermediates or as 
catalysts in many catalysed reactions.3,4 Soft metal ions and their complexes are highly 
demanded for the design of anti-cancer drugs which specifically target proteins or 
enzymes with SH or SeH moieties.6 The importance of metal complexes in the field of 
medicine is enormous as it can be seen in the use of antimony (Sb), bismuth (Bi), gold 
(Au), iron (Fe) and silver (Ag) as anti-protozoa, anti-ulcer, anti-arthritic, anti-malaria and 
anti-microbial respectively.7  The ten most active metals usually used in medicine are: 
antimony, arsenic, bismuth, gallium, gold, iron, platinum, rhodium, titanium and 
vanadium.7 Arsenic compounds such as realgar (a compound of arsenic sulfide) has been 
applied as a therapeutic agent by Chinese for more than twenty centuries.8 Recently, it 
was reported that arsenic compounds especially, white arsenic (AS2O3) induced apoptosis 
in blood and other cancer cells with minimal side effects.8 Arsenic trioxide was known to 
be an effective agent against acute Promyelocytic leukemia (APL)9,10 It was also used for 
the treatment of other ailments such as diabetes, malaria rheumatism and 
tuberculosis.11Trivalent antimonial induces apoptosis on APL cells in a manner that 
resembled that of arsenic oxide.12 Antimony has proved to be a good candidate as 
antileishmania drug.13The efficacies of antimony is evident in the management of patients 
with deadly diseases that has no cure.14 Bismuth derivative has been demonstrated to be 
effective in the treatment of gastrointestinal ailment.15 It also exhibits significant toxicity 
against microbial,16 leishmanial17 and cancer agents.18 Certain properties of gallium have 
made it a potential candidate as therapeutic agent especially in the field of bone diseases,19 
infectious diseases20 and cancer treatment.21  Iron oxide plays a significant role in medical 
processes. It acts as a source of iron for animals and human cells.22 It also useful in the 
treatment of anemia in cancer patients.23 It is very important in metabolic processes such 
as respiration and DNA synthesis.7 Furthermore, it plays a significant role in the citric 
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acid cycle and oxidative phosphorylation.24 The physico-chemical properties of platinum 
made it suitable as a therapeutic agent.25,26 Its usage as anticancer agent began with 
cisplatin.27 The efficacy of cisplatin encourages the synthesis and testing of more 
platinum compounds on cancer cells. However, out of about 30 compounds that reached 
the clinical stage, only 4 are currently on the market today. These are cisplatin,28 
oxaliplatin, carboplatin29 and nedaplatin.30  
                                                 
Figure 2: Structure of cisplatin 
 
Rhodium derivatives have recently attracted interest due to their inhibitory properties 
against various mammalian tumour cells.31,32 It was suggested that the inhibitory property 
of dirhodium(II) carboxylates may have similar structural analogy to cisplatin by binding 
to DNA.33 Rhodium(III) complex was reported to be a potential candidate for the 
treatment of inflammatory bowel disease.34 It  was also the first metal based inhibitor of 
lysine-specific demethylase 1 (LSD1) with a promising antitumour activity against 
human prostate cancer cells.35 Titanium alloys are one of the most useful materials for 
biomedical applications. They found applications in various implant devices such as 
artificial knee and hip joints, artificial hearts bone plates etc.36 Titanium derivatives have 
been reported as a potential candidate against platinum-resistant antitumour 
drugs.37Titanocene dichloride was reported  as an effective anticancer agent.38 Vanadium 
derivatives have been suggested as useful probes in many biological processes.39 It has 
been reported to behave in a similar way to insulin in many target tissues.40 Vanadyl(IV) 
sulfate showed an interesting toxicity against mammary gland neoplasia.41 The use of 
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organometallic complexes in medicine is rapidly developing and novel metallic 
complexes with special emphasis on targeting and biotransformation are now having 
great impact in modern medicine. The importance of specificity and targeting cannot be 
over emphasized, as most metallic complexes are usually associated with toxicity. 
Therefore, if they can be delivered directly to the desired receptors and tissues, then, the 
toxic side effects may be greatly reduced. Also, understanding of the process of deligation 
and ligand substitution reaction may lead to the effective use of metallic complexes in 
pharmaceutical and medicinal applications.42 Essential metals could be delivered into its 
target in the body system while toxic metals could also be removed from the body by 
chelation therapy. Chelating agents usually binds to metal in the body’s tissue forming a 
chelate complex which is then eliminated from the body by the kidney through excretory 
system.43 Many drugs on the market today are basically derived from organic compounds. 
This is due to the fact that synthetic compounds are believed to have toxic side effect or 
bio-compatibility problem. In spite of this perception, the use of organo-transition metals 
in medicine has improved tremendously over the years because they exhibit different 
oxidation states which enable them to interact with negatively charged radicals. Based on 
this property, organo-transition metals have been utilized by many researchers to treat 
various human ailments.44 Transition metals offers a great diversity in their actions: they 
are important in catalysis, synthesis of new materials, supramolecular, cosmetic, 
photochemistry and biological systems.45,46 Medicinal applications and commercial 
values of organometallic complexes are increasing tremendously over the years. The 
study of organometallic chemistry could be divided into two major classes. These are 
toxic ligands that are specific on certain metals ions either free or protein bound and when 
the main feature of the reaction mechanism is centred on metal ions. Organo- transition 
metals have an array of coordination spheres, varying oxidation states versatile ligand 
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design and appropriate redox potential which are employing in altering the kinetic and 
thermodynamic parameters of the complexes in relation to prospective receptors.47 
Literature has it that about 30% of all human enzymes contained transition metal ion in 
their core protein.48 Metal nanoparticles have been exploited in bio diagnostic, 
biophysical studies and in other field of medicine. Because of small size, metal 
nanoparticles are usually conjugated with target analyte in order to achieve molecular 
specificity. Unlike photoabsorbing and fluorescent dyes, metal nanoparticles are photo 
stable and allow longer probing times thereby increase sensitivity.49 Metallotherapy has 
grown constantly over the past six decades; however, despite the landmark achievement 
of a few metallodrugs, the field is still less fully developed as compared to the traditional 
medicinal chemistry.50The introduction of metal ions into the body is for a dual purpose. 
It may be for diagnostic or for therapeutic purpose.50 Metal ions are essential for the 
proper functioning of human body. Deficiency of some metals in the body can lead to 
diseases. Typical examples include anaemia which is caused by deficiency of iron and 
retardation growth caused by zinc deficiency.51 Metals have wide applications in material 
science, catalysis and biochemistry. Transition and main group metals in cyclic 
phosphanes and phosphazenes have proved to be useful candidates in medicine, catalysis 
and precursors for synthesis of new materials such as polymers and semiconductors.52 
Transition metals with η-cyclopentaldienyl, an η-arene as ligands have proven to be 
useful in catalysis, new materials, biological and medical sciences.53 Many diseases have 
been identified to occur as a result of imbalance of metals in the body. Typical examples 
include Alzheimer’s and Parkinson’s diseases that involved abnormal build-up of metals 




    
 
I.2. Gold Complexes 
Gold is a soft bright yellow metallic element. It is found in nature as a free metal or in 
combined state. It usually exhibit unusual physical and chemical properties compared to 
lighter members of group 11 elements because of relativistic effect.56 Atomic gold has 
the electronic configuration [Xe]4f14 5d10 6s1. The 6s orbital is contracted and stabilised 
and giving gold several properties. Gold is potentially more interesting than other metals 
due to its stable oxidation state during a reaction. Gold is a Lewis acid and usually exhibits 
two principal oxidation states (I) and (III). The (II) oxidation state usually forms 
polynuclear compounds or transforms into (I) or (III). The first oxidation state has been 
the major interest of study in which the complex has a linear structure: L-Au-X. Gold(I) 
and gold(III) complexes have different reactivity and do not always react with the same 
compound. Gold(III) possesses similar d8 electronic structure with platinum(II) 
complexes thus exhibits geometrical configuration analogy to that of platinum(II).57 It 
was believed that the square planar geometry of platinum(II) in solution influences its 
anticancer properties.58 Therefore, this similar features made gold(III) a potential 
candidate as antitumour agents with little or no side effect.59 The first oxidation state is 
preferred because the complexes are more stable and a comparative study has been 
reported between the complex gold(I) and gold(III).60 This complex can be neutral, 
cationic and anionic. The L-ligands are usually phosphines while the X-ligands can be 
alkyls, aryls or halides.61,62Arabic and Chinese physicians of old used gold for the 
treatment of various diseases. Over the past two decades, interest has increased in the 
organogold complexes for their high medicinal activities. Their structural design with 
simple and potent ligands are key aspects of medicinal inorganic chemistry with uses 
targeting varied afflictions such as asthma, malaria, rheumatoid arthritis, HIV63  and 
cancer.64,65 Furthermore, gold complexes are excellent prototypes for the rational design 
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and development of novel and effective anti-cancer agents.66 Recently, auranofin was 
reported to be effective in the treatment of rheumatoid arthritis by oral administration 
therefore, it relieves the patient of pain through injection and nitritoid reaction usually 
associated with injectable gold drugs.67,68 
                                        
Figure 3: Structure of auranofin 
Mirabelli reported that an array of phosphine gold(I) complexes showed significant in 
vivo and in vitro cytotoxicity against spectrum of human and mouse tumour models.69 
However, the increased interest for the gold complexes is due to the anti-bacterial 
properties of [Au(CN)2]
- and other compounds with various structure like linear or 
polymeric.70  We have reported the potential for gold(I) complexes to serve either as 
vectors for specific drug delivery into hyperpolarized cancer cells or as orthogonal drugs 
when bearing biologically active ligands.71 We have also provided further proof that 
gold(I) complexes inhibit thioredoxin reductase (TrxR), an enzyme that catalyses the 
reduction of thioredoxin which is responsible for cell growth,72  due to complexation with 
a selenocysteine residue.73 The inhibition of this enzyme which is over-expressed in 
cancerous cells further leads to cell apoptosis.74 Though gold complexes appear to 
specifically target hyperpolarized cancer cells without affecting the healthy cells,75 little 
is known about the mechanism of action of the cell permeation and the ligative equilibria 
involved. The lack of fundamental understanding of the complex interactions within the 
coordination sphere of gold(I) in catalysis76,77 is mirrored in its use in the biological 
environment, as the dynamic ligation/deligation processes around the gold nucleus 
remain very unclear during cell permeation and uptake by cancer cells.72,78 Providing 
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visual tools to understand the distribution of gold(I) and its ligated or free ligands will 
help understand its role as a chemotherapeutic agent, as well as a homogenous catalyst.79 
Gold complexes were used also as a catalyst in reaction of hydroamination and 
hydroalkylation of alkynes for example. But in this case the mechanism has not been 
ascertained to this date.80,81 Over the last few decades, application of gold(I) complexes 
as catalyst for transformation of different organic synthetic reactions has atract interest.82 
An array of transformations has been reported. Gold(I) complexes have shown to be 
useful as catalysts for selective organic hydro amination of unactivated alkenes, alkynes, 
allenes and 1,3-dienes.83 Cyclization of enynes using highly alkynophilic gold(I) 
complexes with biphenyl phosphine ligands.84 as well as the use of gold(I) complexes as 
highly efficient tools in catalysing acid addition to alkynes with huge amount of  
turnover.85 
I.3.Behaviour of Gold(I) Complexes in Solution 
It is evident that the capability of gold to form stable complexes is crucial in determining 
its behaviour in solution. The stability of the complexes depends on the type of atom in 
the ligand, which is directly bonded to gold (that is the ligand donor atom). For gold(I) 
and gold(III)  the stability of their complexes decreases with increasing electronegativity 
of the ligand donor atom.86 Triphenylphosphine usually forms stable complexes with 
gold(I) because of the stronger  π-bonding of phosphine to gold(I).87 It is apparent that 
gold(I) complexes undergo disproportionation in aqueous medium but are stable in 
organic solutions.88 X-ray crystallographic structures have shown that gold(I) complexes 
with nearly tetrahedral species in solution exist at -80 oC.89  Mixed ligand clusters were 
analysed in order to understand how the number of methyl and cyclohexyl groups in the 
ligands and the size of the gold clusters influences the extent and stability reaction and 
found that the ligand loss fragmentation is correlated with the relative electron donating 
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ability of the ligands.90  It has been established that Ph3PAu
+ reacts with Ph3P to generate 
higher coordinate complexes.91 The ligand exchange reaction of gold in solution and 
formation as well as transformation of different oxonium and sulfonium moieties were 
investigated by NMR spectroscopy in solution. Detection and characterisation of the 
intermediate and mechanism of process involved in multiple reactive species were 
achieved.13 Studies have shown that electronegativity of the substituents and angles 
between them were the two key factors influencing the 31P NMR chemical shifts of 
gold(I) complexes with tertiary phosphine sulphide ligands.92 X-ray structures of four 
coordinate gold(I) complexes (tetrakis (triphenylphosphine) gold(I) have been reported 
in which the steric bulk of PPh3 plays a key role thus none of the three modifications 
shows the expected geometry.93 The never-ending search for new variant of phosphorous-
based ligands is due to their ability to adjust readily in coordination behaviour with 
transition metals and because of their use in new domain of synthetic applications. 
Essentially, they provide stupendous flexibility in the interaction of a wide array of steric 
and electronic properties at phosphorous atom which in turn facilitate the development of 
necessary metal complexes that can enhance the homogeneous catalytic properties under 
mild conditions.94,95 In recent years, various complexes containing 
tricyclohexylphosphine and triphenylphosphine ligands have attracted increasing interest 
due to their wide applications as useful catalysts. 95 31P is an elegant spectroscopic tool 
for its long chemical shift range with high sensitivity of the shift to quick adjustment 
relating to slight changes in structures and reactions. The 31P spin coupling values often 
give additional information with respect to the structures that arise.96 31P NMR is an 
important analytical tool for structural elucidation and equilibrium studies of complexes 
containing phosphine ligands in solution. It gives evidence that two or more coordinate 
gold(I) compounds composed of phosphine are synthesised in solution.97 31PNMR study 
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of tertiary phosphine gold(I) complexes has revealed that stoichiometry and ligand 
exchange properties depends on the electronic and steric behaviour of the ligands. It also 
reveals the higher coordination of gold(I) particularly four coordinate species.98 Albeit 
the affinity of soft gold(I) π-Lewes acids for alkynes has been investigated by 
Widenhoefer99 very little is known about the behaviour of cationic gold with triaryl and 
trialkyl phosphines, and the ability of triphenylphosphine to deligate and form more 
complexes species that may in turn alternates the mechanism that is usually acknowledge 
in the literature. The existence of polyligated gold is rarely mentioned, yet evidence for 
precomplexation of gold amide with alkynes prior to deligation of the amide ligand has 
been reported.100 
I.4. Silver 
Silver  can be found in nature in pure elemental form 101 but is usually associated with 
lead and copper ore.102Pure metallic silver is malleable, ductile and usually harder than 
gold.101 Silver exhibits the following oxidation state. Ag(0), Ag(I), Ag(II) and Ag(III). 
Ag(I) is the most stable while Ag(II) and Ag(III) are very reactive and usually unstable.101 
Silver compounds readily ionize in water and body fluids to release ( Ag+).103silver ion is 
very reactive and readily interact with macromolecule in the blood.103 It also exhibits 
greater affinity for hard donor atoms like oxygen and nitrogen.104 It is usually regarded 
as a soft cation105 thus it forms most of its stable complexes with polarisable ligands.106 
Its usage was at par with gold and copper.107 It has been used extensively for currency, 
jewellery, food preservatives and recently as consumer products.102 It was the most 
effective antimicrobial before the advent of the antibiotics. 107 In the ancient times, silver 
coins is usually drop in fluid vessel to prevent spoilage without knowing that it was the 
prevention of bacterial that caused the effect.107 Silver(I) has been used extensively in the 
treatment of skin diseases, recent wounds and burns.108Though, antibiotics still remain 
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very important but the rise in bacteria resistance has made the use of silver the major 
therapy in the healing of wounds and burns.108 Recently attention has been shifted to the 
use of silver(I) as therapeutic agent because it has no side effect at moderate 
concentration.109 One of silver derivatives (Silver(I) sulfadiazine) has been reported to be 
so effective against catheter infections.110  
                                                            
Figure 4: Structure of silver sulfadiazine 
In an attempt to produce novel complexes of silver with higher antibacterial and 
antifungal properties, silver complexes of norfloxacin were synthesised and screened for 
their anti-fungal and antibacterial properties using gram positive and gram negative 
bacteria. They were reported to show promising result .111 Most silver derivatives act by 
absorbing fluid from the wound which then lead to ionisation and release of biologically 
active Ag cations into the wound bed.112 Then, the positively charged Ag+ ions usually 
react with the negatively charged protein, DNA and RNA in bacterial and fungal cells.112 
I.4.1.Silver-Organic Complexes 
Bis(acridine-N)(nitrato-O,O’)silver(I) was the first complex of acridine and silver to be 
reported.113 The nitrate ion coordinated to silver as an asymmetrically chelating bidentate 
ligand.113 A spectrum of mono, di and polynuclear silver(I) containing  2-pyrazole 
substituted 1,10-phenanthroline complexes have been synthesised and their 
photoluminescence properties have been extensively studied.114 Heteroleptic 
coordination of  Ag(I) with spectrum of phenanthroline ligands and various bi-phosphine 
have been reported.115 Silver coordinated to different organic ligands including but not 
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limited to phosphine, N-heterocyclic carbenes, N-heterocycles having spectrum of 
properties such as antibacterial antifungi, antiseptic and anticancer have been reported.116 
The coordination chemistry of Ag(I) and its design of coordination network, as well as 
polymer  made from nitrogen-donor ligands has been reported.117 The coordination of 
AgX salts (where X is F-, Cl-, Br-, I-, BF4-, PF6
-,NO3
-) and ligands in group 15 with 
particular interest in monodentate and bidentate tertiary phosphine derivatives was 
reviewed.118 It was observed that the reaction condition and stoichiometry of the reaction 
influence the structure formed.118 Metallic nature influences the architecture of a 
supramolecular assembly. To this end, Ag(I) ion usually act as a building block due to its 
spectrum of coordination mode.104 In attempt to investigate the binding mode of Ag(I) 
ion, 1,2,3-triazole linked crown ether with coordination to Ag(I) ions were examined.119 
Different modes of coordination were observed based on the stoichiometry of the 
formation of the complexes.119 It was reported that sulfur atoms were more favoured than 
the nitrogen atoms119 Application of nanoparticles in the field of medicine and industry 
has increased tremendously over the years120 due to incorporation of spectrum of novel 
products. Silver nanoparticles showed interesting physicochemical properties and high 
antimicrobial properties that made them to stand aloof as a better alternative to the 
antibiotic resistant strains.121 Ag(I) ions have been reported to showed greater 
antibacterial toxicity than AgNPs(I) and AgNPs(II).122 Though, the mode of action of the 
three silver drugs were similar therefore they have potential to be used as antibacterial 
drugs.122 Supramolecular polymer chemistry is an emerging field of study in which 
polymer chemistry is combined with supramolecular chemistry.117 Recently, attention has 
been shifted to coordination polymers based on Ag(I).117 This due to the fact that they are 
readily available, highly labile and generally reversible.117Ag(I) coordination sphere is 
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flexible and usually exhibit various coordination number from two to six and adopt a 
spectrum of geometries.117   
I.4.2.Silver as Anticancer Agent 
Anticancer activity of Ag(I) derivatives of mixed nitrogen and sulfur containing ligands 
has been reported. It was observed that these complexes displayed an interesting 
antitoxicity against Ehrlich’s ascites tumour cells.109 Silver bearing 2,6-disubstituted 
pyridine ligands were synthesised123 and tested on different human cancer cell lines 
including hepatocellular carcinoma (HePG2), breast adenocarcinoma (MCF7), colon 
carcinoma (HT29) and lung adenocarcinoma (A549).123 They were found to exhibit 
significant activity against all tested cancer cell lines even more than the reference 
drugs.123 Anticancer activity of silver derivatives stem from their unique mechanism of 
action, which differ from other metal complexes.116 Silver has the capability of killing 
bacteria in different ways.124 It may kill the bacterial by damaging the cell wall in a similar 
manner to the way penicillin works.125 It may also kill the bacteria by damaging the major 
enzymes126 and metabolic pathways in the cells.125 Another way it may do so is by 
impairing with the respiratory process by destroying the electron transport system of the 
cell, since Ag+ readily oxidises ATP giving rise to the formation of Ag(0).125 Furthermore, 
it may kill bacterial by binding to the DNA and RNA impairing the protein encoding and 
replication of bacterial just like the way cisplatin works.127 However, in spite of catalogue 
of investigative research on the mechanism of action of silver complexes, the exact 
mechanism and mode of action is not yet understood128 until date. Meanwhile it was 
generally believed that the nature of atom coordinated to silver with the resultant bond 
formed and neither the charge, chirality, solubility nor the polymerisation degree 
influences the efficacy of the silver derivatives.129  
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I.5.Acridine Derivatives  
Naturally occurring acridone alkaloid are plant metabolites which were first extracted 
from rain forest plant in Australia in 1948.130 Series of natural acridine/acridone 
derivatives were extracted from plants and pyridoacridine alkaloids derived from various 
marine organisms.131 Recent years have seen a resurgence of interest in the synthesis of 
novel compounds that has high cytotoxic activity, among which acridine derivatives play 
a significant role.132 Synthetic acridine and their naturally occurring alkaloids have been 
reported to exhibit an array of biological activities.133  They were among the earliest 
useful bioactive agents. Their usage was dated back to 1940s when 9-aminoacridine was 
used as an antibacterial.132 Since then, acridine derivatives have also found wide 
application as antimalarial, antiprotozoal and anticancer agents.134 Different chloro-1,3-
dihydroxyacridone derivatives has been reported to be promising candidate as antiviral 
drugs.133,135 Reasons for their usage as bioactive agents include: biological stability, 
ability to be readily synthesise and their intercalative properties with DNA in mammalian 
cells. These compounds are found to contain a planar chromophore in form of a tri- or 
tetra-cyclic ring system (Figure 1) usually combined with one or two flexible substituent 
groups,136that was believed to be sufficient size to intercalate with DNA base pair and 
exert its pharmacological effect which generated reactive species that could initiate free 
radical chain reactions.137 Intriguingly, the mode of action of acridone/acridine 
derivatives were not really understood for many centuries, but it was presumed that the 
inhibition of DNA topoisomerase II/Protein Kinase C enzymes were involved.133They 
were believed to intercalate with DNA and inhibit topoisomerase/telomerase enzymes in 
the protein of their target.131,138The cytotoxicity activity of these compounds were 
attributed to the planarity of their aromatic structure which allowed them to intercalate 
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within the DNA double stranded structure thus impairing the cellular machinery of the 
biological organism.138,139 
 
Figure 5: Structure of acridine 
I.5.1.Acridine as Drugs 
Acridine derivatives have been used to locate malignant cells in tumour tissues.140–143 
They were also used as fluorescent markers for detecting and inhibiting tumours in 
vivo.140 They have greater capability to play a dual role: target-specific drug and vector 
to carry other drugs and monitor their movement. Acridine scaffold is an interesting 
phamacophore for the  design of structural activity relationship of a novel anticancer drug 
targeting DNA.137 Acronycine (the first acridine derivative isolated from Australian plant 
in 1948) was reported to exhibited significant activity over wide range of tumour cells 
but failed clinical trials due to solubility problem and its moderate potency. 144It was 
reported that in order to observe a significant cytotoxic activity in acronycine the 1,2 
double bond is an important structural requirement.144,145 For their antitumour activity 
over wide range of tumour cells, two different compounds of 9-anilinoacridine derivatives 
were synthesized and tested against mouse tumour cell L1210 and human tumour cell 
HL60, and found out that both exhibited interesting cytotoxic activity.146 Literature had 
it that cytotoxicity of 9-anilinoacridine derivatives could be enhanced by the addition of 
a strong electron-donating group on the position 4 of the ring substituent.147 Spectrum of 
9-dialkyaminoalkylaminoacridine has been reported to show significant activity against 
different tumour cells.147 A wide range of fluoro substituted acridone derivatives were 
investigated for their cytotoxic activity against spectrum of drug sensitive and drug 
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resistant cancer cells, and they were found to be promising anticancer agents.148Recently, 
Szymański screened 32 acridine based compounds for their anticancer activity and found 
out that tetrahydroacridine and cyclopnetaquinoline derivatives with 4-fluorobenzoic 
were the most effective and that they induced apoptosis in lung cancer cells by activation 
of DNA  damage signaling.149  
I.5.2.Acridine as Fluorescent Probe 
Fluorescent compounds have found useful applications in physiological monitoring, cell 
visualisation and sensing. Acridine derivatives are found useful as biological fluorescence 
probes.132Among them, acridine containing cyanide dyes have been given more attention 
because of their relative chemical stability, high molar absorptivity and fluorescence 
quantum yield.150Fluorescent probes for transition metals have been described because of 
their applications in a range of chemical, biological and environmental processes. 
Acridine based pH sensor fluorogenic properties as well as its G-quadruplex binding 
ligands have been reported.151 However, acridine dyes are usually used for development 
probes for DNA conformational determination and structures because of their high 
quantum yield and binding affinity.151–153 Microscopic observations of subcellular study 
on binding in hepatocyte cells indicated that acridine derivatives are more specific for 
mitochondria subcellular investigations.154 It was observed that acridine orange 
accumulated easily in pure lysosomal particles in vivo and there was a good correlation 
between the quenching of its fluorescence and change in the pH across the lysosomal 
membrane. Therefore, the change in pH across lysosomal membrane could be studied by 
measuring the fluorescence of acridine orange.155Acridine based probe was reported to 
exhibit excellent selectivity and sensitivity to Cr3+ and PO4
3-.156 The probe has potential 
application in biological and environmental studies.156A robust acridine based fluorescent 
probe was developed as an indicator for protein analysis with high sensitivity, short 
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reaction time and excellent reproducibility.157Fluorescent probes can be used to 
investigate lymphocyte stimulation at cellular level.158 It could also be applied in the study 
of acidic organells and autophagy.159 Acridine orange derivatives have been reported to 
bind cardiolipin in vitro thus used as a stain to assay cardiolipin in order to study the 
mitochondria  content.160 In this research work however, acridine derivatives were chosen 
to serve as ligands because they present many advantages. First of all, they are highly 
fluorescent due to their conjugated ring system. In view of this, they can be useful to 
provide a method to understand the mechanism of gold(I) complexes either as a catalyst 
or as a drug  Moreover, they can bind as an L-ligand through the nitrogen lone pair 
forming a fluorescent neutral gold complex, or as an X-ligand which would form a 
cationic gold Complex 
I.6. Pyrazole 
Pyrazole is a five-membered ring compound consisting of three carbon atoms and two 
nitrogen atoms in adjacent positions with molecular formula C3H4N2. 
161( Figure 2) One 
of the two hydrogen is neutral while the other one is basic.162They were classified as 
alkaloids because of their basic composition and unique therapeutic effect on human.161 
The first pyrazole derivative to be isolated naturally was 1-pyrazolyl-alanine which was 
obtained from watermelon in 1959.161Recent increase in utilization of pyrazole as a core 




    
 
 
Figure 6: Structure of pyrazole 
Pyrazole was investigated because of its high medicinal value.164 They are important 
building blocks used in pharmaceutical and agrochemical industries.165,166,167 Pyrazole is 
a special class of heterocyclic compounds that can not only coordinate to enzymes 
(through van der Waals interactions) but also to metals, making them useful template for 
the design of novel drugs.164,168 Their motif is also present in many biologically active 
compounds.169 The structural activity relationship (SAR) of pyrazoles alone has been 
extensively investigated and they were found to bind to a variety of receptors, enhancing 
the activity of many anti-angiogenesis agents.170   
I.6.1.Applications of Pyrazole  
Most of successes achieved in the field of drug discovery process is being guided by 
careful choice of design of new therapeutic agents.171 Thus privileged small organic 
molecules have proved to be useful scaffolds for the design of novel drugs.172In this 
context, pyrazole has proven to be small molecule modulators of several targets.171 
Pyrazoles have also shown great pro-apoptotic potential against lung cancer cell lines173 
as well as  excellent cytotoxicity against p53 cancer mutant Y220C, but their gold 
complexes have never been tested against HepG2 hitherto to the best of our knowledge.174 
Pyrazolates and imidazolates substituted with deactivating groups were used to synthesise 
neutral azolate gold(I) phosphane complexes and were found to act as anti-cancer  
agents.175 The inhibitory properties of neutral gold(I)  triphenylphosphine complexes on 
E. coli dihydrofolate reductase was found to be toxic against different human cancer cell 
lines.176 It was reported that pyrazole derivatives displayed an interesting anti-
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inflammatory and antimicrobial177 activities better than standard drug (Diclofenac 
sodium).178Pyrazole derivatives have also shown to exhibit antitubercular, antibacterial 
and antifungal activities.179Furthermore they have been reported to have 
antidepressant,180 antiepileptic,181 antipyretic,182 anti-ulcer, anticonvulsant,180 
antidiabetic183 and anticancer184 activities. In attempt to develop novel potential antiviral 
agents, a series of pyrazole derivatives bearing acetyl or thiocarbamoyl moieties were 
synthesised and tested on various viruses in different cell cultures and found out that they 
showed an interesting cytotoxicity against vesicular stomatitis virus relative to the used 
drugs.185Furthermore, Pyrazole are usually used as the basic moiety in several compounds 
for many applications such as catalysis, agro-chemicals and core motif of other 
compounds and in medicine.186 The versatility of pyrazole and its derivatives make them 
attractive for the synthesis of a large number of analogues with different scaffold in them 
thus enhance the properties of the resultant compounds.186  A spectrum of novel nickel(II), 
iron(II), and cobalt(II) complexes based on (pyrazolyl)-(phosphinoyl) pyridine ligands 
were synthesised and activated with EtAlCl2 to form an active catalyst which afford 1-
butene as the main product.187 Recently, oligomerisation of ethylene has attracted a lot of 
attention due to the fact that it is one of the major application of homogeneous metal 
catalyst.188 Some of the products obtained by oligomerisation process are essential 
commodities for industrial and household applications.188 These include, detergents, 
synthetic lubricants, plasticisers189 and monomeric unit for low density polyethylene.188 
Pyrazole derivatives has been incorporated into several transition metals such as iron 
cobalt nickel zinc, palladium etc as nitrogen donor ligands for olefin oligomerisation and 
polymerisation catalyst.190–192Pyrazole based complexes has also been reported to be used 
in epoxidation of olefins.193In our search for dual action orthogonal drugs, we investigated 
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in this research, the role of delocalised cationic gold(I) pyrazole complexes and pyrazole 
based silver(I) complex against HepG2 human liver cancer cell lines. 
I.7.Delocalised Lipophilic Cations (DLCs)  
Delocalised lipophilic cations are positively charged molecules that can penetrate through 
lipid membranes. They are a group of compounds that selectively accumulate in 
mitochondria guided by the negative transmembrane potential.194Members of this group 
are structurally diverse and selectively target the mitochondrial.194  Studies have revealed 
the significant of lipophilicity and positive charge in molecules that accumulate in 
mitochondria. Mitochondria have been generally recognised as the powerhouse of a cell. 
They provide ATP for almost all cellular activities. Beside their role as energy provider, 
they are also recognised as integrators of a plethora of intrinsic and extrinsic pathways to 
cell death.195 These dual role of energy production and cell apoptosis makes the organelle 
a major target in cancer treatment. Most especially, the permeability of their outer 
membrane becomes a major point during apoptosis. Thus, several designs usually aimed 
at targeting this event by preventing the activity of antiapoptotic or by interfering in the 
major functions of mitochondrial may help to overcome the phenomenon of drug 
resistance.194DLCs are attracted by the negatively charged mitochondria matrix and thus 
been used as probes for imagining mitochondria.196 DLCs selectively accumulate in 
cancer cell mitochondria and thus elicit apoptosis of cancer cells. Because of their affinity 
to mitochondria, DLCs have been used for numerous applications such as visualisation 
of tumour cells, drug deliveries, photosensitizers and therapeutic agents. As a target to 
mitochondria, two conjugates of acridine orange and rhodamine were designed and 
synthesized as photosensitizer.197 Each conjugate contained a single delocalized 
lipophilic cation and their photodynamic activities were evaluated.197 It was observed that 
both conjugates showed higher phototoxicity which made them potential candidates for 
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effective photosensitisers.197DLC could also be embedded into peptides to enhance drug 
delivery into the mitochondria.198 Though this require a balance between a charge 
distribution and lipophilicity in order to ensure localization within 
mitochondria.198Highly water soluble rhodacyanine dye as DLC was reported to exhibit 
interesting toxicity activity against spectrum of model system.199 Based on its impressive 
antitumour activities in preclinical studies it has been chosen for further clinical 
studies.199 Several DLC have been reported to show significant antitumour activities due 
to their selective uptake and retention in mitochondria of cancerous cells.200 Many 
researchers have used DLCs to improve the effect and efficacy of existing antitumour 
modalities.200 For instance, it was reported that selective retention of rhodamine-123 by 
human glioma cells with its associated photoactivated cytotoxicity shows that rhodamine-
123 could be a potential candidate for photosensitising drugs for the treatment of tumour 
glioma cells.201Intramitochondrial dyes allowed selective damaged of carcinoma 
cells.202It was also shown that human ovarian carcinoma cells has elevated mitochondria 
membrane potential that made them more sensitive to DLC.203 Thus one can chose cells 
with low mitochondrial membrane potential using DLC.203 It has been reported that 
dequalinium exhibited excellent anticarcinoma activity than several established 
anticancer drugs in mice with intraperitoneally implanted mouse bladder tumour cells and 
human subcutaneous implanted colon tumour cells.204 Therefore, this could be exploited 
for anticancer treatment by DLC since it was established that DLC selectively 
accumulated in the mitochondrial leading to death of carcinoma cells.204Literature stated 
that ‘the relationship between the structure of chemical compounds and their specific 
effects on cancer cells are not well understood’.205However, in attempt to understand the 
structural determinants of selective phototoxic activity of selected DLC towards tumour 
cells, a study of the relationship between molecular structure and selectivity on tumour 
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cells using a spectrum of DLC dyes of the group of triarylmethane as mitochondrial 
photosensitizers model.205In view of this it was observed that the lipophilic/ hydrophilic 
properties of these DLC dyes influence tumour selectivity.205 Also, a model which 
identified processes and molecular properties that usually lead to selective accumulation 
of drugs in tumour cells in the mitochondrial has been reported.206Increase in 
mitochondrial membrane potential usually induce the DLC to be selectively accumulated 
on the tumour cells in the mitochondrial,207 the general mechanisms by which they 
accumulate in the mitochondrial208 have been discussed but the way and manner by which 
each DLC exhibits  it toxicity on the tumour cells in the mitochondrial varies and based 
on structural differences.209,210 It has been reported that D112, one of the promising DLCs 
selectively bonded to transformed cells impaired the DNA in mitochondrial and induce 
reactive oxygen species (ROS).150 ROS production is necessary for Bax activation and 
subsequently leads to cell apoptosis.150  Interestingly, it was observed that the positive 
charge on DLCs is vital to their unexpected similar role in cancer cells and cardiac muscle 
cells.211 Both cancer and cardiac muscle cells displayed high negative plasma membrane 
potential which induced the uptake of DLCs.211 The positive charge and the lipophilicity 
of DLC are central to their toxicity in these two different types of cells.211   
I.8. Fluorescence 
I.8.1.Fluorescence and Phosphorescence  
Fluorescence and phosphorescence are two phenomena that involve emission of photons 
during molecular relaxation from exited states.212 Fluorescence is ‘radiative decay 
between state of the same multiplicity while phosphorescence is radiative decay between 
state of different multiplicity and persists after the exciting radiation is removed’213 When 
emission of light occurs simultaneously with absorption of the excitation light as a result 
of short time delay between absorption of photon and emission usually in a period of less 
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than microsecond. The phenomenon is called fluorescence. Phosphorescence exists or 
occurs when emission persist longer after the excitation light has been extinguished. In 
fluorescence, the compound is excited by absorbing a photon from its ground electronic 
state to one of different vibrational states in the excited electronic state.214 Collisions with 
other molecules results in a loss of vibrational energy of the molecule until it reaches the 
vibratory state lower than the excited electronic state. In the ground state, the electrons 
are all spin paired when excited the electron maintains its orientation, if the energy gap 
between the first excited state is small the electron can relax, emitting a photon, this 
phenomenon is known as fluorescence.214The Jablonski diagram (figure 3) offers a 
convenient representation of the excited states structure and the relevant transitions. The 
molecule absorbed light given rise to a singlet-excited state (S1, S2, S3, etc.). The main 
characteristics used to describe the process include absorption maxima (λmax) which 
corresponds to the absorption wavelength for which there is a maximum absorption on 
the spectrum and the extinction coefficient at λmax (ε).
215 Following excitation to the first 
excited state, there is loss of energy due to rapid relaxation to the first singlet excited state 
(S1). Fluorescence occurs when this excited state relaxes to the ground state (S0) through 
emission of photons. Alternatively, the excited molecule may relax by splitting into 
radiative and non-radiative. Non-radiative emission usually occur due to interaction with 
the solvent or other molecule in the surrounding. Thereby leading to dissipation of energy 
in form of kinetic energy. Furthermore, intersystem crossing to the triplet state may occur.   
The fluorescence lifetime is the average time the molecule remains in the excited state 




    
 
 
Figure 7: Jablonski diagram 
The fluorescence Quantum yield (ϕ) gives the efficiency of the fluorescence process. It is 
the ratio of photon emitted to photon absorbed:  
Φ = emitted photons/ absorbed photons  
Every photon absorbed results in a photon emitted. The maximum fluorescence quantum 
yield is 1.0 and compounds with quantum yield of 0.10 are still considered fluorescent. 
Vibrational energy is lost when electrons relax from the excited state back to the ground 
state as a result of the energy loss; the emission spectrum of an excited fluorophore is 
usually shifted to longer wavelengths when compared to absorption or excitation 
spectrum. This is known as Stokes shift. At wavelength higher than 200 nm, two lowest 
energy transition are usually obtained due to the energy available from photons. The 
available transition are n→π*and π →π*.216 When compounds are radiated by light, 
having the same energy with possible electronic transition within the molecule, part of 
the energy would be absorbed and the electron would be promoted to the higher energy 
orbital. That is from Highest Occupied Molecular Orbital (HOMO) to the lowest 
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unoccupied molecular orbital.213 Therefore, the energy difference between the lowest 
vibrational energy level ( the singlet ground state S0 ) and the excited vibrational level 
(the singlet excited state S1  ) is the excitation energy.
216 Fluorescence usually occurred in 
aromatic systems because of the presence of mobile electrons, which arise from 
delocalisation in the ring system. These mobile electrons are easily excited because they 
are loosely bonded to the atoms.217 The observed excitation and emission spectra are 
usually mirror images of each other due to the similarities in the vibrational transition 
between the ground and excited states. Typical fluorophores include fluorescein, 
rhodamine B, quinine and acridine orange. Emission from polycyclic aromatic such as 
anthracene and perylene are usually used for environmental monitoring of oil pollution. 
Pyridine 1 and rhodamine are often used in dye laser. Acridine orange is usually used as 
DNA stain.217The use of acridine dyes as reagents for the selective luminescence 
determination of polycylic aromatic hydrocarbons has been reported.218 Phosphorescence 
is not prominent in fluid substances at room temperature due to different deactivation 
processes that compete with emission, such as quenching and non-radioactive decay 
processes.217 There are many factors that influence the excitation energy of a compound. 
These include level of aromaticity or conjugated double bond. The incremental in 
conjugated double bond implies that incremental addition of π bonds in a compound gives 
rise to decrease in energy gap between the HOMO and LUMO, allowing for excitation 
by lower energy UV light.219Interaction of solvent with the molecule may lead to an 
asymmetric emission spectrum due to the redistribution of solvent molecules around the 
chromophore in order to account for the electronically induced dipole of the excited 
state.213 The freedom of the π electron in polyaromatic compounds can be enhanced by 
substituent group and heteroatoms leading to increase in fluorescent properties.220  Other 
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factors affecting the intensity of fluorescence include concentration, pH, temperature and 
stability of compound in light.220 
I.8.2.Fluorescence Quenching 
Fluorescence quenching is a process that decreases the intensity of the fluorescence 
emission.221This may occur from the following factors, dynamic or collisional quenching, 
where noninteractive random collision of a small molecule deactivates the excited state 
of the fluorophore221and when a small molecule makes a ground state complex with the 
fluorophore thus becomes nonfluorescent.221It can also occur by other factors such as 
attenuation of the incident light by the fluorophore itself or other absorbing species.217 
I.8.3.Fluorescence Microscopy 
 Fluorescence microscopic technique is an integral part of biomedical sciences and 
material sciences due to attributes that are not readily available in traditional optical 
microscopy. This is a powerful technique for sensing changes in the environment of the 
fluorophore. Thus it could help in providing clues to the de-ligation processes.222 It is also 
one of the main techniques used to obtain the images of organometallic compounds in 
biological environment. Fluorescence is also useful in a number of safety applications as 
a scientific research tool, and in investigative medicine. Fluorescence microscopy is in a 
state of rapid evolution with novel techniques, probes and equipment emerging almost on 
a daily basis.214There are several factors that affect the quality of fluorescence image.214 
These include choice of fluorophore, concentration of fluorophore, wavelength of the 
exciting light, magnification, quenching, bleaching, background fluorescence, 
degradation of fluorophore, detector sensitivity214 etc. Confocal microscopy was used to 
study Au(III) complexes that were effectively ‘switch on’ fluorescence thiol probes and 
also act as anticancer agents.6 In that study, it was reported that only the ligand released 
on thiol mediated Au(III) to Au(I) reduction was fluorescence hence its description as a 
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thiol probe.6Incoporation of fluorescence through aurophilic (Au-Au) interaction in 
dinuclear Au(I) carbine has been reported.223 In this study, confocal microscopy revealed 
that the complexes accumulated in the lysosome though they possessed anti 
mitochondrial activities.223 In this research, attempts were made to develop novel 
fluorescent anticancer agents based on gold(I) in other to understand the deligation 
process. Therefore acridine derivatives were chosen to serve as ligands due to their 
biocompatibility and liphopholicity. The potential mechanism of action of gold(I) 
complexes are described in figure 4 
 
Figure 8: Ligation and cell permeation 
I.9.Human Cancer 
Cancer are diseases caused by cells which are unable to form stable functional structure 
which multiply sporadically and invade the organism.224 They involve dynamic changes 
in the genome.225 The hallmark of cancer consists of six biological capabilities acquired 
at different stages of human tumour development. These include sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis.226 Literature 
has established that cancer is in essence a genetic disease.227,228 Viruses caused about 15 
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percent of human cancer in the world. Viruses accounted for about 80 percent of cervix 
and hepatocellular carcinoma.229 Cancer is one of the major public health concern 
worldwide and is the second leading source of death in the United States.230 Over the  past 
two decades, the  cancer incidence rate remained stable in women but decline by about 
2% annually in men.230 However, the combined cancer death rate decline by about 26% 
for the past two decades230due to advance in the fight against cancer and wider application 
of cancer control knowledge, including  reduction in the rate of smoking, cancer screening 
and HPV vaccination.230 Cancer treatment with extensive surgery, radiation therapy and 
toxic multiagent chemotherapy were all given hope that by adopting new strategy of 
multidisciplinary treatment teams using collaboration to build new and sustaining 
treatment, the war against cancer could be won in not too distant future.231 
I.9.1. Liver Cancer 
Hepatocellular carcinoma (HCC) is the major primary liver cancer and the most dreaded 
complication of chronic liver disease.232 It is the fifth worldwide most common cancer 
and the third most common cause of cancer-related death.233In spite of wide scope of 
research on systemic chemotherapy for HCC, it has been so ineffective due to low 
response rate and no survival benefit.233 However, studies are ongoing on the molecular 
pathways involved in hepatocarcinogenesis as potential therapeutic target.233 It is widely 
established that HCC is one of the cancer cells with poor chemosensitivity to drugs.234 
Factors such as lower flow capability of blood in the solid tumour and lower permeability 
to drugs are part of the obstacles to HCC chemotherapy.234 Furthermore, both intrinsic 
drug resistance and acquired drug resistance are also known obstacles in this regard.234It 
has been reported that SUMOylation –activating enzyme UBA2235 and activation of Nrf2 
by microcystin-LR236 involved in proliferation of liver tumour cells.235 Many of the liver 
cancer are diagnosed at a later stage when just a few therapeutic options are available.237 
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However, cancer specific aptamers were generated as molecular probes for early cancer 
diagnosis and basic mechanism studies.237 It has been reported that three triterpenic acids, 
oleanolic acid, ursolic acid and maslinic are potent antiangiogenic agents to reduce and 
invasion and migration in liver cancer cell lines.238Sorafenib, an orally-available kinase 
inhibitor has been reported to exhibit excellent cytotoxicity against HCC.239The effect of 
anticin A, anticin C and methyl anticinate A (MAA) derived from Antrodia camphorata 
were studied on the proliferation of human liver cancer cell lines HepG2 and normal cell. 
It was observed that all the compounds selectively exhibit high toxicity against tumour 
cells living the normal cell.240 
I.10. Aims and Objectives 
 This research work  is therefore aimed at providing insights and understanding into the 
cytotoxic activity of Au(I) complexes so as to facilitate their development and potency 
maximization via the following objectives:  
(1) To synthesise an array of fluorescent Au(I) complexes bearing acridine derivatives.  
(2) To characterise the complexes synthesised in (1) above using NMR, IR, MS, UV-vis 
and X-ray crystallographic studies  
(3) To test/assay the cytotoxicity of these fluorescent Au (I) complexes against human 
liver cancer, cell lines.  
(4) To modify the complexes synthesised in aim (1) above using a variety of functional 
moieties.  
(5) To perform aim (3) above with the modified moieties.  
(6) To perform aim (1) above with pyrazole derivatives.  
(7) To study the behaviour of fluorescent gold(I) complexes in solution.  
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(8) To investigate the photophysical properties of acridine bearing diverse substitution 
motifs 
(9) To investigate the photophsical properties of fluorescent gold(I) complexes.  
(10) To synthesis a spectrum of Ag(I) bearing acridine derivatives 
























    
 
CHAPTER II. RESULTS AND DISCUSSION 
II.1. Literature Background 
Davis and Pizzini in 1960 reported that p-substituted nitrobenzenes condense with 
arylacetonitriles in methanolic potassium hydroxide solution to give anthranil, which 
rearranged under the right conditions to produce acridine (Scheme 1).241 Wrόbel modified 
this in 2007 and found out that under appropriate reaction conditions, efficient formation 
of the σH-adduct of substituted nitrobenzene and aryacetonitrile followed by reductive 
transformation of the nitro group in the presence of silylating agents usually led to the 
production of the corresponding acridine.242 
 
Scheme 1: Reaction scheme for Davis acridine synthesis as modified by Wrόbel243 
An array of acridines were synthesised by reacting the corresponding nitrobenzene and 
arylacetonitrile with TBDMSCl and t-BuOK as Lewis acid and base respectively in 
anhydrous THF, as aprotic solvent. The reaction conditions were adapted from Wrόbel . 
However, discrepancies on the reaction conditions were noted. For example, they stated 
in 2007242 that the yield was improved for 2-chloroacridine carbonitrile with 2.2 
equivalent of the base, t-BuOK being added in the second addition and in 2015243 
indicated that an increase of the base from 1.1 to 2.0 equivalent was detrimental to the 
yield ( from 85 % to 50 % respectively). Intriguingly, further increase to 2.5 equivalent 
partially recovered the yield to 74 %. It is acknowledged that conversion to acridines goes 
via benzisoxazoles, which are converted, to acridones and finaly acridines under 
markedly different conditions. The dilute concentration of the released cyanide ions 
makes their involvement unlikely and the 3-position (where attack would need to occur) 
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is sterically hindered. More probable is a variety of ring opening and degradation 
reactions; these reaction mixtures contain a variety of reactive species, making side 
reactions likely.  The target of their 2015 publication was benzisoxazoles not acridines, 
consequently the discussion were not focussed on acridines. Certainly some aspects of 
their results went without discussion: the time difference between the formation of 
benzisoxazoles (1-2 hours) and acridines (~48 hours), the bulkier silylating agent (SA) 
favouring acridine formation, DBU giving solely benzisoxazole formation and perhaps 
most puzzlingly the ability to control the resulting motif purely by ratio of reagents using 
TBDMSCl and t-BuOK. Interestingly, the benzisoxazole was not observed as a side 
product at any point during the project described herein. 
II.2. Synthesis of Novel Acridine Ligands 
 
Scheme 2: General synthetic pathway for acridine derivatives. 
We modified the method and synthesised an array of acridine ligands using a modification 
method outlined by Wrόbel according to the reaction in scheme 2. It required 4-
halonitrobenzene and benzyl cyanide as the starting materials and proceeded via the 
formation of a σH-adduct. The reaction was carried out under inert atmosphere and started 
at low temperature (-78 oC) until the second equivalent of the base was added. The 
reaction was monitored by thin-layer chromatography (TLC), and a fluorescent product 
can be observed and confirmed that the reaction proceeded. Indeed, the first step of the 
reaction is the formation of the σH-adduct which is blue fluorescent. Then, the reaction 
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was maintained at room temperature until it is subsequently quenched and work up carried 
out to isolate the product. 
II.2.1 Mechanism of the Reaction 
The mechanism involves a vicarious nucleophilic substitution of hydrogen (VNS) 244 
(scheme 3).  It provides a suitable method for the introduction of a specific substituent or 
moiety into heterocyclic ring systems.245,246 The first step is the use of first equivalent of 
the base to de-protonate the α-H of cyano group ready for the first addition of the benzyl 
cyanide 1 onto the nitrobenzene 2 and subsequent conversion to σH-adduct 3. Blue 
fluorescent under UV-light confirmed this. Next was the addition/elimination reaction of 
TBSCl leading to transformation of σH-adduct into nitroso carbanion242 4 which gave 
orange colour in solution. The carbanion deprotonated and transformed into oxime 5 




    
 
 
Scheme 3: Proposed mechanism of reaction 
Table 1: Substituted Acridines synthesised based on scheme 2 
Entry R1 R2 R3 R4 product  Yield 
(%) 
1 Cl H H H  7      79 
2 Br H H H 8  75 
3 Cl H OCH3 H 9  73 
4 Cl H F H 10  68 
5 Br H OCH3 H 11  82 
6 Br H F H 12  87 
7 Cl H Cl H 13  84 
8 I H H H 14  75 
9 Cl OCH3 OCH3 OCH3 15  92 
10 I OCH3 OCH3 OCH3 16  78 
11 I H OCH3 H 17  85 
12 I H F H 18  90 
13 Br OCH3 OCH3 OCH3 19  91 
14 I H OCH3 OCH3 20  77 
15 Cl H OCH3 OCH3 21  78 
16 Cl H Br H 22  82 
17 Br H OCH3 OCH3 23  80 
18 SCH3 H OCH3 H 24  84 
19 SCH3 H F H 25  82 
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Entry R1 R2 R3 R4 product  Yield 
(%) 
20 SCH3 H Cl H 26  78 
21 SCH3 OCH3 OCH3 OCH3 27  79 
22 OCH3 H F H 28  87 
23 OCH3 H Cl H 29  90 
24 OCH3 H OCH3 OCH3 30  88 
25 OCH3 H Br H 31  88 
26 SCH3 H OCH3 OCH3 32  86 
27 SCH3 H Br H 33  81 
28 H H H H 34  83 
29 H H OCH3 H 35  86 
30 H H F H 36  83 
31 H H Cl H 37  79 
 
II.2.2. Synthesised Product Characterisation 
The structure of the product was confirmed by 1H NMR, 13C NMR, IR, melting point 
analysis and mass spectrometry. The acridine derivatives in table 1 were chosen to 
investigate the impact of the substituents on their fluorescent properties and their 
cytotoxicity. Since acridines can intercalate with DNA247,248 we believe they could play 
a role in the drug mechanism. In the synthesis of these derivatives, we intended to have a 
cyano group at position 9 and a halogen group at position 2 and then modify other 
positions. The cyano group is key to design a potential drug because it is a functional 
group which can be easily modified, for example, an alkyl chain can be added to increase 
liphophilicity or the cyano group can be replaced by many other functional groups such 
as acids, amines, amides, etc. which can increase drug potency. The initial procedure 
reported by Wrόbel was not successful: it required extensive reaction times and we 
observed significant decomposition of the intermediates during the work-up phase, 
leading to problematic flash chromatography purification to separate the desired 
compound from the crude. Modification of the procedure to a two-step recrystallisation 
in methanol and ethyl acetate. This required 4-halonitrobenzene and benzyl cyanide as 
the starting materials and proceeded via the formation of a fluorescent σH-adduct 
intermediate. The reactions were performed under inert atmosphere and started at low 
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temperature (-78 oC) until further equivalents of the base were added. The progress of the 
reaction was monitored by thin-layer chromatography and a fluorescent product 
confirmed that the reaction proceeded smoothly. However, the work-up outlined by 
Wrόbel was removed and also the purification procedure was changed which improved 
the purity of the products as well as the yields from about 20% to 92%. The reaction 
periods were also reduced from 6 days to 42 hours. 
II.2.3. Process Optimisation 
Initially, we found out that the aqueous work up proposed by Wrόbel was detrimental to 
purity and yield. We therefore replaced this process by concentrating the reaction mixture 
on the rotary evaporator followed by acetone recrystallisation. Recrystallisation is an 
attractive purification method in this case because of the longer period of time (3 days) 
required to achieve satisfactory separation through column chromatography. In addition, 
it is comparatively environmentally friendly, cheap and scalable. The use of silica and 
large volumes of organic solvents pose unnecessary risks to human health and the 
environment. However, we later found out that the acetone recrystallisation used 
previously reduced reproducibility. On standing, in a minimal amount of acetone, 
multiple new spots appeared in TLC, including one faint fluorescent spot. The pH of this 
was found to be zero; it therefore seems likely that the residual water in acetone caused 
quenching of the TBDMSCl releasing HCl. Another result of acetone recrystallisation 
from a concentrated reaction mixture was the significant amount of inorganic impurities 
left in the product, giving misleading yields. Nitrobenzene, one of the starting materials, 
is partially soluble in acetone and having a basic centre it would follow that this solubility 
was increased at lower pH values. Then, a solvent that would either solubilise the reactant 
without solubilising the product or vice versa was proposed. Methanol was effective in 
precipitating the product; however, heating did not solubilise it. Nevertheless, methanol 
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trituration followed by dissolution in CH2Cl2 and filtering to remove any inorganic 
contaminants, then a final recrystallisation in either methanol or ethyl acetate was found 
to give highly pure acridine in moderate to good yields.  
II.2.4.Substituent Effects 
 The nature and position of the substituent on the nitroarene and phenylacetonitrile 
usually determined the degree of formation of the σH-adduct and consequently dictated 
the feasibility of the process for a particular derivative. The reason being that each 
substituent is expected to exert its electronic effects on the ring system of the nitroarene. 
Whilst the substituent on the phenylacetonitile are also expected to affect the rate of 
reaction to certain degree. For optimum yield of chloronitroarene, 2.9 equivalents of base 
and 5.0 equivalents of silylating agent is required. For the bromonitroarene, 2.9 
equivalents of base and 6.1 equivalents of silylating agent gave the best yields. However, 
3.5 equivalent of base and 7.5 equivalents of silylating agent is required to obtain 
optimum yield for the iodonitroarene. The halogen groups ( F, Cl, Br, I) are electron 
withdrawing through inductive effect (- I) in the order of F >Cl >Br >I while the methoxy 
groups are electron donating through mesomeric effect (+M).249 The position of the 
substituents on the ring system influences the yield. When the halogen and methoxy 
groups were positioned in such a way that their effects cancelled out, thus higher 
percentage yields were expected. This proposition was in tandem with our experimental 
observations as excellent yields were obtained when we have both on either side of the 
reaction. For example, the yield for 2, 3, 4-trimethoxy-7-cholroacridine-9-carbonitrile 15 
was 92% which was greater than 91% obtained for 19 2, 3, 4-trimethoxy-7-
bromoacridine-9-carbonitrile (Figure 9). 
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Figure 9: Structures of compounds 7-22 
This was also greater than 78% yield obtained for 16 2,3,4-trimethoxy-7-iodoacridine-9-
carbonitrile. When there was no substituent on the phenylacetonitrile, the chloro 
substituted acridine synthesised 7 gave the highest yield of 79 % compared with bromo 
substituted 8 and iodo substituted 14 that have equal percentage yield of 75 %. When 
there was a fluoro  substituent on the phenylacetonitrile, the iodo substituted acridine 18 
gave the best yield followed by bromoacridine 12 with chloroacridine 10 substituted 
having the least in order of 90 % > 87 % >68 %. Experimental observation on the 
synthesis of only one methoxy substituted on the acridine are in the order of Cl< Br< I 
(that is 9 with 73 % < 11 with 82 % < 17 with 85 %). Our experimental conditions and 
work up procedures met improvements on the previous acridine synthetic procedures as 
the yield were considerably increased and various substituted acridines not readily 
synthesised by one pot methodology could be readily synthesised. Our procedure gave 
better yield compared with almost all the similar acridine synthesised in the literature. For 
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example, while the yield in non-substituted acridine in the literature was 20 %  acridine-
9 carbonitrile242 our procedure gave 83 % (34) (Figure 10). 
 
Figure 10: Structures of compounds 23-37 
The synthesised 7-chloro-2,3-dimethoxyacridine-9-carbonitrile 21 was 78 % while it was 
66 % in the literature.242 Also, our 2-bromoacridine-9-carbonitrile 8 was 75 % against 74 
% in the literature.242 It is worth mentioning that there was no data in the literature for the 
reaction of arylacetonitriles with p-fluorobenzene forming a desired product through σH-
adducts intermediate. We assumed that this may be due to the tendency of fluorine to 
dissociate from the system or it may undergo displacement reactions with other 
substituents due to high reactivity of fluorine. In other word, it may lead to formation of 
4-nitrodiphenylacetonitrile instead of the σH-adducts intermediate.  However, it should be 
noted that not all acridine attempted to synthesised were successful. These include: 4-
nitrophenylacetonitrile, 4-aminobenzylcyanide, 2,4-dimethoxyl-1-nitrobenzene, 4-
hydroxylphenylacetonitrile, 4-isocyanatobenzylcyanide and benzyl phenyl sulfone. The 
reason for unsuccessful results for these reagents could be due to the reactivity of their 
functional group with TBDMSCl leading to production of unwanted products. In 
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addition, the no observable product obtained in 4-nitrophenylacetonitrile, 4-
isocyanatobenzylcyanide and 4-aminobencylcyanide may be due to the role of nitro group 
in the proposed mechanism. For 4-hydroxylphenylacetonitrile, oxygen in a hydroxyl 
group (OH) is electron withdrawing by induction (-I) because the oxygen atom is 
relatively electronegative and is uncharged in that bonding arrangement. Therefore, the 
OH group may ionized (loss of proton) prior to deprotonation of the α-H of the nitroarene.  
In order words, there could be a competitive formation of para σH –adducts which cannot 
be transformed into a desired product. Then, for 2,4-dimethoxy-1-nitrobenzene, this can 
be explained also by competitive formation of the σH –adducts as one of the ortho position 
of the nitro arene has been blocked. 
II.3. Alternative Routes 
II.3.1. First Alternative Route  
In an attempt to propose a simple way for the synthesis of acridine derivatives with 
varying substituents, we explored a one pot process proposed by Pordel.250,251 as shown 
in the scheme 4 below: 
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Scheme 4: Proposed reaction for Pordel acridine synthesis252 
The reaction is initiated by nucleophilic substitution of the α-hydrogen of the 
nitrobenzene with benzyl cyanide in basic methanol solution followed by intramolecular 
electrophilic aromatic substitution which afforded the products in a low yields.252 This 
method shows some advantages over the previous method, notably, it is a single reaction 
step and has shorter reaction time (24 h) compared with our modification of the Wrόbel 
reaction (42 h).  In addition, it requires simple reagents and conditions compared with 
low temperature condition. Some of the acridine derivatives were prepared using a 
modified method proposed by Pordel. However, the major setback of this method is that 
it gave low yield of product (36% for 2-chloro-9-acridinecarbonitrile) compared with the 
modified Wrόbel method (79% for the same compound). 
II.3.2. Modification of the Pordel work up 
 Initially, the synthesis of a series of acridine was carried out without a single success by 
following the step by step in their report. A simple work up was proposed in their paper: 
procedure removed methanol on a rotary evaporator followed by washing the precipitate 
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with water and with ethanol, and then air dried to afford the desired product. The work-
up proved to be unsuccessful. We then modified the work up by washing the precipitate 
in water and ethanol after concentrating on the rotary evaporator and then dissolving the 
precipitate in CH2Cl2. Filtration was performed to remove the residual inorganic 
impurities while the yellow filtrate was concentrated on a rotary evaporator to remove the 
solvent, then dissolved in small amount of ethyl acetate and filtered. The yellow residue 
were dried under reduced pressure to give the desired compounds. 
II.3.2.1 Modification of the Reaction Conditions 
Further attempts were made to improve the yield by increasing the reaction temperature 
from room temperature to 50 oC (Scheme 5) and increase the reaction time from 24 h to 
42 h. The Reactions were monitored by TLC. These conditions slightly improve the yield 
(from 36 % to 54 % for 7 and from 31 % to 47 % for 8)  
 
Scheme 5: Modification reaction conditions of the Pordel acridine synthesis 
It should be noted that some substrates do not work with either methods. These include 
4-nitrophenylacetonitrile, 4-aminobenzylcyanide, 2, 4-dimethoxyl-1-nitrobenzene, 4-
hydroxylphenylacetonitrile, 4-isocyanatobenzylcyanide and benzyl phenyl sulfone. 
II.3.3. Second Alternative Route  
Alternatively, we used a rearrangement of heterocyclic system253–257 leading to a desired 
product as proposed by Elliot et al (Scheme 6).253  
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Scheme 6: Alternative reaction for acridine synthesis by Elliot 
In an attempt to synthesise 39 (R=Cl), Chloroisatin and copper oxide were suspended in 
dimethyacetamide (DMAc). 1-bromo-4-fluorobenzene was subsequently added dropwise 
over 1 h. The reaction mixture was heated to 150 oC for 24 h. The product was filtered 
through celite R 521 and the filtrate poured into an ice-water slurry and then stirred for 
30 minutes. The resulting red/ brown precipitate was isolated by filtration and dried. It 
was then re-dissolved in acetone and filtered for a second time through celite R 521 to 
remove any insoluble materials. The filtrate was concentrated on the rotary evaporator to 
remove the solvent. Then, purified by column chromatography using CH2Cl2 as eluent. 
The result was not the desired product. However, several attempts were made to 
synthesise fluorinated acridine derivatives using the above stated methods but were not 
successful. 
II.4. Preparation of Monodentate Cationic Gold 
In order to generate active cationic gold(I) species as potential candidate for the 
complexation reaction a monodentate cationic gold(I) was prepared. It has been 
established that monodentate cationic gold PPh3Au
+ with non-coordinating or weakly 
coordinated anions react with PPh3  to produce mixtures of higher coordinated complexes 
of the type (Ph3P)2Au
+ , (Ph3P)3Au
+ or (Ph3P)4Au
+ . However, it was also stated that 
(Ph3P)3Au
+ and (Ph3P)4Au
+  (equations 3 and 4 below) could not be observed at room 
temperature by NMR because of fast exchange of ligands,258–260 which we also observed 
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at room temperature. Since it has been established that three or four coordinated species 
of triphenylphosphine gold(I) may not be observed by 31P NMR at room temperature, we 





Scheme 7: Step by step reactions for formation of higher gold(I) complexes 
The solution of cationic gold [Ph3PAu
+,ClO4
-], was prepared from Ph3PAuCl and a 
solution of AgClO4. Due to solubility problems, the reaction was performed in two 
different solvents. While the solution of gold(I) was prepared in deuterated chloroform, 
the solution of silver perchlorate was prepared in dry THF. Then, the solution of silver(I) 
was added to the solution of gold(I). The silver solution was protected from light because 
of the sensitivity of silver(I) salts. The silver solution was added to the gold solution and 
the mixture was protected from light by covering the reaction vessel with black cover and 
stirred. A white precipitate of silver chloride was formed immediately. Then the mixture 
was filtered on glass microfiber filter into an NMR tube placed in an NMR Schlenk. 31P 
NMR was done to check the presence of the intermediate. The peak shifted from 33 ppm 
(which was the peak for the starting material that is Ph3PAuCl) to between 27 and 29 ppm 
depending on the concentration. Thereafter, solutions of the ligand were prepared and 
added directly to the NMR tube using Schlenk conditions in order to prevent air oxidation 
of the analyte. In order to prove that the filtration of the AgCl precipitate does not affect 
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the reaction, we ran the 31P NMR of the mixture before and after filtration. The shift was 
the same in both cases (28.3 ppm). Therefore, the solution was filtered for all the reactions 
presented to obtain the cleanest solutions as much as possible. 
II.5. Reactivity of Gold(I) with Triphenylphosphine 
Gold(I) usually coordinates with two ligands to give a linear structure but sometimes 
undergo advance in coordination numbers. Studies of some ligands such as PEt3, 
P(C6H4Me-p)3, P(C6H11)3 and PPh3 with two, three and four coordinate fashion has been 
reported.260,261 In addition,  X-ray data of the solid state structure of some complexes such 
as the three co-ordinate [(PPh3)2AuX] (X = C1 or I) and four-co-ordinate [Au(PPh3)3-
(SnCl3)] has been established.
262 However, 31P NMR study of tertiary phosphine 
complexes of gold(I) revealed that the maximum coordination number depends on the 
type of the ligand and the steric and electronic properties of the ligand.258 For proper 
understanding of the ligation of phosphorous ligands on cationic gold(I) species, the  
reactivity of gold(I) in complexation reaction was studied. On many occasions, a  peak 
around 44 ppm was observed by 31P NMR for the reaction of complexation and has been 
proven to be a peak for the bis[triphenylphosphinegold(I)], [Au(PPh3)2]
+.263,264 Therefore, 
many experiments were carried out to understand and confirmed the possible side 
products of the complexation reaction as well as the dynamic exchange around gold to 
identify species and to determine the different structures of gold(I). 
II.5.1. Impact of the Sequential Addition on the Shifts 
The first experiment was to determine whether free PPh3 could be observed in solution. 
To this end, PPh3 was added until the peak of free PPh3 could be visible in 
31P NMR. 
The reaction was performed in an NMR tube in dry tetrahydrofuran (THF) A few drops 
of deuterated chloroform (CDCl3) were added for deuterium lock. THF was used for 
this reaction because PPh3 was readily soluble in it. THF was also used in order to 
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easily compared, the results with the VT-NMR results.  The concentration in PPh3 was 
modified accordingly to keep the concentration in gold constant in the NMR sample. 
Practically, the same volume of PPh3 at the same concentration was added before the 
tube was concentrated to return to the original concentration in gold between each NMR 
recorded. The results are summarised in table 2 and were acquired with a minimum of 1 
h between each addition 
Table 2: Sequential addition of PPh3 
Equiv. of PPh3 added 1 (ppm) 2 (ppm) Ratio 
1 44.0 32.6 85:15 
2 31.6 24.0 96:4 
3 26.4 21.4 2:98 
4 27.0 14.0 1:99 
5 27.1 7.0 <1:99 
6 27.1 6.3 <1:99 
7 27.5 2.9 1:99 
8 27.5 0.0 <1:99 
9 27.6 -0.2 1:99 
10 27.8 -0.9 1:99 
11 27.8 -1.2 1:99 
12 28.4 -1.3 2:98 
Broad peak are in red indicating fast exchange of ligands 
The first interesting point was that the peak of free PPh3 was never observed, even after 
12 equivalents were added. The 31P NMR spectrum of PPh3 was recorded in THF and the 
peak was found at –5.9 ppm. The experiment was stopped after the addition of 12 
equivalent because there were only limited changes observed after 8 equivalents. 
Addition of one equivalent of PPh3 gave two sharp 
31P NMR resonance at 44.0 and 32.6 
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ppm in the ratio 85:15 .The peak at 44 ppm was confirmed to be that of complex 
[Au(PPh3)2]
+. It is important to note that after the addition of the second equivalent, a 
white precipitate of AgCl was observed. The peak by 31P NMR was broad probably due 
to partial suspension or to a fast ligand exchange. Then, the suspension was filtered with 
glass micro fibre filter paper and the supernatant was then collected and 31P NMR of it 
was recorded but the result was found to be the same. However, the addition of further 
equivalents were continued once it was established that the precipitate did not interfere 
with the result. On addition of the third equivalent, two peaks were observed, one sharp 
minor peak at 26.4 ppm and one broad major peak at 21.4 ppm. Presumably, the broad 
peak was an indication that [Au(PPh3)2]
+  undergoes rapid exchange with PPh3. On further 
addition of the fourth equivalent, the minor peak shifted downfield to 27.0 ppm while the 
major peak shifted upfield to 14 ppm. It should be noted that after the addition of a third 
equivalent and with subsequent addition of further equivalents, two peaks were always 
observed in approximately ratio 1:99 except for the addition of 12 equivalent, with the 
one downfield shifted downward progressively as the concentration increases while the 
upfield peak also shifted progressively upfield. The minimum of shift reached was at –
1.3 ppm. 
II.5.2. Thermodynamic Aspects: Equilibrium Between the Ligands and Gld(I) 
With two equivalents added, the peak at 44 ppm shifted and with five equivalents, the 
amplitude of the shift started to decrease. This is the reason why the experiment was 
repeated only with these two and five equivalents but separately. The results were 





    
 
Table 3: Addition of 2 and 5 equivalents of PPh3 separately 
Equiv. of PPh3 added 1 (ppm) 2 (ppm) Ratio 
2 44.1 25.6 93:7 
5 25.7 23.8 5:95 
Broad peak 
The results obtained were not the same with that previously obtained. The peak at 44 ppm 
was present with two equivalents and the shifts were different without logical reason for 
the moment. The results observed in the sequential addition and in the direct addition of 
two and five equivalents differed. This observation required confirmation to ensure 
whether the repeatability of the reactions was not at stake. An apparent loss of sensitivity 
was observed as well as a broad peak at 23.82 ppm between the addition of two equivalent 
and the addition of five equivalent. The same experiment was therefore repeated but the 
addition was performed in the same NMR tube (Table 4). Thus, two equivalent wad added 
first and then three equivalent was added into the same NMR tube and the tube was 
concentrated until it reached the initial volume. 
Table 4: Sequential addition of 2 equivalents followed by 3 equivalents of PPh3 
Equiv. of PPh3 added 1 (ppm) 2 (ppm) Ratio 
2 39.9 24.2 97:3 
2 + 3 24.3 20.3 3:97 
    
Broad peak 
The results were again different, it was impossible to say if there was a problem of 
reproducibility or if the results depend on the mode of addition (direct or sequential 
addition). There is one sharp peak and one broad peak, the hypothesis was that the clean 
peak corresponds to the complex and the other one correspond to an exchange of the free 
ligand. In addition, the sharp peak stays always at the same shift and the other change 
with the number of equivalent of PPh3.  
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II.5.3. Kinetic Aspects: Dynamic Ligand Exchange in the Complexes 
For better results and to reduce the number of scans, the concentration of gold(I) reagent 
was increased from 0.012 mmol to 0.020 mmol. This change established that the NMR 
shift is dependent on the concentration of the sample and on the solvent used. This is the 
reason why it was necessary to ensure that the concentration of gold was the same in each 
reaction but with different equivalent numbers. First time with the new conditions, the 
precipitate before filtration was dark purple and not white as previously observed. It was 
first thought that the colour was due to the increase of the concentration but later found 
out that it was due to the sensitivity of silver salt to light. The same reaction was repeated 
with different equivalents of PPh3 in a mixture of CDCl3 and dry THF and every time a 
VT-NMR was performed at different temperatures. The main goal was to inhibit the 
possible ligand exchange that it is not possible to see at 30 °C (30 °C is the temperature 
of NMR acquisition in normal conditions). At low temperatures, the exchange is much 
slower and we postulated that the various species could be observed at low temperature 
without freezing the solvent in which the reaction is performed. The effect of temperature 
was not investigated by Maier et al.265 We were also interested to see whether it was 
possible for the gold(I) to coordinate to multiple ligands. The experiment was performed 
with 1-5 equivalents of PPh3 added onto Ph3PAu
+, ClO4
-, and the results of the study were 
summarised in Table 5 below. Each VT-NMR experiment was performed during a single 







    
 
II.5.4. VT-NMR Study 
 











































































































































Sharp peak  Broad peak  doublet 
On addition of one equivalent, which indicated that there are two ligands in solution (that 
is, one from singly complexed cationic gold and the added PPh3), there is no change in 
the spectrum. There was only one sharp peak at around 44 ppm regardless of the 
temperature. This result seems reasonable and indicated that there is no exchange between 
singly complexed cationic gold and a gold with two ligands. This result validated the 
experimental method. On the addition of two equivalent of PPh3 , the peak around 44.0 
ppm disappeared completely while a broad singlet peak appeared at 36.4 ppm with a sharp 
small singlet peak high field of it at 28.1 ppm (suspected to be a peak for Ph3PO) in the 
ratio 99:1. Reduction of temperature to 0 oC caused the shifting of the broad peak 
downfield to 39.6 ppm and the sharp singlet peak to 28.7 ppm. (See figure 11) showing 
the broad peak obtained for different equivalent. Presumably, the broad peak was an 
indication of multiple gold(I) species in dynamic equilibration. Then, a further decrease 
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of temperature to -80 oC brought about the growth of new peaks upfield of the NMR 
spectrum. Of particular interest were the two sets of doublet peaks at 3.5 ppm and 1.6 
ppm.                                                                                                                   
 
Figure 11: Showing broad peaks with different equivalent, which is an indication of fast ligand 
exchange between Ph3PAu+ and PPh3 in solution 
Addition of three equivalent resulted in the diminution of the intensity of the broad 
peak, which appeared up field at 29.7 ppm with concomitant increase in the intensity of 
the singlet resonance at 28.2 ppm at room temperature. When the temperature was 
reduced to 0 oC, the two peaks shifted downfield with the broad peak moved to 31.0 
52 
 
    
 
ppm while the sharp peak appeared at 28.8 ppm at -50 oC, the broad peak had shifted 
downfield to 34.1 ppm and the sharp peak appeared at 30.2 ppm. This also resulted in 
the growth of two new peaks at high field, one at 3.5 ppm and the other one at 1.6 ppm. 
On further decrease of temperature to -80 oC, the broad peak remained unchanged in its 
position but the sharp singlet peak shifted a bit downfield to 31.1 ppm. Then, four new 
sets of doublet peaks appeared upfield of the spectrum. They were at 5.5, 4.0, 3.5, and 
1.7 ppm respectively (See figures 12 and 13 for the new appearance of doublet peaks up 
field of the spectrum).  
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Figure 12: Appearance of new peaks up field bellow 10.0 ppm at -80 oC 
54 
 
    
 
 
Figure 13: Expansion of doublet peaks emerged below 10.0 ppm in solution at very low 
temperature of -80 oC. 
The doublets peaks were attributed to a 31P-31P coupling between the phosphorus of the 
coordinated PPh3. On addition of four equivalent of PPh3, the 
31P NMR study of the 
solution at room temperature (that is 30 oC) showed that there was a small sharp peak at 
28.1 ppm and two broad peaks at 18.2 ppm and 17.5 ppm. When the temperature was 
reduced to -80 oC, the sharp peak had shifted downfield to 31.1 ppm while the broad peak 
shifted up field to 17.6 ppm with appearance of four new doublet peaks up field of the 
spectrum. The new peaks were at 5.5 ppm, 4.0 ppm, 3.5 ppm and 1.7 ppm. It was proposed 
that each doublet corresponds to one phosphorous and then, four doublets were equivalent 
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to the four maximum coordination number of gold. However, when the 31P NMR of five 
equivalents was studied at room temperature, it revealed that there was a small sharp peak 
at 28.0 ppm and one broad peak at 20.1 ppm. When the temperature was reduced to -80 
oC the sharp peak had shifted downfield to 30.7 ppm while the broad peak also shifted up 
field to 18.7 ppm. Interestingly, two new doublet peaks also emerged upfield of the 
spectrum at 5.4 ppm and 3.9 ppm. It should be noted that with three or more ligands in 
solution, there is in general one fine peak and one broad peak regardless of the 
temperature (even after repeating the experiment). However, addition of three equivalent 
at 30 oC was one of the exception. The peak at 28.2 ppm was broad peak containing a 
sharp peak. The second exception was the addition of four equivalent, at 30 °C; both 
peaks at 18.2 and 17.5 ppm were broad and much closed to each other. It should be noted 
that as the concentration of PPh3 increases in the solution, the chemical shift tend to shift 
from downfield to up field of the spectrum irrespective of the temperature. In addition, 
31P NMR exhibit increasingly larger differences in chemical shifts when the temperature 
decreases from 30 oC to -80 oC. However, when the temperature was increased back to 
the initial temperature, (that is room temperature of 30 oC) the spectrum was similar to 
the initial one at 30 °C. This result proved that there was no modification or degradation 
during the VT-NMR, and that the thermodynamic equilibrium was reached when the 
spectrum was initially recorded. The temperature dependence can be elucidated by 
hindered rotation around the Au-PPh3 bond, which may be too fast to observe at room 
temperature. Following the same reasoning with the previous sequential addition of PPh3. 
The peak of free PPh3 was never appeared. Also, it is possible for the gold(I) to coordinate 
to multiple ligands and the shift of the complex decrease with the number of ligand. The 
shift of the complex could be the broad peak. Thus, possible structures of gold were 
described in Figure 14. 
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Figure 14: Putative equilibria of gold(I) complex with PPh3 
It is evident that phosphines were non-equivalent in cationic gold complexes under 
investigation due to the 31P-31P 2J couplings observed at low temperature. The coupling 
cannot be tetravalent gold with four P as would be triplet instead. In addition, it cannot 
be silver or 13C-31P because of the natural abundance of isotopes. It cannot be 2D-31P 
coupling because of splitting. Gold is a quadrupolar nucleus therefore, it would not couple 
with P. It has been reported that zero quadrupole splitting of [Au(PPh3)4]ClO4  
substantiates its tetrahedral four coordinate for the cation.266 Distorted gold(I) or C-H 
insertion was also suggested. 
 
 
Figure 15:  Showing hypothetical structure of (a) distorted tetrahedral Au(I) and (b) C-H 
insertion 
Elder et al (1981)89 reported that there was no problem for methyldiphenylphosphine to 
attain tetrahedral coordination in the solid state but this was not possible for a larger 
triphenylphosphine due to steric factors which force P-Au bond to be elongated. If it were 
tetrahedral, ᶲ1 would be equal to ᶲ2. Then, only one signal should be observed but more 
than one signal was observed, which implies that it is not tetrahedral at low temperature. 
It was proposed that it is most likely to be hydrogen insertion. 
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II.5.5. Importance of Perchlorate 
The perchlorate ion is negatively charged. It consists of one chlorine atom and four 
oxygen atoms. It is usually weakly coordinated and can be replaced by a good and useful 
functionality. It can play the role of anionic terminal ligands or act as an anionic moiety 
for the stabilisation of coordination geometry and resulting structure.  It is usually present 
in applications where energetic oxidant is required. Some compounds containing 
perchlorate include: oxidants in airbags, flares, fireworks etc. Ammonium perchlorate is 
among the most important oxidizers in industries.267,268 
II.5.6. Validation of Findings  
In an attempt to validate our findings, the complexation reaction was completed with 
triphenylphosphine oxide (OPPh3) to see whether one of the species observed in our test 
is due to the oxidation of PPh3 in air or by residual gold(III). The results of the 
31P NMR 
were summarised in table 6. 
Table 6: 31P NMR of addition of OPPh3 
Equivalent of 
OPPh3 added 
1 (ppm) 2 (ppm) 3 (ppm) Ratio 
1 41.6 27.2  27.0 53.5 : 5.9 : 
40.6 
2 37.3  27.3  71.9 : 28.1 
Sharp peak  Broad peak 
A broad and a sharp peak were again observed. These values were not observed in our 
experiments with PPh3, which suggests that OPPh3 did not previously complex with gold 
via the oxygen and that the reaction with PPh3 was clean. The hypothetical structures to 
explain the values from Table 6 were shown in figure 16. 
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Figure 16: Possible structures for the complexation of OPPh3 with gold(I) 
First, the peak of free OPPh3 appeared at 28.9 ppm in CDCl3. In the Table 6, in both cases, 
there was a sharp peak at 27.2 ppm. This peak could be attributed to the OPPh3. Then, the 
sharp peak at 41.6 ppm which corresponds to the peak of [Au(PPh3)2]
+. Thus, this peak 
could be the phosphorus from complexed PPh3. In addition, this value is different because 
the second ligand is an OPPh3 and not a PPh3. The reason, which support this hypothesis 
was that the peak was sharp and PPh3 is a stable ligand because there is no peak of free 
PPh3. The broad peak at 37.3 ppm represents an average of the three phosphorus with a 
fast ligand exchange. Furthermore, the ratios could confirm these hypotheses. With one 
OPPh3 in solution is approximatively 1:1 for one phosphorus from complexed PPh3 and 
another one from OPPh3 for one gold(I). The ratio with two OPPh3 in solution is 
approximatively 3:1 for two phosphorus from OPPh3 and one from complexed PPh3 for 
one gold(I). PPh3 was chosen as L-ligand for VT- NMR study instead of OPPh3 because 
OPPh3 is less stable as was revealed by NMR spectroscopy with a broad signal. 
31P NMR 
spectroscopy of the PPh3 was completed and seems to be contaminated by OPPh3. 
Furthermore, the ratio between PPh3 and OPPh3 was 99:1 and very close to the ratio 
obtained during all the experiments. Furthermore, complexation with 
tricyclohexylphosphine P(Cy)3 was also carried out to establish these findings. The results 





    
 



































































Major peak bellow 20ppm             minor peak bellow 20ppm                                             
It should be noted that two peaks were observed in all cases irrespective of the 
concentration and the temperature. These peaks were for the [ Au {P(Cy)3 } ]
+ and free 
phosphine in tandem with the literature.258 31PNMR study of additional phosphine in 
solution revealed that the maximum coordination of P(Cy)3 was 2.
266  
II.5.6.1. More Validation Studies  
Addition of 5 equivalents of water had no immediate impact on the shift of PPh3Au
+ and 
(PPh3)2Au
+, but a black residue were deposited on the wall of the NMR tube after 24 
hours. Two peaks were observed at 44.9 and 27.7 ppm with a ratio 17: 83. A mixture of 
THF (mp = -108.4 °C) and CDCl3 (mp = -64 °C) in ratio 1:1 was initially used to lower 
the freezing point of chloroform. CH2Cl2 has a melting point (mp) at -96.7 ˚C and was 
therefore also attempted for VT-NMR. The reaction did not proceed under the usual 
experimental conditions (where both solutions of gold and silver were prepared 
separately). The conditions were therefore modified and the reagents were added directly 
to a flask as solids and CH2Cl2 was subsequently added. The 
31P NMR with 1 equivalent 
of PPh3 added were similar to the one previously observed in a mixture of THF and CDCl3 
with a peak at 44 ppm. The reaction was tried with another salt, sodium tetrafluoroborate 
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(NaBF4) to avoid any potential interference of unreacted silver(I) salts. Reaction in DCM 
showed a peak between 41 and 37 ppm. 
II.6. Synthesis of Acridine Based Gold(I) Complexes 
II.6.1. Protocol Optimisation 
It should be recalled that one of the objectives of this research work is to synthesise an 
array of gold(I) complexes with fluorescent X-ligands, while keeping the 
triphenylphosphine as an L-ligand. The synthetic procedure used was a modification of 
the method outline by Munakata et al.269It involved the addition of gold precursor 
(Ph3PAuCl), and another reagent. The reagent used here was silver perchlorate, which 
play a dual role. The first role was ligand methathesis. That is abstraction of the chloride 
X-ligand with concomitant formation of active gold species. The second role was to 
stabilise the cationic product formed by acting as a counter anion. The reaction was 
carried out under inert atmosphere. The reaction is as stated in scheme 8 below. 
 
Scheme 8: Synthesis of acridine(triphenylphosphine)gold (I) perchlorate 
AgClO4 and Ph3PAuCl were dissolved in methanol with constant stirring for thirty 
minutes in the dark (using black felt) because of the sensitivity of silver salt to light. A 
white precipitate of silver chloride appeared.  Then, acridine ligands were added in DCM 
with vigorous stirring for thirty minutes. The mixture was filtered under nitrogen, with a 
glass microfiber filter into an NMR tube for analysis. The solvent was concentrated under 
vacuum and replaced by deuterated chloroform. 31P NMR, and a single peak between 27 
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and 29 ppm systematically assessed the successful synthesis of the intermediary cationic 
triphenylphosphinegold(I) perchlorate, depending on the concentration. All complexes 
were characterised by 1H, 13C and 31P NMR and their positive-ion ESI-MS displayed the 
[M]+ peaks in agreement with the calculated isotopic pattern. The synthesis of these 
complexes is commonly hampered by long reaction times (two  days and more)269 and so 
our procedure was optimised to give rapid, facile and reproducible results within one 
hour. 
Table 8: Synthesis of acridine gold(I) complexes based on the scheme 8 
Entry R1 R2 R3 R4 product Yield 
(%) 
1 Cl H H H  41    70 
2 Br H H H 42 72 
3 Cl H OCH3 H 43 68 
4 Br H OCH3 H 44 66 
5 Br H F H 45 70 
6 Cl H Cl H 46 72 
7 I H H H 47 69 
8 Cl OCH3 OCH3 OCH3 48 72 
9 I OCH3 OCH3 OCH3 49 75 
10 I H OCH3 H 50 71 
11 Br OCH3 OCH3 OCH3 51 74 
12 I H  OCH3 OCH3 52 78 
13 Cl H OCH3 OCH3 53 78 
14 Br H OCH3 OCH3 54 80 
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Entry R1 R2 R3 R4 product Yield 
(%) 
15 SCH3 H OCH3 H 55 78 
16 SCH3 H F H 56 75 
17 SCH3 OCH3 OCH3 OCH3 57 71 
18 OCH3 H OCH3 OCH3 58 83 
19 SCH3 H OCH3 OCH3 59 72 
20 H H OCH3 H 60 71 
21 H H F H 61 74 
 
II.6.2. Analysis of the Yield of the Complexes 
Complex 58 gave the highest yield with 83 % followed by complex 54 with 80 %. While 
complex 44 produced the lowest yield with 66 %. It should be noted that the yield for 
chloro substituted acridine ligand 41 gave a slightly lower yield (70 %) compares with 
the bromo substituted acridine ligands 42 (72 %) but greater than iodo substituted acridine 
ligands 47 (69 %). Chloro substituted ligand without the electron donating group 41 has  
a higher yield than chloro substituted ligands with a single electron donating group 43 but 
less than chloro substituted with trimethoxy 48 (72 %) and dimethoxy 53 (78 %) in that 
order. Bromo acridine ligand without an electron-donating group 42 gave a higher yield 
(72 %) than than the bromo acridine with a monosubstituted methoxy 44 (66 %) but less 
than bromo acridine with trimethoxy 51 (74 %) and dimethoxy 54 (80 %) in that order. 
While, iodo acridine without an electron-donating group 47 (69 %) gave a lower yield 
than iodo acridine ligand with monomethoxy 50, (71 %), trimethoxy 49 (75 %) and 
dimethoxy 52 (78 %) in that order. It should be noted that in the three halogen substitution 
bearing mono, di and tri methoxy, the di methoxy has the highest yield. Interestingly, the 
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highest yield (83 %) was obtained when we have electron-donating group (methoxy) on 
both side of the acridine ligand 58. In a nut shell, good to excellent yield were obtained 
in all the reactions. 
II.6.2.1. 31P NMR of the Novel Acridine Gold(I) Complexes  
 





 (ppm) Ratio 




2 42 29.96  




4 44 32.39  
5 45 31.29  
6 46 31.92  
7 47 31.76  
8 48 31.29  
9 49 31.53  
10 50 33.10  
11 51 31.76  
12 52 31.50  








15 55 30.00  
16 56 32.86  
17 57 30.58  
18 58 32.08  
19 59 32.39  




21 61 29.72  
Sharp major peak   sharp minor peak 
The 31P NMR spectra of the complexes 41 to 61 were measured at room temperature in 
deuterated chloroform. They all showed only one sharp resonance except for 43, 53, 54 
and 60 as shown in the table 9. The major sharp peak in all the novel complexed 
synthesised ranges from δ 29.72 to 33.00 (Table 9). These chemical shifts were in the 
region usually observed for the triphenylphosphine ligands coordinated to gold(I).270–272 
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This is also in the same region with the PPh3 coordinated to silver(I) complexes.
273 The 
minor peak showed by complex 43, 53 and 60 were proposed to be [Au(PPh3)2]
+. It should 
be noted that the minor peaks were less than 2.5 % in all cases of where they appeared. 
In addition, the absence of broad peak in the entire spectrum suggested that the ligand 
exchange did not show at the room temperature. Thus, a single major sharp peak suggests 
that the dissociation equilibrium of the PPh3 ligands takes place very rapidly in the NMR 
time scale.  
II.7. Synthesis of Novel Pyrazole based Gold(I) Complexes274 
II.7.1 Rational for the Synthesis 
 In our search for dual action orthogonal drug and based on our previous observations of 
the reactivity of gold amide complexes on cancer cells,79 we decided to investigate a 
different class of amide ligands that is known to be active against cancer cells, yet with a 
different pathway to that of gold(I) alone, to further the applicability of anticancer drug 
candidates based on a gold-nitrogen bond.  We investigated the design flexibility 
provided by anti-cancer  agents based on gold(I) and found that gold with an amide 
linkage exhibit substantial activity against mammalian breast cancer cells.79 This 
discovery on the nature of the linkage to gold to retain substantial anti-cancer activity 
regardless of the structure of the ligands is crucial to outsmart cancer resistance and 
improve potency. Ligand design has since been focused on features that are 
complementing the gold apoptotic pathways against cancerous cells. The choice of the 
substitution pattern was based on previous observations whereby substitution at the 4-
position (scheme 1) seemed to stabilise binding to p53-Y220C through London 
interactions in a lipophilic pocket.275 A closer look at the X-ray diffraction of the protein 
shows further possible interactions, notably Debye and Keesom dipolar interactions with 
the carbonyl at P153 and P152. We decided to include a range of substitutive functional 
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groups (pyridine, bromo-phenyl, nitrile and bromine) to verify any impacts of such 
interactions on the activity of our complexes. 
II.7.2. Synthesis of the Complexes 
The complexation of pyrazole ligands (entry 1-5) to form an array of pyrazole gold(I) 
complexes 62-66 (Scheme 9, Table 10) were herein reported. 
 
Scheme 9: Regioselective synthesis of pyrazole triphenylphosphinegold(I) perchlorates 62-66. 
The synthesis of these complexes were carried out following a modification of the 
procedure used by Munakata et al269 as described earlier. The successful synthesis of the 
intermediary cationic triphenylphosphinegold perchlorate was systematically assessed 
by 31P NMR, and a single peak between 27 and 29 ppm, depending on the 
concentration, was observed. All complexes were characterised by 1H, 13C and 31P 
NMR and their positive-ion ESI-MS displayed the [M]+ peaks in agreement with the 
calculated isotopic pattern. Minor partial disproportionation to homoleptic complexes 
and to [Au(PPh3)2]
+ was observed for complex 62 (less than 0.1%) and for complex 65 







    
 
Table 10: Synthesis of gold(I) pyrazole complexes. 
Entry R1 R2 R3 Complex Yield 
1 H H Py 62 83% 
2 H H Br-Ph 63a 94% 
3 H Methyl Br-Ph 64a 88% 
4 C2H4OH H CN 65b 95% 
5 Methyl H Br 66b 87% 
 
II.7.2.1 31P NMR of the Novel Pyrazole Gold(I) Complexes  
The 31P NMR spectra of the novel pyrazole gold(I) complexes 62-66 were measured at 
room temperature in deuterated chloroform. While complexes 63, 64 and 66 gave only 
one sharp peak at δ 31.00, 31.50 and 30.00 respectively (see table 11). Complex 62 gave 
an intense sharp peak at δ 30.00 and a small sharp peak at δ 45.04 in the ratio 99.9: 0.1. 
Then complex 65 gave three sharp resonances at δ 29.70, 44.80 and 75.05 in the ratio 
91.9:4.4:3.7. It should be noted that the small sharp peaks observed at δ 45.04 for 
complex 62 and the small sharp peak observed for 65 at δ 44.80  were attributed to the 
31P chemical shift of the coordinated [Au(PPh3)2]
+








    
 
 





 (ppm) Ratio 





2 63 31.00  
3 64 31.50 
 
 







5 66 30.00  
Major sharp peak       Minor sharp peak 
II.8. Synthesis of Silver(I) Complexes 
II.8.1 Synthesis of Acridine Silver(I) complexes 
 
Scheme 10: Reaction conditions for the synthesis of acridine silver(I) perchlorates 67-71. 
AgClO4 was dissolved in methanol and solution of acridine in CH2Cl2 was added with 
constant stirring for thirty minutes under black protection because of the sensitivity of 
silver salt to light. The mixture was filtered under nitrogen, with a glass microfiber filter 
into an NMR tube. CH2Cl2 was removed under reduced pressure. Then deuterated 
chloroform was added for the NMR analysis. The yield obtained are shown in the table 
12 below.  All silver complexes were characterised by 1H, 13C and IR and their positive-
ion ESI-MS displayed the [M]+ peaks in agreement with the calculated isotopic pattern. 
However, only one acridine ligand was expected to coordinate with silver(I) through the 
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nitrogen atom considering the fact that an equimolar quantity of silver perchlorate and 
acridine solution were used in the reaction but silver(I) formed bis-cordinate complex 
with acridine as revealed by the x-ray of complexes 70 and 71. 
Table 12: Acridine silver(I) perchlorate synthesised from scheme 10 
Entry R1 R2 R3 R4 product Yield 
(%) 
1 Cl H H H  67    78 
2 Br H H H 68 75 
3 Cl H OCH3 H 69 72 
4 Cl OCH3 OCH3 OCH3 70 86 
5 Br OCH3 OCH3 OCH3 71 83 
 
II.8.2. Synthesis of pyrazole based silver(I) complexes 
 
Scheme 11: Reaction conditions for the synthesis of pyrazole silver(I) perchlorates 72a-75b. 
AgClO4 was dissolved in methanol and solution of pyrazole was prepared in CH2Cl2 and 
then added to the solution of silver previously prepared. The mixture was stirred for thirty 
minutes under black protection because of the sensitivity of silver salt to light. Then, the 
mixture was filtered under nitrogen, with a glass microfiber filter into an NMR tube. The 
solvent were vacuum off under reduced pressure. Then deuterated chlroform was added 
for the NMR analysis. Table 13 below shows the product obtained. All the complexes 
were characterised by 1H, 13C and IR and their positive-ion ESI-MS displayed the [M]+ 
peaks in agreement with the calculated isotopic pattern. 
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Table 13: Pyrazole silver(I) perchlorate synthesise from scheme  11 
Entry R1 R2 R3 Complex Yield (%) 
1 H H Py 72a 88 
2 H H Br-Ph 73b 93 
3 H Methyl Br-Ph 74b 91 
4 Methyl H Br 75b 90 
 
II.9. X-Ray Cystallography 
II.9.1. X-Ray of Acridine gold(I) Complexes 
Single crystals of the complexes: 41,42,45,46,47,48,49,50,51,53,55,56,57 and 58 were 
grown by slow diffusion of CDCl3 or CH2Cl2 1:1 n-Hexane. The main results of the 
crystal structure determinations and list of some selected bond lengths and angles are 
reported in Tables 14 -21. Figures 18 and 19 shows the structures in ORTEP format with 
the selected numbering scheme. Selected crystalline specimens of the complexes: 41, 42, 
45, 46, 47, 48, 49, 50, 51, 53, 55, 56, 57 and 58 were mounted on Mitegen loops and 
centered on the goniometer head of a Rigaku Oxford Diffraction Gemini E diffractometer 
equipped with an EOS CCD area detector, data collection was performed at 173 K. 
Complexes 44 and 49 were collected with monochromated MoKα radiation, by means of 
ω-scans, all other complexes were collected with monochromated CuKα radiation. The 
diffraction intensities were corrected with respect to Lorentz and polarization effects. 
Empirical multi-scan absorption corrections, using equivalent reflections, were also 
performed with the scaling algorithm SCALE3 ABSPACK. Raw data collection, data 
reduction and refinalization were carried out with the CrysAlisPro software. All 
complexes were solved by means of the intrinsic phasing method in SHELXT276 and 
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refined by full-matrix least squares methods based on Fo
2 with SHELXL277 in the 
framework of the OLEX2278 software. In the last cycles of refinement all non-hydrogen 
atoms were refined anisotropically; hydrogen atoms were placed and refined as riding 
atoms with their isotropic displacement parameters set to 1.2 times the Ueq of the parent 
atom. In all cases the gold centre is coordinated to P and N with expected Au-P (2.2- 2.4 
Å) and Au-N (2.0-2.2 Å) distances.279,280,281  See figure 17 below.  
 
Figure 17: Comparative graph between distances around the gold(I) centre. 
The solvent perchlorate molecule from the reaction steps and chloroform molecule used 
in growing the crystals were included in the crystal lattice of the complexes: 41, 42, 45, 
46 and 48 but did not show any interaction with the complexes. While Perchlorate and 
dichloromethane used in growing the crystals were included in the crystal lattice of the 
complexes 56 and 57.Whereas, only perchlorate molecule were included in the crystal 
lattice of the complexes 47, 48, 50, 51, 53, 55 and 58  Meanwhile, complex 49 is the only 







































    
 
single point of attachment to gold (I) due to the presence of only one major peak in each 
case. 
Table 14: Crystal Data for complexes 41, 42, 45 and 46 












Formula weight 916.72 961.18 979.17 951.16 
Temperature/K 173.0(1) 173.0(1) 173.0(1) 173.0(1) 
Crystal system Triclinic Triclinic Triclinic Triclinic 
Space group P-1 P-1 P-1 P-1 
a/Å 9.6910(4) 9.8586(4) 9.8356(12) 9.6949(9) 
b/Å 12.7037(5) 12.6661(5) 12.9246(11) 13.25819) 
c/Å 14.3404(5) 14.3922(5) 14.0878(13) 14.1094(10) 
α/° 79.393(3) 79.316(3) 80.059(8) 81.745(6) 
β/° 72.537(3) 72.083(4) 72.326(9) 71.422(8) 
γ/° 79.981(3) 79.646(4) 81.182(8) 82.452(7) 
Volume/Å3 1642.00(11) 1665.82(12) 1671.0(3) 1694.1(2) 
Z 2 2 2 2 
ρcalc/Mg/m-3 1.854 1.916 1.946 1.865 
μ/mm-1 4.977 13.457 13.475 4.904 
F(000) 892.0 928.0 944.0 924.0 





15382 18375 8378 21396 
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Compound 41 42 45 46 
Data/restraints/
parameters 
6661/0/415 6321/0/415 5801/497/424 7349/449/424 
Goodness-of-fita 
on F2 
1.064 1.037 1.110 1.032 
Final R indexes 
[I>2σ(I)] 
R1b = 0.0362,    
wR2c = 0.0755 
R1b = 0.0336, 
wR2c = 0.0854 
R1b = 0.0806, 
wR2c = 0.2224 




1.21/-1.01 1.58/-1.13 2.57/-1.69 3.00/-2.74 
 
a Goodness-of-fit = [Σ(w(Fo
2 – Fc
2)2]/(Nobsevns – Nparams)]
1/2, based on all data. 
b R1 = Σ(|Fo| - |Fc|)/Σ(|Fo|, 
















    
 
 
Table 15: Selected bond lengths (Å) and angles (°) for complexes 41, 42, 45 and 46 
 41 42 45 46 
Au – P 2.2388(12) 2.2430(10) 2.242(4) 2.245(2) 
Au – N1 2.103(4) 2.107(4) 2.114(14) 2.110(6) 
N1 – C1 1.356(6) 1.366(6) 1.38(2) 1.374(10) 
N1 – C13 1.351(6) 1.356(6) 1.36(2) 1.361(9) 
P – C31 1.818(5) 1.820(5) 1.810(19) 1.827(8) 
P – C41 1.803(5) 1.809(4) 1.795(18) 1.812(8) 
P – C51 1.808(5) 1.817(5) 1.798(19) 1.823(8) 
N1 – Au – P 172.66(12) 176.16(11) 171.8(5) 174.71(17) 
Au – N1 – C1 121.2(3) 117.3(3) 120.0(11) 118.9(5) 
Au – N1 – C13 117.6(3) 121.6(3) 117.5(11) 121.1(5) 
C1 – N1 – C13 121.0(4)3 120.7(4) 122.2(14) 119.9(6) 
Au – P – C31 109.39(16) 109.74(16) 115.9(5) 114.8(3) 
Au – P – C41 111.29(15) 111.26(14) 111.7(6) 110.8(3) 
Au – P – C51 116.14(14) 116.8(15) 109.3(6) 112.0(2) 
C31 – P – C41 104.9(2) 105.4(2) 106.9(8) 106.4(3) 
C41 – P – C51 107.7(2) 107.1(2) 104.9(8) 104.9(4) 







    
 
Table 16: Crystal Data for complexes 47, 48, 49, and 50 












Formula weight 888.84 887.43 1098.25 918.83 
Temperature/K 173.0(1) 173.0(1) 173.0(1) 100.0(1) 
Crystal system Monoclini
c 
Monoclinic Triclinic Triclinic 
Space group P2/n P21/c P-1 P-1 
a/Å 17.2159(3
) 
15.5071(4) 12.0780(8) 8.9239(8) 
b/Å 10.0287(1
) 
10.9932(3) 18.1594(12) 10.1339(9) 
c/Å 17.5695(3
) 
21.3096(6) 18.7739(11) 17.2630(12) 
α/° 90 90 77.914(5) 88.576(7) 
β/° 96.448(1) 104.334(3) 87.941(5) 80.748(7) 
γ/° 90 90 71.754(6) 88.500(7) 
Volume/Å3 3014.2(1) 3519.6(2) 3822.0(4) 1540.0(2) 
Z 4 4 4 2 
ρcalc/Mg/m
-3 1.9595 1.675 1.909 1.981 
μ/mm-1 18.867 10.103 16.972 18.515 





















    
 
Compound 47 48 49 50     










1.075 1.032 0.954 0.886 



























2.44/-1.18 0.86/-3.89 5.95/-2.84 2.37/-2.83 
 
a Goodness-of-fit = [Σ(w(Fo
2 – Fc
2)2]/(Nobsevns – Nparams)]
1/2, based on all data. 
b R1 = Σ(|Fo| - |Fc|)/Σ(|Fo|, 



















    
 
Table 17: Selected bond lengths (Å) and angles (°) for complexes 51, 53,55,56,57 and 58. 
 47 48 49 50 
Au – P 2.322(18) 2.2279(7) 2.232(4), 2.239(4) 2.243(4) 
Au – N1 2.102(6) 2.133(2) 2.141(10), 2.161(10) 2.122(12) 
N1 – C1 1.357(9) 1.353(4) 1.338(18), 1.358(18) 1.354(18) 
N1 – C13 1.362(9) 1.363(5) 1.367(18), 1.353(18) 1.318(18) 
P – C31 1.813(7) 1.813(4) 1.816(17), 1.826(17) 1.832(15) 
P – C41 1.821(8) 1.802(4) 1.814(17), 1.792(17) 1.813(14) 
P – C51 1.816(7) 1.824(4) 1.814(15), 1.873(18) 1.794(14) 
N1 – Au – P 178.98(17) 172.29(8) 171.9(3), 173.8(3) 176.4(4) 
Au – N1 – C1 119.9(5) 123.8(2) 121.1(10), 115.4(9) 118.8(10) 
Au – N1 – C13 119.5(4) 116.1(2) 115.6(9), 121.3(9) 118.9(10) 
C1 – N1 – C13 120.0(6) 119.9(3) 122.7(12), 122.3(11) 122.2(13) 
Au – P – C31 112.0(2) 114.36(14) 116.9(6), 116.9(5) 115.0(5) 
Au – P – C41 113.1(3) 110.93(10) 110.4(5), 115.3(5) 111.3(5) 
Au – P – C51 113.2(2) 111.55(11) 109.5(5), 108.0(5) 110.2(4) 
C31 – P – C41 105.4(4) 107.10(17) 107.6(8), 105.9(8) 107.0(6) 
C41 – P – C51 106.4(3) 109.24(18) 106.2(8), 105.2(8) 106.0(7) 









    
 
Table 18: Crystal data for complexes 51, 53 and 55 
 51 53 55 






Formula weight 931.89 957.40 839.02 
Temperature/K 173.0(1) 100.0(1) 100.0(1) 
Crystal system Orthorhombic Triclinic Triclinic 
Space group Pbca P-1 P-1 
a/Å 10.5709(2) 9.3637(3) 9.0096(3) 
b/Å 21.2934(3) 10.3983(3) 10.0468(4) 
c/Å 30.0455(5) 16.9732(5) 17.3820(5) 
α/° 90 107.749(3) 88.295(3) 
β/° 90 99.704(3) 80.028(3) 
γ/° 90 96.082(3) 87.509(3) 
Volume/Å3 6763.0(2) 1529.49(9) 1547.75(9) 
Z 8 2 2 
ρcalc/Mg/m
-3 1.830 1.862 1.800 
μ/mm-1 11.174 11.573 11.233 
F(000) 3632.0 840.0 824.0 
Crystal size/mm 0.21x0.13x0.05 0.579x0.296x0.05 0.03x0.02x0.005 
Reflections collected 15115 15515 14909 
Independent 
reflections/R(int) 
6429/0.0287 5361/0.0500 5374/0.0898 
Data/restraints/parameters 6429/381/436 5361/0/417 5374/0/409 
Goodness-of-fita on F2 1.049 1.095 1.072 
Final R indexes [I>2σ(I)] R1
b = 0.0375,    
wR2
c = 0.0989 
R1




b = 0.0551, 
wR2
c = 0.1364 
Largest diff. peak/hole/e Å-3 2.60/-1.01 3.65/-1.68 2.57/-1.69 
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a Goodness-of-fit = [Σ(w(Fo
2 – Fc
2)2]/(Nobsevns – Nparams)]
1/2, based on all data. 
b R1 = Σ(|Fo| - |Fc|)/Σ(|Fo|, 





Table 19: Selected bond lengths (Å) and angles (°) for complexes 51, 53, and 55 
 51 53 55 
Au – P 2.2275(11) 2.2418(15) 2.2263(16) 
Au – N1 2.138(4) 2.118(5) 2.067(5) 
N1 – C1 1.365(6) 1.376(8) 1.382(9) 
N1 – C13 1.347(6) 1.339(8) 1.156(9) 
P – C31 1.805(5) 1.814(6) 1.808(7) 
P – C41 1.811(6) 1.813(6) 1.826(7) 
P – C51 1.834(5) 1.810(6) 1.816(6) 
N1 – Au – P 171.21(11) 176.06(13) 178.64(14) 
Au – N1 – C1 115.3(3) 117.5 (4) 119.5(4) 
Au – N1 – C13 124.4(3) 121.4(4) 121.0(4) 
C1 – N1 – C13 120.2(4) 120.9(5) 119.4(6) 
Au – P – C31 114.66(16) 113.5(2) 112.3(2) 
Au – P – C41 112.9(2) 113.14(19) 113.3(2) 
Au – P – C51 109.41(15) 109.85(19) 111.3(2) 
C31 – P – C41 108.1(2) 104.5(3) 106.8(3) 
C41 – P – C51 112.9(2) 107.6(3) 106.5(3) 





    
 
Table 20: Crystal Data for complexes 56, 57, and 58 
 56 57 58 







Formula weight 911.91 984.00 852.99 
 
Temperature/K 100.0(1) 100.0(1) 173.0(1) 
Crystal system Monoclinic Triclinic Triclinic 
Space group P21/n P-1 P-1 
a/Å 8.9446(3) 8.4589(2) 9.9443(5) 
b/Å 20.3425(6) 12.4577(3) 10.0794(4) 
c/Å 18.2243(5) 18.4284(4) 16.7111(8) 
α/° 90 80.508(2) 84.071(4) 
β/° 97.325(3) 86.565(2) 77.381(4) 
γ/° 90 75.184(2) 83.931(4) 
Volume/Å3 3288.95(17) 1851.37(8) 1619.81(13) 
Z 4 2 2 
ρcalc/Mg/m
-3 1.842 1.765 1.749 
μ/mm-1 12.114 10.834 10.206 
F(000) 1784.0 972.0 840.0 
Crystal size/mm 0.25x0.02x0.015 0.467x0.099x0.05 0.22x0.12x0.03 
Reflections collected 27463 38192 10012 
Independent 
reflections/R(int) 
5921/0.0661 6462/0.0754 6028/0.0446 
Data/restraints/parameters 5921/0/425 6462/0/473 6028/0/427 
Goodness-of-fita on F2 1.047 1.042 1.018 
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 56 57 58 
Final R indexes [I>2σ(I)] R1
b = 0.0524, 
wR2
c = 0.1394 
R1
b = 0.0356, 
wR2
c = 0.0828 
R1
b = 0.0363, 
wR2
c = 0.0884 
Largest diff. peak/hole/e 
Å-3 
2.41/-1.76 1.64/-1.11 1.95/-1.18 
 
a Goodness-of-fit = [Σ(w(Fo
2 – Fc
2)2]/(Nobsevns – Nparams)]
1/2, based on all data. 
b R1 = Σ(|Fo| - |Fc|)/Σ(|Fo|, 





Table 21: Selected bond lengths (Å) and angles (°) for complexes 56, 57, and 58 
 56 57 58 
Au – P 2.2451(16) 2.370(11) 2.2542(11) 
Au – N1 2.121(6) 2.130(3) 2.115(4) 
N1 – C1 1.345(9) 1.361(6) 1.355(6) 
N1 – C13 1.350(9) 1.370(5) 1.358(6) 
P – C31 1.798(7) 1.809(4) 1.816(6) 
P – C41 1.798(7) 1.805(4) 1.810(6) 
P – C51 1.822(7) 1.819(5) 1.814(5) 
N1 – Au – P 174.34(16) 178.30(10) 176.29(11) 
Au – N1 – C1 118.5(4) 123.0(3) 117.9(3) 
Au – N1 – C13 119.9(4) 116.6(3) 120.0(3) 
C1 – N1 – C13 121.6(6) 120.3(4) 121.6(4) 
Au – P – C31 113.9(2) 108.34(15) 113.66(19) 
Au – P – C41 114.4(2) 114.49(14) 109.70(17) 
Au – P – C51 109.6(2) 113.99(14) 110.97(17) 
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 56 57 58 
C31 – P – C41 105.7(3) 105.2(2) 106.9(3) 
C41 – P – C51 106.5(3) 107.0(2) 108.5(3) 
C31 – P – C51 106.1(3) 107.4(2) 106.9(2) 
 
Figures 18 and 19: ORTEP views of complexes 41 as a representative of the complexes 
with perchlorate and chloroform. 47 as a representative of the complexes with perchlorate 
only while 56 represent the complexes with perchlorate and dichloromethane in their 
crystal lattice. In addition complex 48 is shown as the only complex with regioisomer. It 
also shows the numbering scheme used. Thermal ellipsoids have been drawn at the 40% 












































Figure 18: ORTEP views of complexes 41 and 47 
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I.9.2. X-Ray Crystallography of Pyrazole gold(I) Complexes 
Suitable crystals for x-ray crystallography of complexes 63-66 were obtained by slow 
evaporation of dichloromethane and n-hexane in a [1:1] ratio although the crystals for 
complex 62 were too small for x-ray diffraction. The crystals were characterised by X-
ray crystallography to confirm the atom connectivity and molecular geometry. The main 
results of the crystal structure determinations are reported in Table 22. Table 23 lists 
some selected bond lengths and angles of the four complexes.  
Table 22: Crystal Data for complexes 63a, 64a, 65b and 66b 










Formula weight 810.80 796.78 710.85 819.64 
Temperature/K 100.0(1) 173.0(1) 173.0(1) 173.0(1) 
Crystal system Triclinic Orthorhombi
c 
Triclinic Monoclinic 
Space group P-1 Pbcn P-1 P21/c 
a/Å 12.7645(4) 18.9094(6) 13.2511(11) 13.8129(4) 
b/Å 15.6061(5) 16.3880(5) 14.8189(13) 6.9184(2) 
c/Å 16.4732(4) 17.9115(5) 15.7353(12) 29.6985(9) 
α/° 105.959(2) 90 66.312(8) 90 
β/° 93.268(2) 90 74.845(7) 103.268(3) 
γ/° 112.402(3) 90 66.970(8) 90 
Volume/Å3 2868.22(16) 5550.6(3) 2584.0(4) 2762.33(14) 
Z 4 8 4 4 
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 63a 64a 65b 66b 
ρcalc/Mg/m
-3 1.878 1.907 1.827 1.971 
μ/mm-1 12.982 13.404 12.601 15.222 
F(000) 1568.0 3072.0 1384.0 1576.0 
Reflections collected 31051 10573 15895 16828 
Independent 
reflections/R(int) 
10158/0.0544 5023/0.0393 9215/0.0310 5048/0.0394 
Data/restraints/param
eters 
10158/60/707 5023/331/343 9215/8/671 5048/39/327 
Goodness-of-fita on 
F2 
1.093 1.057 1.022 1.151 
Final R indexes 
[I>2σ(I)] 
R1





















5.17/-2.72 2.10/-1.10 1.25/-1.83 3.26/-1.29 
 
a Goodness-of-fit = [Σ(w(Fo
2 – Fc
2)2]/(Nobsevns – Nparams)]
1/2, based on all data. 
b R1 = Σ(|Fo| - |Fc|)/Σ(|Fo|, 










    
 
Table 23: Selected bond lengths (Å) and angles (°) for complexes 63a, 64a, 65b and 66b 
 63a 64a 65b 66b 
Au – N1 2.048(7)  2.075(3), 2.055(4) 2.056(7) 
Au – N2 2.042(6) 2.068(10)   
Au – P 2.238(2), 
2.233(2) 
2.241(3) 2.234(1), 2.223(1) 2.234(2) 
N1 – N2 1.368(9), 
1.374(8) 
1.341(15) 1.368(5), 1.374(5) 1.367(11) 
N1 – C5 1.337(10), 
1.330(10) 
1.317(16) 1.325(6), 1.333(6) 1.317(12) 
N2 – C3 1.338(10), 
1.355(9) 
1.354(15) 1.351(6), 1.343(6) 1.357(12) 
C3 – C4 1.393(11), 
1.405(10) 
1.382(16) 1.402(6), 1.407(6) 1.398(13) 
C4 – C5 1.412(11), 
1.396(11) 
1.379(16) 1.384(6), 1.383(6) 1.395(13) 
C3 – N6  1.393(10), 
1.410(10) 
1.327(17) 1.342(6), 1.337(6) 1.340(13) 
C4 – C7 1.477(10), 
1.470(11) 
1.484(16) 1.419(6), 1.418(6)  
C4 – Br7    1.859(9) 
P – C9 1.815(8), 
1.817(7) 
1.803(12) 1.812(4), 1.814(4) 1.812(9) 
P – C10 1.818(8), 
1.811(7) 
1.805(12) 1.813(5), 1.801(5) 1.816(9) 
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 63a 64a 65b 66b 
P – C11 1.808(7), 
1.816(7) 
1.795(15) 1.819(4), 1.805(4) 1.813(9) 
N1 – Au – P 176.68(19)  176.01(11), 
176.98(11) 
175.3(2) 
N2 – Au – P 178.56(17) 175.3(3)   
Au – N1 – N2 123.3(5)  125.7(3), 125.1(3) 124.4(6) 
Au – N2 – N1 123.4(5) 119.9(8)   
Au – N1 – C5 131.1(5)  125.7(3), 127.6(3) 125.5(6) 
Au – N2 – C3 130.3(5) 133.0(9)   















N1 – N2 – C3 111.6(6), 
105.6(6) 
106.5(10) 110.4(3), 110.4(3) 110.3(8) 
N2 – C3 – C4 107.5(7), 
110.1(6) 
109.3(10) 106.5(4), 106.4(3) 106.1(8) 
C3 – C4 – C5 104.6(7), 
104.9(6) 
104.9(10) 105.8(4), 106.3(4) 106.2(8) 
C4 – C5 – N1 110.7(7), 
108.2(6) 
 
108.8(11) 110.5(4), 109.8(4) 109.9(8) 
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 63a 64a 65b 66b 
C5 – N1 – N2 105.5(6), 
111.1(6) 
110.5(10) 106.8(3), 107.0(3) 107.4(8) 
N2 – C3 – N6 120.8(7), 
121.2(6) 
120.7(12) 124.5(4), 124.0(4) 125.3(9) 
N6 – C3 – C4 131.6(7), 
128.7(7) 
129.9(12) 128.9(4), 129.4(4) 128.3(9) 
C3 – C4 – C7 129.2(7), 
128.2(7) 
126.2(10) 126.5(4), 126.6(4)  
C7 – C4 – C5 126.2(7), 
126.9(7) 
128.8(11) 127.6(4), 127.0(4)  
C3 – C4 – Br7    125.6(7) 
Br7 – C4 – C5    128.2(7) 
C4 – C5 – C8 129.6(7), 
131.3(7) 
   
C8 – C5 – N1 119.6(7), 
120.5(7) 
   
 
Figures 20 and 21 show ORTEP views of complexes 63a, 64a, 65b and 66b, with the 
numbering scheme used. Thermal ellipsoids have been drawn at the 40% probability 
level and hydrogen atoms have been omitted for clarity. Figure 22 and 23 show ORTEP 






















































Figure 21: ORTEP view of complexes 65b and 66b 
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Figure 22: ORTEP view of complex 71 




    
 
Selected crystalline specimens of the complexes 64a, 65b and 66b were mounted on 
Mitegen loops and centered on the goniometer head of a Rigaku Oxford Diffraction 
Gemini E diffractometer equipped with an EOS CCD area detector, data collection was 
performed at 173K. Complex 63a was collected on a Rigaku Oxford Diffraction 
007HFM/AFC11 diffractometer equipped with a Saturn 944+ CCD area detector at 100K. 
All complexes were collected with monochromated CuKα radiation, by means of ω-
scans. The diffraction intensities were corrected with respect to Lorentz and polarization 
effects. Empirical multi-scan absorption corrections, using equivalent reflections, were 
also performed with the scaling algorithm SCALE3 ABSPACK. Raw data collection, 
data reduction and refinalisation were carried out with the CrysAlisPro software. All 
complexes were solved by means of the intrinsic phasing method in SHELXT276176and 
refined by full-matrix least squares methods based on Fo
2 with SHELXL277in the 
framework of the OLEX2278software. In the last cycles of refinement all non-hydrogen 
atoms were refined anisotropically; hydrogen atoms were placed and refined as riding 
atoms with their isotropic displacement parameters set to 1.2 times the Ueq of the parent 
atom. The best crystal of complex 63a necessitated the collection on the Rigaku 007HFM 
due to its small size. In complex 64a, there is a small amount of disorder relating to the 
ligand binding through N2 or N1. The amount of disorder was too low to model 
satisfactorily, so this has been left unmodelled. The molecular structures of all complexes 
contained a two- coordinate Au centre with expected Au-P (2.2-2.4Å) and Au- N (2.0-
2.2Å) distances and linear coordination irrespective of the state of molecularity in the 
crystal (Table  19).279 The Au-P were in very good agreement with 2.25 Å reported by 
Keter et al282 and 2.26 Å results of Cambridge Structural Database (CSD).282 The 
perchlorate molecule was included in the lattice of the complexes 63-66 and CH2Cl2 was 
present only in the lattice of complex 66b. These do not show chemical interactions with 
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the complexes. Ligand in entry1 has a pyridine at the fourth position, which provides 
another possible point of attachment compared to others. There is four possibilities for 
the point of attachment to gold (I). Therefore, four peaks were expected by 31P NMR but 
only one peak at 30.0 ppm was observed indicating that there is only one possible linkage. 
Ligand in entry 2 is a pyrazole with a bromophenyl at position 4 with three possible points 
of attachment but only one peak at 31.0 ppm was observed. X-ray crystallography also 
confirmed one linkage. The point of attachment was the nitrogen at the position one 
replacing the proton in that position but leaving a positive charge on the nitrogen ligand 
in entry 3 has a similar structure to ligand in entry 2 but with a methyl group at position 
three. Three points of attachment were also possible but the 31PNMR indicated a single 
attachment point to gold (I) by given only one peak at 31.50 ppm. X-ray result also 
confirmed the single point of attachment but indicated that complex 64a is a regioisomer 
with a positive charge on the nitrogen in position 1.  Ligand in entry 4 has a cyano group 
at position four and an ethyl alcohol at position two given different likely point of 
attachment. However, 31P NMR of the complex gave a single peak at 29.7ppm indicating 
a single point of attachment to gold (I). X-ray diffraction indicated that complex 65b is a 
regioisomer with only one point of attachment to gold (I).  Ligand in entry 5 has a bromo 
substituent at position 4 and a methyl group at position one. 31P NMR indicated only one 
point of attachment with a single peak at 30.0 ppm and attested to by the x-ray diffraction 
study. The point of attachment was at position 2. Complex 66b is non regioisomeric. 
II.10. Fluorescence Properties 
II.10.1.UV-VIS and Fluorescence 
To evaluate the fluorescence properties of this new class of compounds, an array of 
fluorescent cationic gold(I) complexes were prepared. The photo physical properties of 
these complexes and their constituent free ligands were determined at room temperature. 
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The solvent selected for these measurements was ethanol, as larger stoke shifts are usually 
obtained when polar solvents are used.250As stated in the literature the fluorescence 
absorption and emission maxima in polar solvent exhibit solvatochromic red shift with 
increasing polarity.250 Fluorometry measurements of these novel gold (I) catalysts 
revealed all the tested complexes were fluorescence active.  The UV-Vis spectra of most 
of the acridine ligands and their complexes showed an absorption maximum at two 
different wavelengths. The first excitations were between 360-456 nm and the second 
within the range of 265-270 nm. It was observed that the second excitation deviated from 
expected results, as the compounds’ concentration at different dilution measured against 
UV-Vis absorption did not obey Beer Lambert law and their emission bands were not 
mirror symmetrical to their absorption band. It was hypothesised that the first excitation 
was the fluorescence from S1→ S0 as against the fluorescence from the second excitation 
S2→ S0 (Figure 24) which usually occurred with loss of energy from internal conversion 
or photobleaching which may lead to decrease in fluorescence intensity.283 Attention was 
then shifted to the first excited state for the fluorescence analysis of the compounds where 
each compound shows the emission band, which is mirror symmetrical to its maximum 
absorption band.  
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Figure 24: Transition moments for acridine derivatives.286 The blue arrow represented 
π→π* transition (S0→S2) while the red arrow represented n→π* transition (S0→S1) 
UV-Vis spectroscopy was used to identify an appropriate excitation wavelength. The 
results showed that 365 nm would be the most viable, as it yielded high absorption values 
for both the target compounds and the selected standard.284 There should be a linear 
relationship between the analyte concentration and absorbance, which is usually achieved 
when the absorbance values lie between 0.05 and 0.04.284 When emission intensity is 
above0.05 values tend to deviate from the linear dependence on the concertation because 
most instruments lacks precision in this range.284 linear dependence between the 
absorbance and the concentration is very important because it shows that only the 
monomeric units are present in the solution. It should obey the Beer-Lambert law 
(equation below).  
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                                                    A = ԑcl                                                  
Where A is the absorbance at a given wavelength, ԑ is the molar absorptivity, C is the 
concentration of the sample and l is the path length.285 The typical linear relationship 
obtained for acridine derivatives and their complexes in ethanol for concentration ranging  
from 1x10-9 M to 1x10-5 M are shown in figure 25. This shows that only monomer units 







The wavelengths of emission maxima ranges from 385.0 nm to 526.0 nm indicating that 
by proper selection of the appropriate acridine ligand the emission could easily be used 
to achieve a variety of visible colours.  



















Figure 25: The linear relationship between emission intensity and 
concentration of 9 showing that Beer-Lambert law is obeyed. 
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Figure 26: Selected acridine ligands under UV light (λ=365nm) L-R 7, 9, 11, 12, 13, 14, 15 and 
16. 
II.10.1.1.Possibility of Excimer or dual Excitation 
Excimer formation implies that more than a single unit of monomer is in solution but dual 
excitation usually occurs because of isomerization dynamics of the compound. A 
monomer may have resonance hybrid which may excite at different wavelength.286–288  It 
was reported that alkyl ester of 9-anthrilic acid isomerised in solution when photoexcited 
but the reason for the formation of stereoisomer by this compound has not been proved.289 
The photochemical isomerization of anthracene derivatives has been studied 
extensively.290 It has been reported that 2-methoxy-substituted anthracene exhibited dual 
emission wavelengths, which originate from two different interconvertible species in 
solution.288Though, it was reported that 9-amino acridine belong to the class of 
compounds that dimerises easily at higher concentrations291 but it only dimerises in the 
excited state.292 It was observed that some of the spectra, particularly the methoxy 
substituted derivatives gave more than one emission maxixma.  In an attempt to identify 
whether excimer formation or dual excitation was responsible for this phenomenon a 
concentration dependence study on 2-iodo-6-methoxy-9-acridinecarbonitrile was 
undertaken (Figure 27). 
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Figure 27: Concentration dependence studied of 2-iodo- 6-methoxyacridine-9-carbonitrile 17 
If it were to be an excimer, at low concentration the dimer would not form therefore a 
pure fluorescence spectrum was expected to be observed and as the concentration 
increases the dimer should be more probable and the excimer peak should be more 
pronounced. In other words, the occurrence of a new peak at higher concentration 
confirm the formation of excimer.  Surprisingly, the higher the concentration, the purer 
the spectra. Therefore, the absence of a new peak at higher concentration rules out the 
possibility of dimerization.292 It was then proposed that this could be due to dual 
excitation as the compound may isomerised in solution when photoexcited (figure 28) 



























    
 
 
Figure 28: Geometrical isomerisation of compound a to compound b when photoexcited or vice 
versa 
II.10.2.Sustituent Effect on Photophysical Properties of Acridine 
II.10.2.1.Substituent Effect on the Absorption and Emission of Acridine 
The term substituent was defined by Exner in 1996,293 as structural entity that fulfils at 
least one of the following criteria: 
(i) The substituent is a smaller part of a molecule which can be introduced by a (simple) 
chemical operation, particularly when it can directly replace a hydrogen atom. 
(ii) The substituent is a smaller and less important part of a molecule which influences 
the properties of the molecule in a quantitative sense but does not alter its general 
character; the latter is controlled by another group present: the functional group (or the 
reaction site).”293 In other word, substituent is a fractional part of a molecule that can 
replace a hydrogen atom thereby influences the quantitative properties of the molecule 
but has no effect on its general character.293,294 Substituent effect is one of the major 
concept of structural effect that determines the photo physical and chemical properties of 
a compound.295 Literature revealed that addition of substituent on polycyclic aromatic 
compound influences the photophysical properties such as fluorescence intensity, 
absorption and emission maxima, Stokes shift and quantum yield etc. Substituents can 
affect the fluorescence properties in many ways depending on a number of factors. These 
include nature of the substituents i.e. whether it is electron donating or electron 
withdrawing group, the position and number of the substituents, on both side of the 
polycyclic aromatic hydrocarbons and the dipole moment of the molecule. In this 
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research, it was attempted to study the influence of electron donating group (EDG) and 
electron-withdrawing group (EWG) on the fluorescence properties of acridine. In this 
regard, mono, di, tri and tetra substituted acridine-9-carbonitrile were synthesised to 
determine the influence of substituent position. Furthermore, the combined effect of 
simultaneous multiple addition of substituent group such as double, triple and tetra 
substitution are also investigated. Monosubstituted acridine derivatives were synthesized 
with different halogens at position 2 and methoxy, methythiophene and halogens were 
alternated at position 2, 3, 4, 5 and 7 for poly substitutions. 
II.10.2.2. Effect of halogen Substituents on Absorption and Emission wavelength of 
Acridine 
A number of acridine-9-carbonitrile analogues were prepared (7, 8, and 14) with different 
halogens substituted at position 2. The order of absorbance intensity observed was 
Cl >Br >I (Figure 29). The order of maximum absorbance was Cl < Br < I, this was 
expected heavy atom such as bromine and iodine substituent on a fluorescent compound 
are believed to disturb and quench the fluorescence state by increasing the spin-orbit 
coupling thereby creating a charge-transfer complex.296 They also induce intramolecular 
intersystem crossing. Their effect on aromatic molecule usually leads to a decrease in 
fluorescence intensity and fluorescence lifetime. 297,298 The excitation wavelength in 
halogenated aromatic compounds are assumed to be influenced by balance between two 
major interactions: (a) Resonance effect which takes place due to interaction between 
nonbonding orbital of the halogen and the C=C π orbital of the chromophore. (b) The 
second type of interaction is due to the inductive electron withdrawing effect of the 
halogens.299 The higher bathochromic shift observed in the absorbance maxima for iodine 
relative to that of chlorine and bromine is assumed to be due to the difference in the 
electronegativity of the halogens. Electronegativity decreases down the group, thus iodine 
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is less electronegative than chlorine and bromine, and as a result, it is less inductivity 
withdrawing on the adjacent ring system. In other words, the electrons on the iodine atom 
are more loosely held because of its lower electronegativity compared with chlorine and 











This implies that resonance effect influences the absorbance maxima more when 
considering the electron withdrawing cum electron donating capacities of a halogen on 
aromatic ring system.300. In addition, it was observed that both emission intensity and 
emission wavelength maxima for 7, 8 and 14 followed the same trend as that of the 
absorption (Figures 30 and 31). That is, 7> 8 > 14 in terms of emission intensity while 
the emission maxima increases as the electronegativity of the halogen decreases. It was 
proposed that the absorbance and emission maxima of halogenated acridine derivatives 






























Figure 29: Normalised absorption (dashed line) and emission (solid line) spectra of 7. 8 
and 14. 7 in red line, 8 in green line and 14 in blue line at identical concentrations  
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Figure 30: Normalised absorption intensities and wavelength for 7(red), 8 (green) and 14 (blue) 














































Figure 31: Normalised emission intensities and wavelength for 7 (red), 8 (green) and 14 (blue). 
II.10.2.3.Effect of Electron Donating Group on the Absorption and Emission 
wavelength of Acridine 
The effect of double substitutions was also considered.  In the first set of acridine 
derivatives, the electron-donating group (EDG) methoxy was placed on position 6 and 
varied the halogen substituent on position 2. These compounds were synthesised in order 
to ascertain whether an EDG/ EWG pair on acridine could have a stronger effect on the 
intensity and wavelength of absorbance as well as that of the emission. Interestingly, the 
observed trend in absorbance intensity is quite different from that of the emission intensity 
(Figures 32, 33 and 34). While the absorbance intensity was highest in compound 11, 





























    
 
trend was reversed, with compound 9 the highest and 11 the lowest. These results 
suggested that a pair of EDG (methoxy)/ EWG (halogen) has no defined trend on the 
intensity of the absorbance and emission of acridine derivatives. However, absorbance 
and emission maxima increases as the size of the halogen atom increases. Thus, the 
absorbance for 9, 11 and 17 were 367.0 nm, 367.0 nm and 370.0 and the emission maxima 
were 481.25 nm, 493.5 nm and 500 nm respectively. Concisely, the absorption and 






















Figure 32: Normalised absorption (dashed line) and emission (solid line) spectra of 9 (green), 





















































Figure 33: Normalised absorption intensities and wavelength of 9 (green), 11 (blue) and 17 






















































Figure 34: Normalised emission intensities and wavelength of 9 (green), 11 (blue) and 17 
(orange) at the same concentrations  
II.10.2.4.Effect of Increasing the Number of Methoxy Group on the Absorption 
and Emission Wavelength 
The effect of multiple EDG (methoxy) as substituents on acridine derivatives was 
investigated. Firstly, the effect of di-methoxy group as substituent on acridine were 
studied. Halogens were varied on position 7 and added di-methoxy groups at position 2 
and 3. To obtain 7-iodo-2,3-dimethoxyacridine-9-carbonitrile 20, 7-chloro-2, 3-
dimethoxyacridine-9-carbonitrile 21 and  7-bromo-2, 3-dimethoxyacridine-9-carbonitrile 
23. It was observed that the intensities for both absorbance and emission decreases down 
the halogen group (Figure 35). Chloro substitution has the highest followed by bromo 





























    
 
and emission intensity of dimethoxy halogenated acridine derivatives decreases as 
inductive effect of halogen decreases. However, the wavelength of absorbance and 
emission maxima did not follow the same trend figures (36 and 37). It was observed that 
bromo substitution 23 has the highest absorbance (402.0 nm) and emission (457.5 nm) 
maxima while iodo substitution 20 has absorbance (380.0 nm) maxima next to it but with 
the lowest emission (448.5 nm) maxima. The chloro substituted acridine derivative 21 
has the lowest absorbance (367.0 nm) maxima but with higher emission (455.75 nm) 
maxima. The lowest emission wavelength observed in the iodo substituted may be due to 
















Figure 35: Normalised absorption (dashed lines) and emission (solid lines) properties of 20 





















































Figure 36: Normalised absorbance maxima and intensities of 20 (orange), 21 (green) and 23 





















































Figure 37: Normalised emission maxima and intensities of 20 (orange), 21 (green) and 23 
(blue) at the same concentration 
II.10.2.5. Effect of Quadruple Substitution on the Absorption and Emission Properties  
The effect of four substituents on acridine-9-carbonitrile was also examined 
(figure 38). Here the number of methoxy groups were increased to three, resulting in a 
configuration with methoxy groups at position 2, 3 and 4 and varied the halogen on 
position 7. It was observed that there was no clear-cut correlation in the intensities of 
the absorbance as the bromo substituted 19 has the highest intensity followed by iodo 
substituted 16 while the chloro substituted 15 has the least intensity. This could be 
explained based on the EWG/EDG effect in which the bromo substituted has the 
electron density that falls in- between the iodo substituted and chloro substituted 





























    
 
halogen decreases. The iodo-substituted derivative 16 has the highest absorbance 
maxima (398.0 nm) followed by bromo substituted 19 (396.0 nm) with chloro 
substituted 15 has the lowest absorbance maxima. But the chloro substituted has the 
highest emission maxima (480.5 nm) followed by iodo substituted (475.0 nm) with 













Figure 38: Normalise absorbance (dashed lines) and emission (solid lines) properties of 15 
(green), 16 (orange) and 19 (blue) at the same concentrations (1x10-6 M) 
 
II.10.2.6.Chloro-Substitution with Increase in the Number of Methoxy Group 
The effect of multiple substitution of EDG (methoxy) at position 2,3 and 4 on acridine 
































    
 
41). The absorbance intensity was reduced when one methoxy was added compares to 
when there was no methoxy. This could be as a result of push-pull system which is 
usually experience when EDG/EWG are substituted across a ring system.301–303 
Contrary to our expectation, progressive addition of methoxy group did not result  in a 
progressive  red shift of the absorption maxima as observed by Griffits.304 They 
observed a progressive shift into longer wavelength in arylamine as the addition of 
electron donating group increases. The absorbance maxima for 2-chloro-9-carbonitrile 7 
(377.0 nm) was greater than absorbance maxima of 2-chloro-6-methoxyacridine-9-
carbonitrile 9 (367.0 nm). Even addition of two methoxy groups 21 did not change the 
absorbance maxima (367.0 nm).  However, on addition of three methoxy group, the λmax 
value was displaced to longer wavelength (392.5 nm). The emission maxima followed 
the expected progressive increment up to the addition of two methoxy group. (i.e. 412.2 
nm for 7, 492.5 nm for 9 and 492.5 nm for 21). Nevertheless, the value decreased on 
further addition of the methoxy. (15 has 480.5 nm). 
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Figure 39: Normalised absorbance (dashed lines) and emission (solid lines) properties of 7 




































































































































Figure 41: Normalised emission spectra of 7 (red), 9 (green), 15 (orange) and 21 (blue) at the 
same concentrations. 
II.10.2.7.Bromo Substitution with Increase in the Number of Methoxy Group 
It was observed that the absorbance intensity of mono-methoxy 11 was lower than the 
bromine only substituted acridine 8 (figure 42). However a progressive increase in 
intensity was observed (Figure 43) as the number of methoxy (EDG) increased to two 23 
and three 19. It is noteworthy to state that there was negative halochromism (i.e. reversible 
shift of the absorption band to shorter wavelength on further addition of the EDG)304 
between 8 (377.0 nm) and11 ( 367.0 nm) which was also present between 23 (402.0 nm) 






























    
 
3-dimethoxyacridine-9-carbonitrile 23 (figure 44) and others. It should be noted that the 
lowest emission intensity was observed in the mono-methoxy substituted compound 11. 
However the emission maxima increases progressively as the number of methoxy 
substitution increases except for the mono-methoxy substituted which has the lowest. (i.e. 















Figure 42: Normalised absorption (dashed lines) and emission (solid lines) spectra of 8 (red), 

























































Figure 43: Normalise absorption spectra of 8 (red), 11 (green), 19 (orange) and 23 (blue) at the 




















































Figure 44: Normalised emission spectra of 8 (red), 11 (green), 19 (orange) and 23 (blue) at the 
same concentrations. 
II.10.2.8.Iodo Substitution with Increase in the Number of Methoxy Group 
It was observed that there was a reduction both in intensity and absorbance maxima with 
monosubstitution of methoxy on iodo acridine derivative 17 relative to 2-iodoacridine-9-
carbonitrile 14. Figures 45-47 elucidated all cases examined. Interestingly, there was a 
progressive red shift in the absorbance maxima as the number of methoxy substitution 
increases progressively. This was also accompanied with concomitant increase in the 
absorbance intensity. There was a red shift in absorbance maxima from mono-substitution 






























    
 
Surprisingly, the emission intensity for di-substitution was too high compares with others. 



















Figure 45: Normalised absorption and emission spectra of 14 (red), 16 (orange), 17 (green) and 20 




















































Figure 46: Normalised absorption spectra of 14 (red), 16 (orange), 17 (green) and 20 (blue) at 

















































Figure 47: Normalised emission spectra of 14 (red), 16 (orange), 17 (green) and 20 (blue) at the 
same concentrations. 
II.10.2.9.Methylsulfide Substitution with Increase in Number of Methoxy Group 
In order to investigate the effect of poly substitution of EDG exclusively, without the 
influence of electron WDG on the photophysical properties a number of acridine 
derivatives were synthesised. In these compounds the halogen on one side of the ring was 
replaced with methyl sulphide. Our observation are presented in figures 48-50.  
Interestingly, both absorbance and emission intensities increased with increasing 
methoxy substitution. However, absorbance maxima decreased from mono-substitution 
24 (455.5 nm) to di-substitution 32 (409.5 nm). A red shift of 15.0 nm in absorbance 






























    
 
emission maxima indicated that the more the substitution the lower the emission maxima. 
That is mono-substituted 24 (with 514.5 nm) has the highest emission maxima followed 
by di-substituted 32 (with 494.5 nm), whilst tri-methoxy 27 (with 467.0 nm) has the 















Figure 48: Normalised absorption (dashed lines) and emission (solid lines) spectra of 24 








































































































Figure 50: Normalised emission spectra of 24 (orange), 27 (blue) and 32 (green) at the same 
concentrations. 
II.10.2.10.Comparism of Halogen Substituent on the Complexes 
In order to understand the photophysical properties of acridine based gold(I) complexes 
so that it could be used as tools to unravel the mechanism of gold complexes, the effect 
of varying the halogen on position 2 of the organic ligand on the fluorescence properties 
of triphenyl phosphine gold(I) complexes was investigated. Figures 51-53 showed the 
cases examined. The fluorescence spectra of the complexes are modified significantly on 
changing the substituent and their position in the organic ligand.305,306 It was observed 
that the absorbance intensity of mono-halogen substituted complexes followed no defined 
pattern. Iodo substituted 47 had the most intense absorbance followed by chloro 
substituted and bromo substituted was the least intense. There was a slight red shift in the 





























    
 
(377.0 nm). There was a blue shift on absorbance on the iodo substituted organic ligand 
of the complex. This is due to heavy atom effect. The emission intensity of the halogen 
substituted acridine gold(I) complexes decreased down the group. That is, the lower the 
inductive effect on the organic ligand of the complexes, the lower the emission intensities. 
However, as emission intensities decreases, there was a bathocromic shift in the emission 
maxima. The emission maxima increase as the atomic size increases. Thus, we have 41 















































































































Figure 53: Normalised emission spectra of 41 (red), 42 (blue) and 47 (green) at the same 
concentrations. 
II.10.2.11.Effect of Methoxy Group on the Complexes 
Effect of EDG-EWG on acridine based triphenyl phosphine cathionic gold(I) complexes 
was also investigated. When the mono methoxy was substituted on the position 6 as 
electron donating group and halogen on position 2 as electron withdrawing group through 
inductive effect, it was observed that the chloro substituted had the highest intense 
absorbance. As expected, there was a bathocromic shift in the absorbance maxima from 
chloro substituted to iodo substituted. The absorbance maxima increases as the inductive 





























    
 
less than 44 (367.5 nm) less than 50 (371.0 nm). The emission intensities decreases 
(Figure 54) as the inductive effect decreases while the emission maxima increases as the 
inductive effect decreases. It was proposed that the absorbance and emission maxima of 
halogenated mono methoxy acridine triphenyl phosphine gold(I) complexes increase as 
the inductive effect of the halogen decreases. For the halogenated di-methoxy acridine 
gold(I) complexes, it was observed that the most intense absorbance was from the iodo 
substituted followed by chloro substituted and the bromo substituted was with the least 
intense absorbance. There was a red shift in the absorbance maxima of the bromo 
substituted 54 (402.0 nm) compares with the chloro substituted 53 (374.0 nm). A blue 
shift was observed for the iodo susbstituted 52 compares with the bromo substituted. The 
emission intensity decreases with decrease in inductive effect (figure 55). A red shift was 
observed for the emission maxima for bromo substituted compares with chloro 
substituted but there was a blue shift in iodo substituted compares with bromo substituted 
which could be attributed to intersystem crossing. Both the absorbance intensity and 
absorbance maxima increases as the inductive effect decreases for the halogenated 
trimethoxy acridine gold(I) derivatives (figure 56). Nevertheless, the emission intensity 
of bromo substituted was the highest followed by chloro substituted while iodo 
substituted was the least intense. Emission maxima for both chloro and bromo were the 
same while there was a blue shift compare with emission maxima for the iodo substituted 
derivative. It is noteworthy, to state that the absorption maxima showed expected progress 
shift to longer wavelength as the EDG increase on the ring.304 The exception to the rule 
was the bromo substituted complex which showed a blue shift for trimethoxy substituted 
compared with the di-methoxy substituted.  
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Figure 54: Normalised absorbance (dashed lines) and emission (solid lines) spectra of 43 


























































Figure 55: Normalised absorption (dashed lines) and emission (solid lines) spectra of 52 

























































Figure 56: Normalised absorption (dashed lines) and emission (solid lines) spectra of 48 (blue), 
49 (orange) and 51 (green) at the same concentrations. 
II.10.2.12.Comparism of the Fluorescence Properties of the Free Ligands with the 
Corresponding Complex 
It was observed that the absorption and emission intensities were higher in most of the 
complexes when compared to their corresponding free organic ligand (figures 57-61). 
The exceptions to this observed trend were cases when all the substituents are EDG. For 
instance when there is a methyl sulphide on position 7 and methoxy group were present 
on position 2, 3 and 4 (figures 58 and 59). The intensities of the ligands were greater than 
their corresponding complexes. For comparison of the absorbance and emission maxima, 














































Figure 57: Normalised absorption and emission spectra of compound 7 and its corresponding 









































Figure 58: Normalised absorbance and emission spectra of compound 8 and its corresponding 
















































Figure 59: Normalised absorbance and emission spectra of compound 21 and its corresponding 


















































Figure 60: Normalised absorbance spectra of compound 27 and its corresponding 





































Figure 61: Normalised emission spectra of compound 27 and its corresponding complex 57 at 
the same concentrations. 
II.10.2.13.Stoke shift for ligands and complexes 
The differences in the wavelength between the position of absorption maxima and the 
emission maxima of the same electronic transition of a compound is called the Stokes 
shift. If the molecule fluoresces, the emitted photon has a lower energy than the excitation 
photons and that is why the emission spectra is red shifted when compared to the 
absorption spectrum.307 A stoke shift of a chromophore suggests the displacement in 
potential surface between the ground state and excited state with a loss of vibrational 
energy in the excited state.308 Fluorescent dyes with large stokes shift and good photo-
























    
 
considered to exhibit small Stokes shift if its less than 80 nm and large if it is above that 
value. 309 Small Stoke shift proposes that the molecular structure of a compound in the 
ground state is the same with that in its excited state. 310 It gives rise to reabsorption of 
emitted photons leading to unwanted background interferences.309The Stokes shift values 
on the prepared complexes and their constituent free ligands are provided below (Table 
24-26). Interestingly, there was a considerable stoke shift for both the ligands and the 
complexes. For the ligands, the smallest Stokes shift was observed in the compound 18 
with 13.5 nm while both compounds 9 and 21 has the highest value with 125.5 nm each. 
It is worth to note that more than half of the free ligands under investigation have high 
Stokes shift values of 80.0 nm and above. For the complexes, compound 49 has the lowest 
observed Stokes shift with the value of 17.5 nm, while compounds 48 and 51 has the 
highest value of 133.0 nm. Also more than half of the complexes showed high Stokes 
shift of 80.0 nm and above. It should be added that considerable number of these novel 
acridine ligands and complexes exhibited a great differences in the Stokes shift between 
the ligands and their corresponding complexes as observed in table 26. Ligand 11 and its 
corresponding complex 44 has the highest Stokes shift difference of 81.0 nm while 











    
 
Table 24: Stokes shift for the ligands 
Entry compound λmax Abs λmaxEmi Stoke’s shift 
1 7 377.0 412.5 35.5 
2 8 377.0 422.5 45.5 
3 9 367.0 492.5 125.5 
4 11 367.0 385.0 18.0 
5 13 351.1 431.5 80.4 
6 14 381.5 453.5 72.0 
7 15 392.5 480.5 88.0 
8 16 398.0 475.0 77.0 
9 17 370.5 476.5 106.0 
10 18 371.5 385.0 13.5 
11 19 396.0 473.0 77.0 
12 20 380.0 413.5 33.5 
13 21 367.0 492.5 125.5 
14 23 402.0 458.0 56.0 
15 24 455.5 514.5 59.0 
16 25 443.5 523.5 80.0 
17 27 414.5 467 52.5 
18 28 360 473 113.0 
19 29 365 476.5 111.5 
20 30 398.5 462 63.5 
21 32 409.5 494.5 85.0 






    
 
Table 25: Stoke shift for the complexes 
Entry compound λmax Abs λmaxEmi Stokes shift 
1 41 377 412.5 35.5 
2 42 379 414.5 35.5 
3 43 365 476.25 111.25 
4 44 367.5 493.5 126 
5 45 369 427 58 
6 46 371 431 60 
7 47 380 413 33 
8 48 392 525 133 
9 49 397 414.5 17.5 
10 50 371 500 129 
11 51 392 525 133 
12 52 374 448.5 74.5 
13 53 374 455.75 81.75 
14 54 402 457.5 55.5 
15 55 455 521.5 66.5 
16 56 445 526 81 
17 57 385 413 28 
18 58 378 466.5 88.5 








    
 
Table 26: Ligands Stokes shift compares with their corresponding complexes 
 































412.5 35.5 41 377.0 412.5 35.5 0.0 0.0 0.0 
2 8 377.
0 





43 365.0 481.25 111.
25 
2.0 13.3 14.3 
4 11 367.
0 
412.0 45.0 44 367.5 493.5 126 0.5 81.5 81.0 
5 13 351.
1 





453.5 72.0 47 380.0 413.0 33.0 1.5 40.5 39.0 
7 15 392.
5 
480.5 88.0 48 392.0 525.0 133.
0 
0.5 44.5 45.0 
8 16 398.
0 





50 371.0 500.0 129.
0 
0.5 23.5 23.0 
10 19 396.
0 
473.0 77.0 51 392.0 525.0 133.
0 
4.0 52.0 56.0 
11 20 380.
0 





53 374.0 455.8 81.7
5 
7 36.8 43.8 
13 23 402.
0 




514.5 59 55 455 521.5 66.5 0.5 12.5 7.5 
15 25 443.
5 
523.5 80.0 56 445.0 526.0 81.0 1.5 1.5 1.0 
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II.10.2.14.Qantum Yield for Ligands and Complexes 
Fluorescence quantum yield determines the efficiency of fluorescence process.284 It is 
usually denoted as the number of emitted photons divided by the number of absorbed 
photons.311 In order   to investigate the quantum yield of the novel acridine derivatives 
and their corresponding complexes, 9,10-diphenylanthracene was used as the standard. 
This was chosen as it absorbed and emit in a similar region to investigated compounds in 
ethanol solvent.312,313 The quantum yield was calculated using the equation delineated 
below: 
ᶲF(x) = ᶲF(s) x (Fx/ Fs) X (Abs/Abx) X (nx/ ns)
2  
Where ᶲF(x) is the fluorescence quantum yield of unknown, ᶲF(s) is the fluorescence 
quantum yield of the standard, Abs is the absorbance of the standard at the excitation 
wavelength, Abx is the absorbance of the unknown at the excitation wavelength and n is 
the refractive index of the solvent. Subscripts x and s refer to unknown and the standard. 




    
 
Table 27: Quantum yield of the ligands 
ENTRY COMPOUND QUANTUM YIELD 
1 7 0.16 
2 8 0.62 
3 9 0.30 
4 11 0.61 
5 13 0.14 
6 14 0.30 
7 15 0.22 
8 16 0.41 
9 17 0.71 
10 18 0.59 
11 19 0.29 
12 20 0.36 
13 21 0.60 
14 23 0.51 
15 24 0.15 
16 25 0.39 
17 27 0.85 
18 28 0.30 
19 29 0.42 
20 30 0.91 
21 32 0.25 
22 33 0.30 
 
 
Table 28: Quantum yield for the complexes 
ENTRY COMPOUND QUANTUM YIELD 
1 41 0.21 
2 42 0.37 
3 43 0.95 
4 44 0.23 
5 45 0.19 
6 46 0.23 
7 47 0.24 
8 48 0.30 
9 49 0.24 
10 50 0.17 
11 51 0.18 
12 52 0.13 
13 53 0.11 
14 54 0.17 
15 55 0.29 
16 56 0.55 
17 57 0.18 
18 58 0.74 




    
 
Interestingly, good to excellent quantum yield were observed for both the free ligands 
and the complexes when compared with the literature values of similar compounds. The 
quantum yield of acridine derivatives varies widely in the literature depending on the 
substituents attached or the solvent used.  For example neutral acridine orange in ethanol 
has quantum yield of 0.20 while cationic acridine orange in ethanol has a quantum yield 
of 0.46.314 9- amino acridine in ethanol ᶲF was 0.99 while acridone in ethanol was 
0.83315,316 The quantum yield obtained for the ligands ranges from 0.15 to 0.91 while that 
of the complexes ranged from 0.11 to 0.95 It was proposed that the electron donating 
group influences the quantum yield both in the free ligands and the complexes. This was 
based on the fact that the highest quantum yield (0.91) for ligands was observed in the 
ligand 30 with only electron donating group in both side (Figure 62) followed by 27 (0.85) 
followed by 17 (0.71), followed by 21(0.60).Also, the highest quantum yield (0.95) in 
complexes was observed for compound 43 followed by compound 58 (0.74). It is 
noteworthy to state that both of these compounds contained electron-donating group 
(figure 63). However, halogen may influence the rate of intersystem crossing in 
compounds 52, 53 and 54 leading to low quantum yield observed.290,317  
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Figure 62: Structures of compounds 17, 21, 27 and 30 
 
Figure 63: Structures of the compounds 43 and 58 
II.11. Cell Viability Assays 
II.11.1 Cytotoxicity of The Pyrazole Gold(I) Complexes 
The biological activity of the complexes were assessed after dilution in 
DMSO/H2O (10% v/v) and addition to HepG2 cells. Assays were performed in 96-
well plates using the Promega CellTiter-Blue assay as an endpoint method with a 
2-hour incubation with the assay reagent. This assay measures cell viability and is 
based upon the ability of living cells to convert a redox dye (resazurin) into a 
fluorescent product (resorufin). Each well received 90 μL of cell suspension at a 
density of 22,500 cells per well and was cultured overnight (at 37 °C/5% CO2 
humidified air) before 10 μL of the test sample was added. The experiments were 
set up in triplicate. The mock control wells received 90 μL of cell suspension and 
10 μL of the appropriate buffer (DMSO/H2O). Wells that contained just 100 μL of 
cell culture medium served as background fluorescence controls. Fluorescent 
readings were taken using the GloMax-Multi Detection System (Promega). The 
five complexes shown in Table 10 all indicated that they possessed reasonable 
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activity against this cell line in a preliminary screen (data not shown). To confirm 
this activity various doses were then tested alongside their respective un-
complexed ligands. Figure 64 shows that even at the lowest dose tested (20 μM) 
all of the complexes showed high activity. In contrast the free ligands showed no 
significant activity at the same concentrations (Figure 65). Due to the high level of 
activity observed, further dilutions were made and tested (Figure 66). These data 
indicate that complexes 63a, 64a, 65b and 66b remain highly toxic at 2 μM while 
62 is significantly less toxic at this concentration. IC50 values were calculated as 
1.75 μM (6), 0.19 μM (7b), 0.31 μM (8b), 0.13 μM (9a) and 0.23 μM (10a). 
 
Figure 64: Toxicity data for the gold complexes 62-66b against HepG2 cells. Five doses of 
each compound were tested, background fluorescence was subtracted from each reading and the 
resulting values are shown relative to a buffer-only control (100% viability). Controls 
performed under full assay conditions confirmed that none of the compounds, or the 
separate ligands, interfered with the readings when tested at a concentration of 18 μM in 
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Figure 65: Toxicity data for the free pyrazole ligands indicated that there was no significant 
activity against HepG2 cells at the same concentration. 
 
 
Figure 66: Dose response assay of gold complexes against HepG2 cells. Five doses of each 
complex were tested, background fluorescence was subtracted from each reading and the 
resulting values are shown relative to a buffer-only control (100% cell viability). 
II.11.2. Cytotoxicity of Acridine Gold(I) Complexes 
To assess their activity against the human cancer cell line HepG2 eight complexes were 
initially tested at a single dose of 20 µM and the results are shown in Figures 67 and 68. 
Complexes 48, 49 and 51 showed little toxicity at this concentration whereas 42, 45 and 
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Figure 67: Toxicity of the acridine / gold (I) complexes against HepG2 cells. Background 




Figure 68: Toxicity of the acridine / gold (I) complexes against HepG2 cells. Background 
fluorescence was subtracted from each reading and the resulting values are shown relative to a 
buffer-only control 
To confirm that the toxicity associated with the latter three complexes was not due to the 
ligand alone a further assay was performed just with the free ligands (Figure 69). None 
of these showed significant toxicity confirming that complexation with gold was required 
for activity. Since complexes 42, 45 and 47 showed significant toxicity at 20µM further 
assays were performed using higher dilutions (Figure 70). All three complexes showed a 
dose-dependent toxicity and from these data IC50 values were calculated as 11.18µg/ml 












100 80 60 40 20 100 80 60 40 20 100 80 60 40 20 100 80 60 40 20










100 80 60 40 20 100 80 60 40 20 100 80 60 40 20 100 80 60 40 20





    
 
indicated that the activity of the complexes greatly depended on the number and chemical 
nature of the substituents. The complexes 41, 42 and 47 which were the analogues of 
complexes 48, 49 and 51 exerted an interesting cytotoxicity on HepG2 cancer cell lines. 
Comparison with the results observed for complexes 48, 49 and 51 indicated that addition 
of methoxy at position 2, 3, and 4 greatly reduced the activities of the complexes. 
Furthermore, addition of second Chloro at position 2 (46) slightly reduced the 
cytotoxicity of the compound when compared with mono chloro compound (complex 
41). Interestingly, the toxicity increases as the electronegativity of the halogen substituent 
decreases, I other words as the inductively withdrawing effect of the halogen substituent 
decreases on the acridine ring system the toxicity of the complexes increases. As indicated 
by complexes 41< 42 < 47.  Surprisingly, the addition of fluoro and bromo substitution 
(45) has little or no effect on the activity of the complex. It has been reported that acridine 
derivatives induced p53 dependent apoptosis of tumour cells at the concentration of 20 
μM 142 which was higher than the activity observed in these complexes.  However, the 
observed activity was slightly higher than the value reported for acridine derivatives 
against human glioblastoma cell with IC50 of 176.9 nM and human colon cancer cell line 
with IC50 of 166.7 nM.
140 Furthermore, the observed activity was  higher than the toxicity 
of pyrazole gold(I) complexes reported for the same cancer cell line with IC50 values 
ranges from 0.13µg/ml to 1.75µg/ml.274 The choice of acridine as a ligand for the gold 
was based on the fact that these molecules have a natural fluorescence that alters upon 
complexation. This potentially provides the means to better understand the mechanism of 
action of these toxic complexes through detailed real-time imaging of exposed cells. As 
a proof-of-concept experiment cells were exposed to either buffer or complex 47 and the 
fluorescent signal associated with the complex observed (Figure 71). As can be seen after 
exposure to the complex fluorescence is seen to concentrate in the cells over time 
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Figure 69:  Toxicity of the acridine / gold (I) complexes against HepG2 cells. Background 




Figure 70: Toxicity of selected complexes against HepG2 cells. Background fluorescence was 
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Figure 71: Imaging of HepG2 cells unexposed (A) or exposed (B) to complex 47 by 
fluorescence microscopy. The stills were taken over a period of 50 minutes 
II.11.3. Cytotoxicity of Acridine Silver(I) Complexes 
To investigate the activity of these novel Ag(I) bearing acridine complexes against human 
cancer cell line HepG2 five complexes synthesised were tested at a dose of 100 µM to 20 
µM and the results are shown in figure 72 
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Figure 72: Toxicity of complexes 67-71 against HepG2 cells. Background fluorescence was 
subtracted from each reading and the resulting values are shown relative to a buffer-only 
control. 
It was observed that all the complexes tested showed an interesting cytotoxic activity 
against human HepG2 cancer cell lines at these concentrations. Therefore, further test 
were carried out with higher dilution and the result are shown in figure 73. All these 
complexes showed a dose-dependent toxicity and from these data IC50 values were 
calculated as 1.66µg/ml (Complex 67), 1.87µg/ml (Complex 68), 1.96 (complex 69), 1.69 
µg/ml (complex 70) and 1.68µg/ml (Complex 71). Interestingly, they all show high 





















    
 
 
Figure 73: Toxicity of complexes 67-71 against HepG2 cells at less than 20 μM. Background 
fluorescence was subtracted from each reading and the resulting values are shown relative to a 
buffer-only control. 
II.11.4. Cytotoxicity of Pyrazole Silver(I) Complexes 
To study the activity of the new pyrazole Ag(I) complexes against human HepG2 cancer 
cell lines, the four complexes synthesised in table 11 were tested at a single dose of 2 μM 






















    
 
 
Figure 74: Toxicity of complexes 72a-75b against HepG2 cells at less than 20 μM. Background 
fluorescence was subtracted from each reading and the resulting values are shown relative to a 
buffer-only control 
The four complexes indicated that they possessed interesting activity against this cell 
lines. IC50 values were calculated as 2.203µg/ml (Complex 72a), 2.36µg/ml (Complex 
73b), 2.18 (complex 74b), and 3.06µg/ml (Complex 75b). The result indicated that these 
new complexes showed toxicities in the micro molar range against HepG2 human cancer 


























    
 
CHAPTER III. Conclusions and Future work 
III.1.Conclusions 
A novel series of acridine ligands bearing different substituents were successfully 
synthesised by optimisation of a modified method first outlined by Wrόbel. Through 
altering the method as well as the purification sequence, the yield was improved to 92%. 
The reaction time was also reduced from six days to less than 48 hours. The complexation 
protocol to form gold (I) cationic complexes has been optimised. Some complexes gave 
good crystals and were characterised by x-ray analysis to determine the coordination 
environment of the gold atom.  X-ray studies revealed that complex 49 was the only 
regioisomer while the other complexes were not. 
 Cell viability assays demonstrated that some of the complexes showed toxicities in the 
micromolar range against the hepatocarcinoma cell line HepG2. The fluorescence 
properties will allow future studies to establish subcellular interactions between the 
complex and target/non-target cells. 
Five new monocationic pyrazolium gold complexes were prepared in excellent yields and 
the substitution pattern did not seem to have a notable effect on their activity against the 
cancer cell line described herein. This flexibility in the design is desirable when fine-
tuning structural motifs for druggable applications. The regioselectivity of the 
complexation was found to be dependent on the substitution pattern on the endocyclic 
nitrogen N1, favouring the complexation of the nitrogen proximal to the 5-amino group 
when R1 = H. 
All compounds are highly active against HepG2 cancer cells and display activity in the 
submicromolar range comparable to the previous work on gold complexes and breast 
cancer cell lines.79 Furthermore their efficacy compares well to other chemotherapeutic 
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drugs on this cell line318 including Doxorubicin (IC50 1.1 μM) and Cisplatin (IC50 15.9 
μM) Hepatocellular carcinomas readily acquire resistance to chemotherapeutic drugs – 
usually through the expression of a multidrug efflux pump. It is unknown whether these 
mechanisms would prevent the action of the gold amides or whether they have potential 
in treating resistant cells. This work therefore provides strategic tools to investigate such 
avenues of research. 
Investigation of the reactivity of gold(I) with triphenyl phosphine and trihexyl phosphine 
provided an insight into the behaviour of cationic gold(I) in solution. It showed that the 
exchange of ligands could be observed at low temperature (-80 oC) with maximum 
coordination numbers revealed.  
The photophysical properties of substituted acridine ligands and their complexes have 
been studied. The substituted acridine functionalised by small electronically active groups 
showed a hypsochromic shift to shorter wavelengths when the conjugated π system is 
electron deficient and bathochromic shift to longer wavelengths when the delocalised ring 
bore EDG and EWG. 
The susbstituent effects on absorption and fluorescence properties of acridine derivatives 
were investigated by considering changes in the behaviour on the basis of the position of 
single substitution, double substitution and multiple substitution and the electron 
donating/ withdrawing properties of the substituted acridine. 
Investigations into the effect of halogen substituents indicated a similar trend in the 
excitation and emission wavelengths. The addition of methoxy group lead to 
bathochromic shift which showed a great effect on the Stoke’s shift of the acridine 
derivatives. The position of the substitution and the nature of the substituent has a great 
impact on the stoke’s shift and the quantum yield of the compounds. 
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Novel pyrazole bearing Ag(I) and acridine bearing Ag(I) complexes were also 




















    
 
III.2.Future work 
Fluorescent gold complexes as diagnostic tools for cancer and tuberculosis. 
Description 
The focus here would be on validation with in vitro and in vivo testing on human cancer 
cell lines other than liver cancer cell lines. 
Role of the ligands and deligation on the activity of the complexs: Fluorescence and 
confocal spectroscopy.  
Investigation of fluorescent shift in solution with various solvents and various aurophilic 
molecule 
Catalytic activities of fluorescence gold complexes 
Description: 
Investigation into the connectivity of fluorescent gold complexes to different substrates  
Investigation into their reactivity and stabilities 
Study the influence of electron donating and electron withdrawing group on the reactivity 
and yield of reactions promoted by fluorescent gold complexes. 
Exemplification of the catalytic activity on key transformations. 






    
 
CHAPTER IV. Experimental  
IV.1 Methods and Materials 
The starting materials and solvents were used without further purification from 
commercially available sources unless otherwise stated. All reactions were conducted 
using oven-dried glassware, a nitrogen atmosphere and Schlenk techniques, unless stated 
otherwise. The solutions of silver(I) salts and the mixtures of silver(I) salt and gold(I) 
were protected/ shielded from the light until the filtration of the residual silver chloride. 
The NMR were recorded on a Varian 400 (400 MHz) or Varian 600 (600 MHz). Chemical 
shifts were reported in parts per million (ppm) referenced to residual solvent resonances 
or external 85% H3PO4 as appropriate. The IR spectra were recorded on a Perkin Elmer 
Spectrum One FT-IR spectrometer, equipped with a diamond top plate. Mass spectra were 
obtained using VG Autospec Magnetic Sector MS and Bruker Daltonic FT-ICR-MS 
Apex III 4.7 Tesla instruments, using electrospray ionisation (ESI). 
For the X-ray data acquisition, a selected crystal was placed on an Xcalibur, Eos, and 
Gemini ultra-diffractometer. The crystal was kept at 173.0 K during data collection. Using 
Olex2, the structure was solved with the ShelXT structure solution program using Direct 
Methods and refined with the ShelXL refinement package using Least Squares 
minimisation. 
IV.2. General Procedure for the Synthesis of Acridines 7-37. 
 The Corresponding nitrobenzene (0.63 mmol) and benzylcyanide (0.64 mmol) were 
dissolved in THF (4.7 mL) and the solution cooled to −78 ˚C under nitrogen. A solution 
of t-BuOK (100.9 mg, 0.9 mmol) in THF (1.6 mL) was slowly added at this temperature. 
The solution was stirred for 10 minutes before a solution of t-BuMe2SiCl (473.3 mg, 3.14 
mmol) in THF (1.6 mL) was added. The reaction mixture was stirred for a further 20 
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minutes and a solution of t-BuOK (100.0 mg, 0.9 mmol) in THF (1.6 mL) was 
subsequently added. The dark orange solution was allowed to warm up to the room 
temperature and stirred for 42 hours to give a yellow orange solution which was 
concentrated under reduced pressure. Methanol was added and then heated to recrystallise 
the product. The yellow solid, which was insoluble in methanol, was filtered under 
vacuum to separate it from dark brown solution of impurities. CH2Cl2 was added to 
dissolve the yellow solid product. Then, the solution was filtered under vacuum to remove 
the white KCl impurities. The yellow filtrate solution was concentrated on the rotary 
evaporator. Ethyl acetate was added to recrystallize the yellow product, which was placed 
in a sonic bath for five minutes to obtain a yellow homogeneous suspension and it was 
filtered under vacuum to give the required product as a solid. 
2-chloroacridine-9-carbonitrile 7 
 
Bright yellow solid. (118.6 mg, 79 %). 
MP: 209.5-211.5 0C. Lit242 mp  208-210 0C  
1H NMR (500 MHz, Chloroform-d) δ 8.33 – 8.39 (m, 2H), 8.23 – 8.34 (m, 2H), 7.91 
(ddd, J = 8.8, 6.6, 1.4 Hz, 1H), 7.77 – 7.84 (m, 2H). 
 13C NMR (126 MHz, Chloroform-d) δ 148.4 (13-C), 146.6 (11-C), 135.7 (2-C), 132.4 
(3-CH), 132.1 (12-C), 131.2 (6-CH), 130.5 (4-CH), 129.8 (5-CH), 126.4 (10-C), 126.3 
(8-CH), 125.1 (7-CH), 123.6 (1-CH), 114.6 (9-C), 114.3 (14-C). 
MS (EI) m/z: 238 (100), 203 (17), 176 (12). 
 HRMS (ESI) Calculated for C14H8ClN2:239.0371. Found 239. 0372. Error: -0.75 ppm 
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 IR (diamond, cm-1):3060.32 (aromatic C-H), 2222.39 (CN), 1608.76 (C=C).  
2-bromoacridine-9-carbonitrile 8 
 
Yellow solid. (106.2 mg, 75 %). 
MP: 212.6-214.8 0C. Lit242  mp 212-214 0C   
1H NMR (500 MHz, Chloroform-d) δ 8.55 (q, J = 2.0 Hz, 1H), 8.33 – 8.40 (m, 1H), 
8.31 (ddd, J = 8.5, 2.5, 1.1 Hz, 1H), 8.15 – 8.22 (m, 1H), 7.93 (ddt, J = 11.9, 8.2, 2.0 Hz, 
2H), 7.77 – 7.85 (m, 1H). 
 13C NMR (126 MHz, Chloroform-d) δ 148.4 (13-C), 146.7 (11-C), 134.8 (3-CH), 131.9 
(6-CH), 131.3 (12-C), 130.5 (4-CH), 129.8 (5-CH), 127.1 (8-CH), 126.8 (7-CH), 126.3 
(10-C), 125.2 (1-CH), 124.1 (2-C), 114.7 (9-C), 114.3 (14-C). 
MS (EI) m/z: 284 (100), 282 (98), 203 (42) 176(37) 88 (14). 
 HRMS (ESI) Calculated for C14H7BrKN2:320.9424. Found: 320.0938. Error: -4.33 ppm 
 IR (diamond, cm-1): 3055.50 (aromatic C-H), 2221.37 (CN), 1604.68 (aromatic C=C). 
2-chloro-6-methoxyacridine-9-carbonitrile 9 
 
Yellow solid. (123.6 mg, 73 %). 
MP: 216.1-218.10C.  
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1H NMR (500 MHz, Chloroform-d) δ 8.28 (d, J = 2.2 Hz, 1H), 8.19 (dd, J = 14.9, 9.2 
Hz, 2H), 7.78 (dd, J = 9.1, 2.2 Hz, 1H), 7.42 – 7.52 (m, 2H), 4.04 (s, 3H) 
 13C NMR (126 MHz, Chloroform-d) δ 162.0 (6-C), 150.1 (13-C), 146.7 (11-C), 
134.1(2-C), 132.3 (3-CH), 131.2 (12-C), 126.1 (8-CH), 125.4 (4-CH), 124.8 (10-C), 
123.64 (1-CH), 122.9 (7-CH), 114.6 (9-C), 114.2 (14-C), 105.9 (5-CH), 55.9 (15-CH3).  
MS (EI) m/z: 268 (100), 270 (37), 225 (52) 227 (22).  
HRMS (ESI) Calculated for C15H10ClN20: 269.0476. Found: 269.0484.Error: -2.89 ppm. 




Yellow solid. (109.0 mg, 68 %).  
MP: 240.1-241.1 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.34 – 8.43 (m, 2H), 8.26 (d, J = 9.3 Hz, 1H), 
7.94 (dd, J = 9.6, 2.4 Hz, 1H), 7.85 (dd, J = 9.2, 2.2 Hz, 1H), 7.60 – 7.68 (m, 1H). 
  13C NMR (126 MHz, Chloroform-d) δ 163.8 (d, J = 257.0 Hz,) (6-C), 149.0 (13-C), 
147.2 (11-C), 135.6 (2-C), 133.1 (3-CH), 131.6 (8-CH), 127.7 (12-C), 126.0 (4-CH), 
125.8 (10-C), 123.7 (1-CH), 121.9 (7-CH), 115.0 (9-C), 114.3 (14-C), 113.0(5-CH). 
MS (EI) m/z: 256 (100), 221 (20), 91 (12 
 HRMS (ESI) Calculated for C14H7ClFN2:257.0276. Found: 257.0289. Error: -4.86 ppm 
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 IR (diamond, cm-1): 2222.58 (CN), 1627.35 (aromatic C=C).  
2-bromo-6-methoxyacridine-9-carbonitrile 11 
 
Yellow solid. (128.2 mg, 82 %). 
 MP: 216.9 -219 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.49 (d, J = 2.0 Hz, 1H), 8.22 (d, J = 9.3 Hz, 
1H), 8.10 (d, J = 9.2 Hz, 1H), 7.91 (dd, J = 9.2, 2.0 Hz, 1H), 7.44 – 7.53 (m, 2H), 4.05 (s, 
3H). 
 13C NMR (126 MHz, Chloroform-d) δ 162.3 (6-C), 146.5 (13-C), 134.9 (3-C), 130.9 
(8-CH), 127.2 (12-C), 127.2 (4-CH), 126.2 (10-C), 125.6 (1-CH), 125.3 (2-C), 123.0 (7-
CH), 122.5 (9-C), 114.6 (14-C), 105.7 (5-CH), 55.9 (15-CH3). 
MS (EI) m/z: 312 (100), 226 (76), 190 (25), 78 (18).313 (17). 
HRMS (ESI) Calculated for C15H10BrN2O:312.9971. Found: 312.9984. Error: -4.15ppm 
 IR (diamond, cm-1): 2956.20 (saturated CH) 2224.99 (CN), 1628.75 (aromatic C=C), 
1289.47 (C-O).  
2-bromo-6-fluoroacridie-9-carbonitrile 12  
 
Yellow solid. (131.3 mg, 87 %). 
MP: 230.9-232.9 0C.  
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1H NMR (500 MHz, Chloroform-d) δ 8.55 (d, J = 2.1 Hz, 1H), 8.40 (dd, J = 9.4, 5.8 
Hz, 1H), 8.16 (d, J = 9.2 Hz, 1H), 7.94 (dd, J = 9.4, 2.3 Hz, 2H), 7.64 (ddd, J = 9.4, 7.8, 
2.5 Hz, 1H). 
 13C NMR (126 MHz, Chloroform-d) δ 163.8 (d, J = 257.0 Hz,) (6-C), 149.2 (13-C), 
147.4 (11-C), 135.4 (4-CH), 131.6 (8-CH), 127.7 (12-C), 127.6 (4-CH), 126.2 (10-C), 
124.0 (1-CH), 123.6 (2-C), 121.7 (7-CH), 114.8 (9-C), 114.4 (14-C), 113.1 (5-CH).  
MS (EI) m/z: 300 (100), 221 (30), 194 (18), 301 (17). 
HRMS (ESI) Calculated for C14H7N2FBr:300.9777. Found: 300.9772. Error: -.5 ppm 
 IR (diamond, cm-1): 3028.15 (aromatic CH) 2224.57 (CN), 1628.12 (aromatic C=C). 
2, 6-dichloroacridine-9-carbonitrile 13 
 
Yellow solid. (115.2 mg, 84 %). 
 MP: 226.4-228.4 0C  
1H NMR (500 MHz, Chloroform-d) δ 8.34 – 8.46 (m, 1H), 8.29 – 8.34 (m, 2H), 8.27 
(d, J = 9.3 Hz, 1H), 7.85 (dd, J = 9.3, 2.2 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H). 
 13C NMR (126 MHz, Chloroform-d) δ 148.2 (13-C), 147.3 (11-C), 137.7 (6-C), 136.0 
(2-C), 133.1 (3-CH), 132.0 (12-C), 131.1 (8-CH), 128.9 (4-CH), 126.4 (5-CH), 126.2 (10-
C), 124.79 (7-CH), 123.7 (1-CH), 114.8 9-C), 114.3 (14-C).  
MS (EI) m/z: 272 (100), 274 (67), 202 (25). 
HRMS (ESI): Calculated for C14H7Cl2N2:272.9986. Found: 272.9986. Error: -0ppm  
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 IR (diamond, cm-1): 3070.83 (aromatic CH), 2226.94 (CN), 1616.23 (aromatic C=C). 
 2-iodoacridine-9-carbonitrile 14 
 
Bright yellow solid. (497.4 mg, 75 %). 
MP 225.3-228.3 0C. 
 1H NMR (600 MHz, Chloroform-d) δ 8.76 (d, J = 1.7 Hz, 1H), 8.35 (d, J = 8.6 Hz, 
1H), 8.27 (d, J = 8.8 Hz, 1H), 8.08 (dt, J = 9.2, 1.4 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1H), 7.91 
(ddd, J = 8.8, 6.6, 1.2 Hz, 1H), 7.79 (ddd, J = 7.9, 6.7, 1.2 Hz, 1H). 
 13C NMR (151 MHz, Chloroform-d) δ 148.5 (13-C), 146.6 (11-C), 139.8 (3-CH), 133.9 
(1-CH), 131.6 (4-CH), 131.4 (12-C), 130.5 (10-C), 129.6 (6-CH), 127.2 (5-CH), 126.1 
(8-CH), 125.2 (7-CH), 114.7 (9-C), 114.0 (14-C), 96.2 (2-C). 
 HRMS (ESI) Calculated for C14H8IN2:330.12. Found: 330.9727. Error: 0.4 ppm 
 IR (diamond, cm-1): 3049.06 (aromatic H), 2220.45 (CN), 1597.17cm-1 (aromatic C=C). 
7-chloro-2, 3, 4-trimethoxyacridine-9-carbonitrile 15 
 
Yellow solid. (189.8 mg, 92 %). 
 MP: 210.7-212.7 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.24 – 8.33 (m, 2H), 7.69 – 7.76 (m, 1H), 7.26 
(d, J = 6.6 Hz, 1H), 4.26 (s, 3H), 4.11 – 4.18 (m, 6H).  
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13C NMR (126 MHz, Chloroform-d) δ 156.7 (2-C), 146.9 (13-C), 145.9 (4—C), 144.1 
(11-C), 141.9 (7-C), 135.1 (6-CH), 132.3 (3-C), 130.9 (12-C), 125.9 (5-CH), 125.5 (10-
C), 123.0 (8-CH), 115.3 (9-C), 111.2 (14-C), 96.8 (1-CH), 62.5 (17-CH3), 61.7 (16-CH3), 
56.5 (15-CH3). 
MS (EI) m/z: 313 (100), 328 (33), 299 (27), 330 (17) 164 (12). 
 HRMS (ESI): Calculated for C17H14ClN2O3:329.0687. Found: 329.0696. Error:-2.51 
ppm. 
 IR (diamond, cm-1): 2940.08 (saturated CH) 2219.23 (CN), 1621.76 (aromatic C=C), 
1289.80 (C-O). 
7-iodo-2, 3, 4-trimethoxyacridine-9-carbonitrile 16 
 
Bright yellow solid. (655.5 mg, 78 %). 
 MP: 232.2-233.2 0C 
 1H NMR (600 MHz, Chloroform-d) δ 8.68 (d, J = 1.7 Hz, 1H), 8.06 (d, J = 9.1 Hz, 
1H), 8.01 (dt, J = 9.1, 1.4 Hz, 1H), 7.26 (d, J = 2.8 Hz, 1H), 4.24 (s 3H), 4.11 – 4.17 (m, 
6H). 
 13C NMR (126 MHz, Chloroform-d) δ 156.6 (2-C), 146.6 (13-C), 146.3 (4-C), 144.1 
(11-C), 141.7 (6-CH), 138.7 (8-CH), 133.2 (3-C), 131.6 (5-CH), 126.8 (12-C), 125.3 (10-




    
 
 HRMS (ESI): Calculated for C17H14IN203:421.0044. Found: 421.0055. Error: -2.63 
ppm.  




Orange solid. (615.3 mg, 85 %). 
 MP: 235.6-238.6 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.73 (d, J = 1.8 Hz, 1H), 8.23 (d, J = 9.3 Hz, 
1H), 8.07 (dd, J = 9.1, 1.8 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.44 – 7.51 (m, 2H), 4.05 (s, 
3H).   
13C NMR (126 MHz, Chloroform-d) δ 162.2 (13-C), 150.3 (6-C), 147.0 (11-C), 
139.8(3-CH), 133.9 (1-CH), 130.9 (4-CH), 126.2 (12-C), 125.8 (10-C), 125.4 (8-CH), 
122.7 (7-CH), 114.7 (9-C), 113.8 (14-C), 106.0 (5-CH), 94.1 (2-C), 55.9 (15-CH3).  
HRMS (ESI): Calculated for C15H10IN2O:360.9832. Found: 360.9842. Error: -2.82 ppm.  










Orange solid. (627.8 mg, 90 %). 
MP: 247.8-249.8 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.79 (d, J = 1.8 Hz, 1H), 8.40 (dd, J = 9.4, 5.8 
Hz, 1H), 8.09 – 8.15 (m, 1H), 8.00 (d, J = 9.2 Hz, 1H), 7.91 (dd, J = 9.6, 2.5 Hz, 1H), 
7.63 (ddd, J = 9.7, 7.9, 2.5 Hz, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 149.2 (13-C), 147.6 (11-C), 140.4 (3-CH), 134.0 
(1-CH), 131.3 (8-CH), 127.8 (4-CH), 126.7 (12-C), 123.4 (10-C), 121.9 (7-CH), 121.7 
(9-C), 114.5 (14-C), 113.1 (5-CH), 95.9 (2-C).   
HRMS (ESI): Calculated for C14H7FIN2:348.9632. Found: 348.9636. Error: 1.0 ppm. 




Orange yellow solid. (169.9 mg, 91 %). 
MP: 223.6-225.6 0C. 
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 1H NMR (500 MHz, Chloroform-d) δ 8.47 (d, J = 2.0 Hz, 1H), 8.34 (d, J = 9.1 Hz, 
1H), 7.88 (dd, J = 9.2, 2.1 Hz, 1H), 7.28 (s, 1H), 4.27 (s, 3H), 4.12-4.15 (m, 6H).  
13C NMR (126 MHz, Chloroform-d) δ 156.7 (2-C), 146.8 (13-C), 146.0 (11-C), 144.1 
(4-C), 141.9 (6-CH), 133.4 (3-C), 132.1 (12-C), 126.5 (5-CH), 126.4 (10-C), 125.4 (8-
CH), 123.5 (7-C), 115.2 (9-C), 111.1 (14-C), 96.8 (1-CH), 62.5 (17-CH3), 61.7 (16-CH3), 
56.6 (15-CH3). 
MS (EI) m/z: 357 (100), 359 (97) 69 (44), 219 (35), 374 (32), 373 (22). 
 HRMS (ESI) Calculated for C17H14BrN2O3: 373.0182. Found: 373.0193. Error:-2.93 
ppm. 




Pale yellow solid. (602.5 mg, 77 %). 
Procedure 2: 
MP: 231.0-233.0 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.67 (t, J = 1.4 Hz, 1H), 8.01 (dt, J = 9.0, 1.4 Hz, 




    
 
 13C NMR (126 MHz, Chloroform-d) δ 155.1 (3-C), 153.8 (2-C), 146.9 (13-C), 145.2 
(11-C), 138.6 (6-CH), 133.4 (8-CH), 130. 9 (5-CH), 126.1 (12-C), 124.5 (10-C), 115.3 
(9-C), 110.4 (14-C), 107.0 (1-CH), 101.0 (4-CH), 94.19 (7-C), 56.7 (16-CH3), 56. 6 (15-
CH3). 
 HRMS (ESI) Calculated for C16H12IN2O2 :390.9938. Found: 390.9944. Error: -1.58 
ppm.  
 IR (diamond, cm-1): 3090.06 (aromatic H), 2940.05 (saturated CH), 2165.54 (CN), 
1622.80 (aromatic C=C). 
7-chloro-2, 3-dimethoxyacridine-9-carbonitrile 21 
 
Deep yellow solid. (147.2 mg, 78 %). 
 MP: 263.0-265.0 0C. Lit mp 262-263 0C 
 1H NMR (500 MHz, Chloroform-d) δ 8.24 – 8.31 (m, 2H), 7.77 (dt, J = 9.2, 1.7 Hz, 
1H), 7.64 (s, 1H), 7.40 (d, J = 1.2 Hz, 1H), 4.11-4.15 (m, 6H). 
 13C NMR (151 MHz, Chloroform-d) δ 155.7 (3-C), 153.8 (2-C), 145.5 (13-C), 143.3 
(11-C), 134.4 (7-C), 131.7 (6-CH), 129.9 (12-C), 125.0 (5-CH), 124.8 (10-C), 123.3 (8-
CH), 123.2 (9-C), 114.8 (14-C), 105.8 (1-CH), 100.8 (4-CH), 56.7 (16-CH3), 56.7 (15-
CH3). 
MS (EI) m/z: 298 (100), 255 (23), 212 (15) 
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  HRMS (ESI): Calculated for C16H12ClN202:299.0582. Found: 299.0582 Error: 0.05 
ppm.  
 IR (diamond, cm-1): 3009.87 (aromatic H), 2946.16 (saturated CH), 2225.90 (CN), 
1625.66 (aromatic C=C).  
6-bromo-2-chloroacridine-9-carbonitrile 22 
 
Deep yellow solid. (163.5 mg, 82 %).  
MP: 261.0-263.0 0C. Lit242. mp 260.0 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.54 (t, J = 1.5 Hz, 1H), 8.36 (t, J = 1.6 Hz, 1H), 
8.25 (dd, J = 13.7, 9.1 Hz, 2H), 7.86 (ddt, J = 12.6, 9.2, 1.6 Hz, 2H).  
13C NMR (151 MHz, Chloroform-d) δ 148.3 (13-C), 147.1 (11-C), 136.1 (2-C), 133.4 
(3-CH), 133.2 (5-CH), 132.4 (7-H), 132.0 (8-CH), 126.3 (4-CH), 126.1 (11-C), 124.8 (6-
C), 123.7 (1-CH), 114.8 (9-C), 114.3 (14-C). 
MS (EI) m/z: 318 (100), 316 (75), 202 (45), 237 (20). 
HRMS (ESI): Calculated for C14H7BrClN2:316.9476. Found: 316.9490. Error: -2.96 
ppm. 
 IR (diamond, cm-1): 3067.79 (aromatic H), 2225.98 (CN), 1612.84 (aromatic C=C). 




    
 
Orange yellow solid. (136.8 mg, 80 %). 
 MP: 217.8-219.8 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.50 (d, J = 2.0 Hz, 1H), 8.31 (s, 1H), 7.94 (d, J 
= 8.9 Hz, 1H), 7.77 (s, 1H), 7.44 (s, 1H),), 4.15-4.17 (m, 6H). 
 13C NMR (151 MHz, Chloroform-d) δ 155.6 (3-C), 153.9 (2-C), 133.9 (6-CH), 130.2 
(12-C, 5-CH), 126.7 (10-C), 125.5 (8-CH), 124.8 (7-C), 122.7 (9-C), 115.0 (14-C), 106.2 
(1-CH), 100.9 (4-CH), 56.7 (16-CH3), 56.7 (15-CH3).
  
MS (EI) m/z: 344 (100), 192 (30), 299 (23), 256 (17). 
 HRMS (ESI) Calculated for C16H12BrN2O2:343.0077. Found: 343.0069. Error: 2.14 
ppm. 
 IR (diamond, cm-1):   2227.46 (CN), 1616.18 (aromatic C=C). 
6-methoxy-2-(methylthio)acridine-9-carbonitrile 24 
 
Yellow solid.  (138.5 mg, 84 %). 
MP: 214.7-216.7 0C. 
  1H NMR (500 MHz, Chloroform-d) δ8.18 (d, J = 9.3 Hz, 1H), 8.06 (d, J = 9.1 Hz, 
1H), 7.81 (d, J = 2.1 Hz, 1H), 7.66 (dd, J = 9.1, 2.1 Hz, 1H), 7.47 (d, J = 2.5 Hz, 1H), 
7.42 (dd, J = 9.3, 2.5 Hz, 1H), 4.02 (s, 3H), 2.69 (s, 3H). 
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 13C NMR (126 MHz, Chloroform-d) δ 161.4 (6-C), 140.8 (11-C), 131.0 (2-C), 129.3 
(8-CH), 126.0 (12-C), 125.3 (10-C), 125.3 (4-CH), 124.7 (3-CH), 122.7 (1-CH), 117.0 
(7-CH), 115.3 (9-C), 110.0 (14-C), 106.0 (5-CH), 55.8 (16-CH3), 15.1 (15-CH3). 
 HRMS (ESI): Calculated for C16H13N2OS:281.0743. Found 281.0743 Error -0.O5 ppm. 




Yellow solid. (129.8 mg, 82 %). 
MP: 190.2-193.20C.  
1H NMR (500 MHz, Chloroform-d) δ 8.34 (dd, J = 9.4, 5.8 Hz, 1H), 8.11 (d, J = 9.2 
Hz, 1H), 7.88 (dd, J = 9.7, 2.5 Hz, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.70 (dt, J = 9.2, 1.4 Hz, 
1H), 7.53 – 7.62 (m, 1H), 2.71 (s, 3H). 
 13C NMR (126 MHz, Chloroform-d) δ 163.2 (d, J = 254.4 Hz,) (6-C), 147.7 (13-C), 
142.6 (11-C), 131.5 (2-C), 129.7 (8-CH), 127.3 (12-C), 126.2 (10-C), 123.5 (4-CH), 
121.1 (1-CH), 120.9 (7-CH), 116.3 (9-C), 115.0 (14-C), 112.8 (5-CH), 14.9 (15-CH3). 
HRMS: (ESI) Calculated for C15H10N2FS:269.0543. Found: 269.0546. Error -1.11 ppm. 








Yellow solid. (131.6 mg, 78 %). 
MP: 207.9-210.9 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.23 (d, J = 8.4 Hz, 2H), 8.08 (d, J = 9.0 Hz, 1H), 
7.77 (s, 1H), 7.64 – 7.71 (m, 2H), 2.70 (s, 3H).  
 13C NMR (126 MHz, Chloroform-d) δ 147.7 (13-C),  147.0 (11-C),  143.2 (6-C),  136.4 
(2-C) , 131.5 (8-CH), 130.5 (5-CH), 130.0 (12-C), 128.9 (7-CH), 126.6 (10-C), 126.2 (4-
CH), 124.6 (3-CH), 116.2 (1-CH), 114.9 (9-C), 112.4 (14-C), 14.9 (15-C). 
 HRMS: (ESI) Calculated for C15H10N2ClS:285.0248.Found:285.0250.  Error -0.75 ppm. 
 IR (diamond, cm-1): 3055.51 (aromatic H), 2221.95 (CN), 1626.19 (aromatic C=C). 
2,3,4-trimethoxy-7-(methylthio)acridine-9-carbonitrile 27 
 
Yellow solid. (158.7 mg, 79 %). 
 MP: 207.5-209.5 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.18 (d, J = 9.1 Hz, 1H), 7.78 (d, J = 2.0 Hz, 
1H), 7.60 (dd, J = 9.1, 2.1 Hz, 1H), 7.23 (s, 1H), 4.24 (s, 3H), 4.12 (s, 3H), 4.11 (s, 3H) 
2.69 (s, 3H). 
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 13C NMR (126 MHz, Chloroform-d) δ 156.2 (2-C), 147.1 (13-C), 145.0 (4-C), 144.4 
(11-C),  141.8 (7-C), 140.5 (3-C), 130.4 (12-C), 129.3 (10-C), 126.3 (5-CH), 125.3 (6-
CH), 116.3 (8-CH), 115.8 (9-C), 110.0 (14-C), 96.85 (1-CH), 62.43 (17-CH3), 61.68 (16-
CH3), 56.48 (15-CH3), 15.03 (18-CH3).   
HRMS: (ESI) Calculated for C18H17N2O3S:341.0954. Found: 341.0956.  Error -0.36 
ppm.   
IR (diamond, cm-1): 2938.39 (saturated CH) 2219.42 (CN), 1600.77 (aromatic C=C). 
6-fluoro-2-methoxyacridine-9-carbonitrile 28 
 
Yellow solid. (129.4 mg, 87 %). 
MP: 191.8-193.8 0C.  
 1H NMR (500 MHz, Chloroform-d) δ 8.30 (dd, J = 9.5, 5.8 Hz, 1H), 8.12 (d, J = 9.5 
Hz, 1H), 7.86 (d, J = 9.7 Hz, 1H), 7.51 – 7.60 (m, 2H), 7.40 (s, 1H), 4.06 (s, 3H). 
13C NMR (126 MHz, Chloroform-d) δ162.8 (d, J = 254.5 Hz,) (6-C), 159.8 (2-C), 146.4 
(13-C), 131.7 (11-C), 127.5 (8-CH), 127.3 (4-CH), 127.0 (12-C), 123.4 (10-C), 120.9 (3-
CH), 120.7 (7-CH), 115.3 (9-C), 113.0 (14-C), 112.8 (5-CH), 100.3 (1-CH), 56.0 (15-
CH3). 
  HRMS: (ESI) Calculated for C15H10N2OF:253.0772. Found: 253.0776.  Error -1.56 
ppm.  
IR (diamond, cm-1):  2224.87 (CN), 1626.23 (aromatic C=C). 
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Yellow solid. (157.2 mg, 90 %). 
MP: 219.2-221.2 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.23 – 8.30 (m, 2H), 8.15 (d, J = 9.4 Hz, 1H), 
7.69 (dd, J = 9.1, 2.1 Hz, 1H), 7.56 (dd, J = 9.5, 2.7 Hz, 1H), 7.43 (d, J = 2.7 Hz, 1H), 
4.07 (s, 3H). 
 13C NMR (126 MHz, Chloroform-d) δ 160.2 (2-C), 148.7 (13-C), 146.2 (11-C), 135.6 
(6-C), 131.9 (8-CH), 130.2 (4-CH), 128.8 (10-C), 127.9 (5-CH), 127.2 (7-CH), 125.8 (3-
CH), 124.4 (9-C), 115.1 (14-C), 100.2 (1-CH), 56.0 (15-CH3). 
 HRMS: (ESI) Calculated for C15H10N2OCl:269.0476. Found 269.0479. Error -1.09 
ppm. 
 IR (diamond, cm-1): 3077.37 (aromatic H), 2222.69 (CN), 1630.27 (aromatic C=C). 
2, 3, 7-trimethoxyacridine-9-carbonitrile 30 
 
Yellow solid. (168.3 mg, 88 %). 
MP: 218.6-220.6 0C. 
 1H NMR (600 MHz, Chloroform-d) δ 8.35 – 8.40 (m, 1H), 7.81 (s, 1H), 7.52 (d, J = 
9.3 Hz, 1H), 7.35 (d, J = 16.5 Hz, 2H), 4.11-4.13 (m, 6H), 4.04 (s, 3H).  
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 13C NMR (151 MHz, Chloroform-d) δ 159.7 (7-C), 155.7 (3-C), 153.7 (2-C), 127.7 (5-
CH), 126.7 (12-C), 126.5 (10-C), 124.8 (6-CH), 115.0 (14-C), 103.8 (1-CH), 101.0 (4-
CH), 100.8 (8-CH), 57.0 (16-CH3), 56.7 (15-CH3), 56.0 (17-CH3). 
  HRMS: (ESI) Calculated for C17H15N2O3:295.1077. Found 295.1074. Error: 0.98 ppm. 
 IR (diamond, cm-1): 3021.91 (aromatic H), 2183.38 (CN), 1618.59(aromatic C=C). 
6-bromo-2-methoxyacridine-9-carbonitrile 31 
 
Yellow solid. (179.6 mg, 88 %). 
MP: 218.7-221.7 0C 
. 1H NMR (500 MHz, Chloroform-d) δ 8.45 (d, J = 1.8 Hz, 1H), 8.14 (t, J = 8.9 Hz, 2H), 
7.79 (dt, J = 9.1, 1.5 Hz, 1H), 7.55 (ddd, J = 9.5, 2.6, 1.2 Hz, 1H), 7.39 (d, J = 2.6 Hz, 
1H), 4.06 (d, J = 1.3 Hz, 3H). 
  13C NMR (126 MHz, Chloroform-d) δ 160.2 (2-C), 146.4 (13-C), 146.2 (11-C), 132.5 
(5-CH), 132.3 (7-CH),  132.0 (8-CH), 128.0 (4-CH), 127.3 (12-C), 125.8 (10-C), 124.6 
(6-C), 123.9 (3-CH), 115.1 (9-C), 112.5 (14-C), 100.2 (1-CH), 56.1 (15-CH3). 
 HRMS: (ESI) Calculated for C15H10N2OBr:312.9971. Found 312.9976. Error -1.46 
ppm.  
 IR (diamond, cm-1): 3079.5 (aromatic H), 2937.15 (saturated CH) 2221.98 (CN), 
1630.45cm (aromatic C=C). 
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2, 3-dimethoxy-7-(methylthio)acridine-9-carbonitrile 32 
 
Yellow solid. (156.8 mg, 86 %) 
.MP: 216.9-217. 9 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.02 (d, J = 9.1 Hz, 1H), 7.63 (s, 1H), 7.55 (d, J 
= 9.1 Hz, 1H), 7.46 (s, 1H), 7.23 (s, 1H), 4.12 (s, 3H), 4.07 (s, 3H), 2.66 (s, 3H).  
 13C NMR (151 MHz, Chloroform-d) δ 154.7(3-C), 153.3 (2-C), 143.9 (13-C), 141.2 
(11-C), 130.1 (7-C), 127.9 (12-C), 125.2 (10-C, 5-CH), 124.2 (6-CH), 116.5 (8-CH), 
115.3 (9-C), 110.1 (14-C), 105.8 (1-CH), 100.9 (4-CH), 56.7 (16-CH3), 56.6 (15-CH3), 
14.9 (17-CH3).  
 HRMS: (ESI) Calculated for C17H15N2O2S:311.0849. Found: 311.0850. Error -0.27 
ppm. 
  IR (diamond, cm-1): 2991.17 (saturated CH) 2181.58 (CN), 1612.81 (aromatic C=C). 
6-bromo-2-(methylthio)acridine-9-carbonitrile 33 
 
Yellow solid. (156.5 mg, 81%). 
MP: 215.7-217.70C. 
 1H NMR (500 MHz, Chloroform-d) δ 8.41 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 9.0 Hz, 
1H), 8.06 (d, J = 9.1 Hz, 1H), 7.71 – 7.81 (m, 2H), 7.63 – 7.69 (m, 1H), 2.69 (s, 3H).  
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 13C NMR (126 MHz, Chloroform-d) δ 147.5 (13-C), 147.1 (11-C), 143.3 (2-C), 132.7 
(5-CH), 132.3 (7-CH), 131.4 (8-CH), 129.9 (12-C), 126.6 (10-C), 126.1 (4-CH), 125.0 
(3-CH), 124.7 (6-C), 116.21-CH), 114.9 (9-C), 112.4 (14-C), 14.9 (15-CH3). 
MS (EI) m/z: 328 (100), 329 (25), 269 (25). 313 (20) 
 HRMS: (ESI) Calculated for C15H10N2BrS:328.9743 Found: 328.9746. Error 1.0 ppm.  
IR (diamond, cm-1): 3054.61 (aromatic H), 2223.30 (CN), 1613.86 (aromatic C=C). 
Acridine-9-carbonitrile 34 
 
Yellow solid. . (137.8 mg, 83 %). 
MP:189.8-191.80C.Lit.242 mp: 186 oC. 
 1H NMR (500 MHz, Chloroform-d) δ 9.20 (d, J = 8.9 Hz, 2H), 8.59 (d, J = 8.7 Hz, 2H), 
8.25 (t, J = 7.8 Hz, 2H), 8.06 (t, J = 7.7 Hz, 2H).  
 13C NMR (126 MHz, Chloroform-d) δ 141.1 (13-C, 11-C), 136.5 (3-CH, 6-CH), 131.0 
(12-C, 10-C, 4-CH, 5-CH), 126.7 (2-CH, 7-CH), 125.7 (1-CH, 8-CH), 123.6 (9-C), 113.0 
(14-C).  
 HRMS: (ESI) Calculated for C14H9N2:205.0760. Found: 205.0749. Error 4.78 ppm. 





    
 
Yellow solid. (163.2 mg, 86 %). 
MP: 196.7-198. 7 0C. 
 1H NMR (500 MHz, Chloroform-d) δ 9.06 (d, J = 8.8 Hz, 1H), 8.50 (d, J = 8.6 Hz, 1H), 
8.38 – 8.46 (m, 2H), 8.19 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H), 7.93-8.00 (m, 1H), 7.63 (dd, J 
= 9.5, 2.3 Hz, 1H), 4.20 (s, 3H).  
 13C NMR (126 MHz, Chloroform-d) δ 167.1 (3-C), 143.3 (13-C), 139.5 (11-C), 136.7 
(6-CH), 129.7 (1-CH), 127.3 (12-C), 127.2 (10-C), 125.9 (5-CH), 124.2 (7-CH), 124.1 
(8-CH), 123.5 (2-CH), 121.7 (9-C), 112.7 (14-C), 98.4 (4-CH), 57.5 (15-CH3).   
HRMS: (ESI) Calculated for C15H11N2O:235.0866. Found: 235.0869. Error -1.34 ppm. 
 IR (diamond, cm-1): 2200.81(CN), 1624.50(aromatic C=C). 
3-fluoroacridine-9-carbonitrile 36 
 
Yellow solid. (148.6 mg, 83 %) 
.MP: 190.8-192.8 0C.  
1H NMR (500 MHz, Chloroform-d) δ 8.67 (d, J = 8.9 Hz, 1H), 8.44 – 8.54 (m, 2H), 
8.34 (d, J = 9.2 Hz, 1H), 8.04 – 8.11 (m, 1H), 7.91 (dd, J = 8.5, 6.8 Hz, 1H), 7.71 (ddd, J 
= 9.9, 7.7, 2.5 Hz, 1H).   
13C NMR (126 MHz, Chloroform-d) δ 164.0 (d, J = 257.4 Hz,) (3-C), 148.0 (13-C), 
132.3(11-C), 129.2 (1-CH), 129.1 (6-CH), 128.0 (12-C), 127.8 (10-C), 127.8 (5-CH), 
125.6 (7-CH), 123.5 (8-CH), 121.5 (2-CH), 121.3 (9-C), 114.5 (14-C), 112.2 (4-CH). 
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HRMS: (ESI) Calculated for C14H8N2F:223.0666. Found: 223.0661. Error 2.23 ppm. 
 IR (diamond, cm-1): 3037.20 (aromatic H), 2230.18 (CN), 1628.25 (aromatic C=C). 
3-chloroacridine-9-carbonitrile 37 
 
Yellow solid. (153.4 mg, 79 %). 
MP: 211.7-212. 7 0C 
1H NMR (500 MHz, Chloroform-d) δ 8.63 – 8.71 (m, 2H), 8.43 (dd, J = 22.0, 8.9 Hz, 
2H), 8.07 (t, J = 7.7 Hz, 1H), 7.88 – 7.95 (m, 1H), 7.79 – 7.85 (m, 1H). 
 13C NMR (126 MHz, Chloroform-d) δ 152.7 (13-C), 132.5 (3-C), 130.8 (6-CH), 129.7 
(1-CH), 129.4 (4-CH), 127.8 (12-C), 126.6 (2-CH), 126.1 (10-C, 5-CH, 7-CH), 125.4 (8-
CH), 124.5 (9-C), 114.4 (14-C).  
HRMS: (ESI) Calculated for C14H8N2Cl:239. 0371. Found: 239.0376. Error -2.24 ppm. 
 IR (diamond, cm-1): 3091.85 (aromatic H), 2223.92 (CN), 1635.21 (aromatic C=C). 
IV.3. General Procedure for the Synthesis of Compounds 41-61. 
AgClO4 (4.2 mg, 0.020 mmol, 1 equiv.) and Ph3PAuCl (10.0 mg, 0.020 mmol, 1 equiv.) 
were dissolved in methanol (0.5 mL), forming a white precipitate instantly.  The mixture 
was stirred for 30 minutes. 31P NMR of this intermediate was completed shifted at 27.5 
ppm. A solution of corresponding acridine (0.020 mmol, 1 equiv) in CH2Cl2 (0.6 ml,) was 
added to the solution of cationic gold prepared previously and stirred for 30 minutes. The 
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mixture was filtered over a glass microfiber filter placed in a syringe and into an NMR 
Schlenk flask, under nitrogen. Solution was dried under reduced pressure and CDCl3 (0.5 
mL) was added. 31P, 1H and13C NMR analysis were recorded with this solution. The 
material was concentrated under reduced pressure to obtain the title complex as solid. 
[Ph3PAu(2-chloroacridine-9-carbonitrile)ClO4] 41 
 
Greenish yellow solid (5.6 mg, 70 %). 
MP: 149.5-150.8 oC. 
 1H NMR (500 MHz, Chloroform-d) δ 9.09 (dd, J = 16.5, 9.1 Hz, 2H), 8.52 – 8.60 (m, 
2H), 8.30 (t, J = 7.9 Hz, 1H), 8.15 – 8.21 (m, 1H), 7.98 (t, J = 7.7 Hz, 1H), 7.55 – 7.66 
(m, 15H).  
 13C NMR (126 MHz, Chloroform-d) δ 146.5 (13-C), 135.8 (11-C), 134.2 (20-C, 26-C, 
32-C), 134.1 (2-C), 132.1 (15-CH, 19-CH,21-CH, 25-CH, 27-CH,31-CH) 131.96 (3-CH), 
132.0 (12-C), 131.7 (6-CH), 130.2 (4-CH), 130.0 (16-CH, 18-CH, 22-CH, 24-CH,28-CH, 
30-CH), 129.3 (17-CH, 23-CH, 29-CH), 129.2 (5-CH) 128.8 (10-C)  128.5 (8-CH)   126.6 
(7-CH), 125.2 (1-CH), 123.6 (9-C), 114.6 (14-C).  
 31P NMR (400 MHz, Chloroform-d) δ 33.00  
HRMS: (ESI) Calculated for C32H22AuClN2P
+:697.0869. Found: 697. 0843. Error: 3.71 
ppm 
  IR (diamond, cm-1): 2245.60 (CN), 1430.65 (PPh3), 616.27 (C-Cl). 
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[Ph3PAu(2-bromoacridine-9-carbonitrile )ClO4] 42 
 
Greenish yellow solid (8.5 mg, 72 %). 
MP: 156.5-157.5 oC. 
  1H NMR (500 MHz, Chloroform-d) δ 8.97 (s, 1H), 8.86 (d, J = 9.3 Hz, 1H), 8.73 (d, J 
= 2.0 Hz, 1H), 8.57 (d, J = 8.6 Hz, 1H), 8.29 (ddd, J = 17.7, 8.9, 1.7 Hz, 2H), 8.01 (t, J = 
7.8 Hz, 1H), 7.58 (ddt, J = 30.0, 13.7, 7.3 Hz, 15H)   
 13C NMR (151 MHz, Chloroform-d) δ 148.3 (13-C), 146.6 (11-C), 134.9 (20-C, 26-C, 
32-C), 134.2(3-CH), 132.3(15-CH, 19-CH,21-CH, 25-CH, 27-CH,31-CH), 131.8 (6-CH), 
131.5 (12-C), 130.4 (4-CH), 129.9 (16-CH, 18-CH, 22-CH, 24-CH,28-CH, 30-CH), 129.5 
(17-CH, 23-CH, 29-CH), 127.1 (5-CH), 126.9 (8-CH), 126.7 (7-CH), 126.3 (10-C), 125.2 
(1-CH), 124.2 (2-C), 114.7 (9-C), 114.4 (14-C).  
31P NMR (162 MHz, Chloroform-d) δ 29.96  
 HRMS: (ESI) Calculated for C32H22AuBrN2P
+:741.0364. Found: 741.0397.Error: -4.42 
ppm  
 IR (diamond, cm-1): 2243.80 (CN), 1431.54 (PPh3), 537.94 (C-Br). 
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Yellow solid (7.9 mg, 68 %). 
MP: 150.3-152.3 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.32 (d, J = 2.1 Hz, 1H), 8.23 (d, J = 9.3 Hz, 
1H), 8.17 (d, J = 9.2 Hz, 1H), 7.79 (dd, J = 9.2, 2.2 Hz, 1H), 7.44 – 7.56 (m, 17H), 4.04 
(s, 3H). 
  13C NMR (151 MHz, Chloroform-d) δ 150.2 (6-C), 134.2  (13-C), 134.1 (11-C), 134.0  
(21-C, 27-C, 33-C),  132.4 (2-C), 132.0 (16-CH, 20-CH,22-CH, 26-CH, 28-CH,32-CH), 
131.9 (3-CH), 131.24 (12-C), 129.25 (8-CH), 129.17 (4-CH), 128.92(17-CH, 19-CH, 23-
CH, 25-CH,29-CH, 31-CH)  , 128.5  (18-CH, 24-CH, 30-CH),  126.18 (10-C) , 123.7 (1-
CH), 123.0 (7-CH), 114.7 (9-C), 114.3 (14-C), 105.9 (5-CH),  55.9 (15-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 31.29   
HRMS: (ESI) Calculated for C33H24AuClN2OP
+:727.0975. Found: 727.1044.Error: -
9.54 ppm  








Orange solid (8.0 mg, 66 %). 
MP: 133.7-135.7 oC.  
1H NMR (600 MHz, Chloroform-d) δ 8.50 (d, J = 2.0 Hz, 1H), 8.23 (d, J = 9.3 Hz, 
1H), 8.11 (d, J = 9.1 Hz, 1H), 7.91 (dd, J = 9.2, 2.0 Hz, 1H), 7.44 – 7.56 (m, 17H), 4.04 
(s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 162.3 (6-C), 135.0 (13-C), 134.2 (11-C), 134.1 
(21-C, 27-C, 33-C), 132.0 (3-C), 131.9  (16-CH, 20-CH,22-CH, 26-CH, 28-CH,32-CH), 
130.9 (8-CH), 129.2 (12-C), 129.1 (4-CH), 129.0(17-CH, 19-CH, 23-CH, 25-CH,29-
CH, 31-CH), 128.5 (18-CH, 24-CH, 30-CH), 126.2 (10-C), 125.6 (1-C), 125.3 (2-C), 
123.0  (7-CH), 122.4 (9-C), 114.7 (14-C), 105.7 (5-CH), 55.9 (15-CH3).   
HRMS: (ESI) Calculated for C33H24AuBrN2OP
+:771.0470. Found: 771.0453.Error: 
4.23 ppm 










Light orange solid (8.4 mg, 70 %) 
.MP:191.8-192.8 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.07 – 8.13 (m, 3H), 7.83 (d, J = 9.4 Hz, 1H), 
7.74 (d, J = 9.4 Hz, 1H), 7.56 – 7.68 (m, 13H), 7.32 (d, J = 16.6 Hz, 2H), 7.26 (s, 1H). 
13C NMR (151 MHz, Chloroform-d) δ 164.9 (d, J = 196.3 Hz,)  (6-C), 155.9 (13-C), 
139.1 (11-C), 134.3 (20-C, 26-C, 32-C), 134.2 (3-CH),  132.7 (15-CH, 19-CH,21-CH, 
25-CH, 27-CH,31-CH), 130.3 (8-CH), 130.2 (12-C), 129.8 (4-CH), 129.7 (16-CH, 18-
CH, 22-CH, 24-CH,28-CH, 30-CH), 127.0  (17-CH, 23-CH, 39-CH), 126.5 (10-C), 
122.5 (1-CH), 122.3 (2-C), 117.4 (7-CH), 117.3 (9-C), 115.6 (14-C), 115.5 (5-CH). 
  31P NMR (400 MHz, Chloroform-d) δ 31.29 
 HRMS: (ESI) Calculated for C32H21AuBrFN2P
+:759.0270. Found: 761.0287.Error: -
5.69 ppm. 






    
 
[Ph3PAu(2, 6-dichloroacridine-9-carbonitrile)ClO4] 46 
 
Orange solid (8.4 mg, 72 %). 
MP: 207.1-209.1 oC. 
 1H NMR (500 MHz, Chloroform-d) δ 8.59 (d, J = 9.3 Hz, 1H), 8.26 (d, J = 9.5 Hz, 1H), 
7.83 – 7.70 (m, 1H), 7.58 – 7.68 (m, 4H), 7.41 – 7.58 (m, 14H). 
 13C NMR (151 MHz, Chloroform-d) δ 163.2 (13-C), 156.3 (11-C), 136.9 (6-C), 134.2 
(20-C, 26-C, 32-C), 134.1 (2-C), 132.9 (3-CH), 132.6 (15-CH, 19-CH, 21-CH, 25-CH, 
27-CH, 31-CH), 132.5 (12-C), 130. 9 (8-CH), 129.9 (4-CH), 129.8 (16-CH, 18-CH, 22-
CH, 24-CH,28-CH, 30-CH), 129.7 (5-CH), 129.5 (17-CH, 23-CH, 29-CH), 127.7 (10-C), 
126.1 (7-CH), 118.6 2 (1-CH), 117.2 (9-C), 114.6 (14-C). 
 31P NMR (400 MHz, Chloroform-d) δ31.92 
HRMS: (ESI) Calculated for C32H21AuCl2N2P
+:731.0479. Found: 731.0492.Error: -1.74 
ppm. 











Deep orange solid (8.6 mg, 69 %). 
MP: 133.0-134.0 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.73 (d, J = 2.0 Hz, 2H), 8.33 (d, J = 8.7 Hz, 
2H), 8.27 (d, J = 8.8 Hz, 2H), 8.07 (dt, J = 9.3, 2.0 Hz, 2H), 7.99 (d, J = 9.3 Hz, 4H), 7.90 
(t, J = 7.8 Hz, 3H), 7.78 (t, J = 7.5 Hz, 2H), 7.39 – 7.70 (m, 5H). 
 13C NMR (151 MHz, Chloroform-d) δ 148.4 (13-C), 146.8 (11-C), 139.9 (3-CH), 134.2 
(20-C, 26-C, 32-C), 134.1 (1-CH), 133.8 (15-CH, 19-CH,21-CH, 25-CH, 27-CH,31-CH),  
131.5 (12-C), 131.5 (10-C), 130.4 (6-CH), 129.7 (16-CH, 18-CH, 22-CH, 24-CH,27-CH, 
30-CH), 129.5 (17-CH, 23-CH, 29-CH), 127.16 (5-CH), 126.1 (8-CH), 125.2 (7-CH), 
114.7 (9-C), 114.0 (14-C), 96.2 (2-C).   
31P NMR (400 MHz, Chloroform-d) δ 31.76  
HRMS: (ESI) Calculated for C32H22AuIN2P
+:789.0225. Found: 789.0298.Error: -9.23 
ppm 






    
 
[Ph3PAu(7-chloro-2, 3, 4-trimethoxyacridine-9-carbonitrile)ClO4] 48 
 
Orange solid (8.9 mg, 72 %). 
MP: 126.4-128.4 oC. 
 1H NMR (500 MHz, Chloroform-d) δ 9.06 (s, 1H), 8.39 (d, J = 2.3 Hz, 1H), 7.85 – 
7.91 (m, 1H), 7.50 – 7.68 (m, 15H), 7.40 (s, 1H), 4.15 – 4.22 (m, 6H), 4.06 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 156.6 (2-C), 146.7 (13-C), 145.9 (4-C), 144.0 
(11-C), 141.8 (7-C), 135.0 (6-CH), 134.2 (23-C, 29-C, 35-C) ,  132.4 (3-C), 132.2 (18-
CH, 22-CH,24-CH, 28-CH, 30-CH,34-CH),  130.9 (12-C),  129.5(19-CH, 21-CH, 25-
CH, 27-CH,31-CH, 33-CH), 125.8(20-CH, 26-CH, 32-CH), 125.4 (5-CH), 123.0 (10-C), 
122.9  (8-CH),  115.2 (9-C), 111.1 (14-C), 96.7 (1-CH), 62.5  (17-CH3), 61.7  (16-CH3), 
56.5 (15-CH3). 
 31P NMR (400 MHz, Chloroform-d) δ 31.29  
HRMS: (ESI) Calculated for C35H28AuClN2O3P
+:787.1186. Found: 787.1177.Error: 
1.18 ppm 
 IR (diamond, cm-1): 3077.60 (aromatic C-H) 2927.4 (saturated C-H) 2169.00 (CN), 
1633.16 (aromatic C=C) 1436.91 (PPh3).  
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[Ph3PAu(7-iodo-2, 3, 4-trimethoxyacridine-9-carbonitrile)ClO4] 49 
 
Brownish yellow solid (10.2 mg, 75 %). 
MP: 120.9-121.9 oC.  
1H NMR (600 MHz, Chloroform-d) δ 8.78 (d, J = 1.8 Hz, 1H), 8.13 (dd, J = 9.3, 1.9 
Hz, 1H), 7.55 – 7.69 (m, 15H), 7.52 (d, J = 8.7 Hz, 1H), 7.40 (s, 1H), 4.15-4.18 (m, 6H), 
4.08 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 156.7(2-C), 144.2 (4-C), 141.6 (11-C), 139.2  
(6-CH), 134.1 (23-C, 29-C, 35-C), 134.0 (8-CH), 133.4 (3-C), 132.5 (18-CH, 22-CH,24-
CH, 28-CH, 30-CH,34-CH), 131.5 (5-CH), 129.7 (12-C), 129.6 (19-CH, 21-CH, 25-CH, 
27-CH,31-CH, 33-CH), 127.5  (20-CH, 26-CH, 32-CH), 127.1 (10-C), 125.7 (9-C), 115.0 
(14-C), 97.2 (7-C), 96.0 (1-CH), 62.9 (17-CH3), 61.8 (16-CH3), 56.7 (15-CH3).   
31P NMR (162 MHz, Chloroform-d) δ 31.53  
HRMS: (ESI) Calculated for C35H28AuIN2O3P
+:879.0542. Found: 879.0517.Error: 2.83 
ppm 
 IR (diamond, cm-1): 2930.13 (saturated C-H) 2258.62 (CN), 1614.85 (aromatic C=C) 









Deep orange solid (9.1mg, 71 %). 
MP: 156.7-157.7 oC. 
  1H NMR (600 MHz, Chloroform-d) δ 8.72 (s, 1H), 8.23 (d, J = 9.3 Hz, 1H), 8.07 (d, J 
= 9.1 Hz, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.66 (d, J = 9.3 Hz, 1H), 7.36 – 7.51 (m, 16H), 
4.04 (s, 3H).  
13C NMR (151 MHz, Chloroform-d) δ 162.2 (13-C), 150.2 (6-C), 147.0 (11-C), 139.8 
(3-CH), 134.2 (21-C, 27-C, 33-C), 131.97 (1-CH), 131.9 (16-CH, 20-CH,22-CH, 26-CH, 
28-CH,32-CH), 130.9 (4-CH), 129.3 (12-C), 129.2 (17-CH, 19-CH, 23-CH, 25-CH,29-
CH, 31-CH), 128.9(18-CH, 24-CH, 30-CH),  128.5 (10-C) 125.5 (8-CH), 122.7 (7-CH), 
114.7 (9-C), 113.8 (14-C), 105.8 (5-CH), 94.1 (2-C), 55.9 (15-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 33.10  
HRMS (ESI) Calculated for C33H24AuIN2OP
+:819.0331. Found: 819.0361.Error: -3.65 
ppm 
 IR (diamond, cm-1): 2923.50 (saturated C-H) 2228.20 (CN), 1628.48 (aromatic C=C) 





    
 
[Ph3PAu(7-bromo-2, 3, 4-trimethoxyacridine-9-carbonitrile)ClO4] 51 
 
Orange solid (9.7 mg, 74 %). 
MP: 137.8-138.8 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.96 (s, 1H), 8.58 (d, J = 2.1 Hz, 1H), 8.00 (d, J 
= 9.1 Hz, 1H), 7.68 – 7.50 (m, 15H), 7.41 (s, 1H), 4.15-4.18 (m, 6H), 4.09 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 156.8 (2-C), 146.0 (13-C), 144.0 (11-C), 141.5 
(4-C), 134.2 (23-C, 29-C, 35-C) , 134.1 (6-CH), 134.0 (3-C), 132.5 (18-CH, 22-CH,24-
CH, 28-CH, 30-CH,34-CH) , 131.7 (12-C), 129.7 (5-CH), 129.6(19-CH, 21-CH, 25-CH, 
27-CH,31-CH, 33-CH),  128.0 (20-CH, 26-CH, 32-CH) 127.6 (10-C), 126.6 (8-CH), 
125.9 (7-C), 123.8 (9-C), 114.9 (14-C), 97.2 (1-CH), 62.8 (17-CH3), 61.8 (16-CH3), 56.6 
(15-CH3).  
 31P NMR (162 MHz, Chloroform-d) δ 31.76  
HRMS (ESI) Calculated for C35H28AuBrN2O3P
+:831.0681. Found: 833.0591.Error: 3.58 
ppm 
 IR (diamond, cm-1): 3069.70 (aromatic C-H) 2936.75 (saturated C-H) 2220.78 (CN), 








Pale yellow solid (10.3 mg, 78 %). 
MP: 161.1-163.1 oC.  
 1H NMR (600 MHz, Chloroform-d) δ 8.27 (s, 1H), 7.80 (d, J = 9.3 Hz, 1H), 6.99-7.87 
(m, 17H), 7.06 (d, J = 8.4 Hz, 1H), 4.03 (s, 3H), 3.97 (s, 3H).  
 13C NMR (151 MHz, Chloroform-d) δ 164.5 (3-C) , 156.0 (2-C), 151.9 (13-C), 149.7 
(11-C), 140.4 (6-CH), 134.2 (22-C, 28-C, 34-C), 132.8 (8-CH), 132.7 (17-CH, 21-
CH,23-CH, 27-CH, 29-CH,33-CH), 129.9 (5-CH), 129.8 (12-C), 129.7 (18-CH, 20-CH, 
24-CH, 26-CH,30-CH, 32-CH), 127.0 (19-CH, 25-CH, 31-CH), 126.6 (10-C), 116.2 (9-
C), 115.7  (14-C), 111.5 (1-CH), 109.6 (4-CH), 89.0 (7-C) , 56.3  (16-CH3), 56.1  (15-
CH3).  
 31P NMR (162 MHz, Chloroform-d) δ 31.50 
 HRMS (ESI) Calculated for C34H26AuIN2O2P
+:849.0437. Found: 849.0392.Error: 5.23 
ppm 
 IR (diamond, cm-1): 3053.90 (aromatic C-H) 2924.00 (saturated C-H) 2226.48 (CN), 





    
 
[Ph3PAu(7-chloro-2, 3-dimethoxyacridine-9-carbonitrile)ClO4] 53 
 
Pale yellow solid (9.3 mg, 78 %). 
MP: 126.6-128.6 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.31 (s, 3H), 7.81 (s, 2H), 7.71 (s, 3H), 7.59 (d, J = 18.3 
Hz, 8H), 7.43 (s, 4H), 4.16 (s, 3H), 4.08 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ155.1 (3-C)  153.7 (2-C), 146.4 (13-C), 144.3 
(11-C), 134.2(22-C, 28-C, 34-C), 134.2 (7-C), 134.1 (6-CH), 131.2 (17-CH, 21-CH,23-
CH, 27-CH, 29-CH,33-CH), 130.7 (18-CH, 20-CH, 24-CH, 26-CH,30-CH, 32-CH), 
129.3(19-CH, 25-CH, 31-CH)  125.0 (5-CH), 124.6 (8-CH), 123.2 (9-C), 115.0 (14-C), 
106.7 (1-CH), 100.8 (4-CH), 56.7 (16-CH3), 56.6 (15-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 30.82    
HRMS (ESI) Calculated for C34H26AuClN2O2P
+:757.1080. Found: 757.1097.Error: -
2.14 ppm 
 IR (diamond, cm-1): 3062.62 (aromatic C-H) 2926.43 (saturated C-H) 2161.54 (CN), 





    
 
[Ph3PAu(7-chloro-2, 3-dimethoxyacridine-9-carbonitrile)ClO4] 54 
 
Orange solid (10.1 mg, 80 %). 
MP: 121.3-123.3oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.47 (s, J = 30.0 Hz, 1H), 8.32 (s, J = 2.2 Hz, 
1H), 8.22 (dd, J = 15.2, 9.1 Hz, 2H), 8.08 (d, J = 9.1 Hz, 1H), 7.77 – 7.94 (m, 3H), 7.29 
– 7.74 (m, 12H), 4.16 (s, 3H), 4.12 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 153.9 (3-C), 148.4 (2-C), 147.2 (13-C), 136.1 
(11-C), 134.2(22-C, 28-C, 34-C), 133.4 (6-CH), 132.1 (12-C), 132.0 (5-C), 132.0(17-CH, 
21-CH,23-CH, 27-CH, 29-CH,33-CH), 129.3 (18-CH, 20-CH, 24-CH, 26-CH,30-CH, 
32-CH), 128.9 (19-CH, 25-CH, 31-CH), 126.3 (10-C), 125.6(8-CH), 124.8 (7-C), 123.6 
(9-C), 115.0 (14-C), 114.2 (1-CH), 100.9 (4-CH), 56.8 (16-CH3), 56.7 (15-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 31.06   
HRMS (ESI) Calculated for C34H26AuBrN2O2P
+:801.0575. Found: 801.0543.Error: 3.40 
ppm. 










Pale orange solid (13.1 mg, 78 %). 
MP: 120.3-122.3oC. 
 1H NMR (600 MHz, Chloroform-d) δ  8.09 (dd, J = 9.2, 3.6 Hz, 3H), 7.98 (d, J = 8.8 
Hz, 3H), 7.86 (s, J = 8.1 Hz, 1H), 7.68 – 7.77 (m, 3H), 7.61 (d, J = 9.1 Hz, 3H), 7.39 – 
7.58 (m, 6H), 7.34 – 7.38 (m, 2H),   3.99 (s, 3H), 2.66 (s, 3H).  
13C NMR (151 MHz, Chloroform-d) δ 161.4 (6-C), 146.8 (13-C), 140.8 (11-C), 134.2 
(2-C), 134.1(22-C, 28-C, 34-C)  132.5(17-CH, 21-CH,23-CH, 27-CH, 29-CH,33-CH), 
129.7 (8-CH), 129.2 (18-CH, 20-CH, 24-CH, 26-CH,30-CH, 32-CH),  129.2 (19-CH, 
25-CH, 31-CH), 127.6 (12-C), 126.0 (10-C), 125.9 (4-CH), 125.2  (3-CH),  122.6 (1-
CH), 118.56, 117.2 (7-CH),  116.9 (9-C), 115.1 (14-C), 105.9 (5-CH),  55.8 (15-CH3), 
15.1 (16-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 30.00.  
HRMS (ESI) Calculated for C34H27AuN2OPS
+:739.1242. Found: 739.1211.Error: 4.21 
ppm. 
 IR (diamond, cm-1): 3056.90 (aromatic C-H), 2924.63 (saturated CH), 2162.16 (CN), 








Greenish yellow solid (12.4 mg, 75 %). 
MP: 137.4-138.4 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.39 (dd, J = 9.4, 5.8 Hz, 2H), 8.33 (s, 1H), 8.06 
(d, J = 9.5 Hz, 1H), 7.87 (d, J = 1.9 Hz, 2H), 7.83 (d, J = 9.2 Hz, 2H), 7.32 – 7.74 (m, 
13H), 2.72 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ  163.3 (d, J = 255.0 Hz,) (6-C), 147.8 (13-C),  
147.6 (11-C), 142.73 (2-C), 134.2 (21-C, 27-C, 33-C),  132.4(16-CH, 20-CH,22-CH, 26-
CH, 28-CH,32-CH), 131.6 (8-CH), 129.5 (17-CH, 19-CH, 23-CH, 25-CH,29-CH, 31-
CH), 127.4(18-CH, 24-CH, 30-CH), 127.4 (12-C), 126.3 (10-C), 123.6 (4-CH), 121.2 (1-
CH), 121.0 (7-CH), 116.4 (9-C), 114.9 (14-C), 112.90,  112.8 (5-CH), 15.0 (15-CH3). 
  31P NMR (162 MHz, Chloroform-d) δ 32.86.  
HRMS (ESI) Calculated for C33H24AuFN2PS
+:727.1042. Found: 727.1070.Error: -3.81 
ppm. 
 IR (diamond, cm-1): 2921.94 (saturated CH), 2219.99 (CN), 1628.91 (aromatic C=C) 









Greenish yellow solid (12.8 mg, 71 %). 
MP: 140.7-142.7oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.16 (s, 1H), 7.84 (d, J = 1.9 Hz, 1H), 7.71 (d, J 
= 8.9 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 7.54 (m, J = 8.6 Hz, 8H), 7.49 (m, 3H), 7.44 -
7.48 (m, J = 31.2 Hz, 4H), 4.16 (s, 6H), 4.11 (s, 3H), 2.70 (s, 3H).  
13C NMR (151 MHz, Chloroform-d) δ 155.0 (2-C), 153.4 (13-C), 141.4 (4-C), 134.2 
(7-C), 134.1(24-C, 30-C, 36-C), 132.0 (19-CH, 23-CH,25-CH, 29-CH, 31-CH,35-CH), 
130.3 (3-C), 129.2 (20-CH, 22-CH, 26-CH, 28-CH,32-CH, 34-CH),  129.1 (12-C), 128.9 
(21-CH, 27-CH, 33-CH), 127.5 (10-C), 127.5 (5-CH) 125.2 (6-CH), 124.3 (8-CH), 116.4  
(9-C), 115.1 (14-C) , 100.9 (1-CH), 80.4 (17-CH3), 56.7 (16-CH3), 56.6 (15-CH3), 15.0 
(18-CH3).  
 31P NMR (162 MHz, Chloroform-d) δ 30.58. 
HRMS (ESI) Calculated for C36H31AuN2O3PS
+:799.1453. Found: 799.1516.Error: -7.85 
ppm 
 IR (diamond, cm-1):  2924.57 (saturated CH), 2227.16 (CN), 1614.65 (aromatic C=C) 
1436.52 (PPh3).  
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[Ph3PAu(2, 3, 7-trimethoxyacridine-9-carbonitrile)ClO4] 58 
 
Orange solid (14.2 mg, 83 %). 
MP: 140.5-142.5 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.33 (m, J = 9.3 Hz, 4H), 7.76 (m, 3H), 7.51 
(dt, J = 12.9, 6.2 Hz, 5H), 7.46 (s, J = 7.3, 2.8 Hz, 1H), 7.18 – 7.39 (m, 7H), 4.14 (s, 
6H), 4.04 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 159.7 (7-C) 155.8 (3-C), 153.66 (2-C), 134.2 
(23-C, 29-C, 35-C), 134.0 (5-CH), 131.2 (18-CH, 22-CH,24-CH, 28-CH, 30-CH,34-
CH), 129.2(19-CH, 21-CH, 25-CH, 27-CH,31-CH, 33-CH), 129.1 (20-CH, 26-CH, 32-
CH), 127.5 (12-C) , 126.8 (10-C), 126.47 (6-CH), 124.7 (9-C), 114.91 (14-C), 103.7 (1-
CH), 100.8 (4-CH), 100.7 (8-CH), 57.0 (16-CH3), 56.7 (15-CH3), 56.0 (17-CH3),  
  31P NMR (162 MHz, Chloroform-d) δ 32.08   
HRMS (ESI) Calculated for C35H29AuN2O3P
+:753.1576. Found: 753.1619.Error: -5.68 
ppm. 
 IR (diamond, cm-1): 3065.70 (aromatic C-H) 2959.00 (saturated CH), 2192.70 (CN), 




    
 
[Ph3PAu(2, 3-dimethoxy-7-(methylthio)acridine-9-carbonitrile)ClO4] 59 
 
Orange solid (12.5 mg, 72 %). 
MP: 120.5-122.5 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 8.16 (s, 1H), 7.84 (d, J = 1.9 Hz, 1H), 7.71 (d, J 
= 8.9 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 7.54 (m, J = 8.6 Hz, 8H), 7.49 (m, 3H), 7.45 (m, 
J = 39.5 Hz, 5H), 4.16 (s, 3H), 4.11 (s, 3H), 2.70 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 155.0 (3-C), 153.4 (2-C), 141.4 (11-C), 134.2 
(23-C, 29-C, 35-C), 134.0 (7-C), 132.0  (18-CH, 22-CH,24-CH, 28-CH, 30-CH,34-CH), 
130.3 (12-C), 129.2 (19-CH, 21-CH, 25-CH, 27-CH,31-CH, 33-CH), 129.2 (10-C), 128.9 
(20-CH, 26-CH, 32-CH), 127.5 (5-CH), 125.2 (6-CH), 124.3 (8-CH), 116.4 (9-C), 115.1 
(14-C), 105.4 (1-CH), 100.9 (4-CH),56.7 (16-CH3), 56.6 (15-CH3), 15.0 (17-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 32.39  
HRMS (ESI) Calculated for C35H29AuN2O2PS
+:769.1347. Found: 769.1329.Error: 2.39 
ppm 
 IR (diamond, cm-1): 3073.20 (aromatic C-H), 2978.00 (saturated C-H), 2163.15 (CN), 




    
 
 [Ph3PAu(3-methoxyacridine-9-carbonitrile)ClO4] 60 
 
Greenish yellow solid (11.3 mg, 71 %). 
MP: 120.9-122.9oC. 
 1H NMR (600 MHz, Chloroform-d) δ 9.01 (d, J = 7.0 Hz, 2H), 8.49 (d, J = 8.2 Hz, 3H), 
8.40 (d, J = 9.8 Hz, 4H), 8.18 (s, 2H), 7.95 (m, J = 7.1 Hz, 3H), 7.62 (d, J = 9.1 Hz, 3H), 
7.42 – 7.54 (m, 5H), 4.07 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 166.9 (3-C), 143.7 (13-C), 136.6 (11-C), 134. 
2(21-C, 27-C, 33-C), 132.0(16-CH, 20-CH,22-CH, 26-CH, 28-CH,32-CH),  131.9 (6-
CH), 129.7 (1-CH), 129.3 (17-CH, 19-CH, 23-CH, 25-CH,29-CH, 31-CH), 129.1 (12-C), 
128.9 (18-CH, 24-CH, 30-CH), 128.46 (10-C), 127.3 (5-CH), 127.0 (7-CH), 125.9 (8-
CH), 124.2 (2-CH), 124.1 (9-C), 112.8 (14-C), 98.9 (4-CH), 57.7 (15-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 30.11   
 HRMS (ESI) Calculated for C33H25AuN2OP
+:693.1365 Found: 693.1391.Error: -3.79 
ppm 
 IR (diamond, cm-1): 3073.08 (aromatic C-H), 2165.13 (CN), 1633.80 (aromatic C=C) 









Yellow solid (11.6 mg, 74 %). 
MP: 124.0-126.0 oC  
 1H NMR (600 MHz, Chloroform-d) δ 8.42 – 8.51 (m, 2H), 8.01 – 8.10 (m, 2H), 7.87 
(t, J = 7.7 Hz, 1H), 7.67 (s, 1H), 7.44 – 7.57 (m, 15H), 7.26 (s, 1H). 
13C NMR (151 MHz, Chloroform-d) δ 134.2 (20-C, 26-C, 32-C), 134.1 (11-C), 132.1 
(1-CH), 132.0 (15-CH, 19-CH,21-CH, 25-CH, 27-CH,31-CH),   129.6 (6-CH), 129.3 (16-
CH, 18-CH, 22-CH, 24-CH,28-CH, 30-CH), 129.2 (12-C), 128.8 (17-CH, 23-CH, 29-
CH), 128.4 (10-C), 128.2 (5-CH), 128.1 (7-CH), 125.6 (8-CH), 123.69 (2-CH), 121.8 (9-
C), 121.6 (14-C), 114.2 (4-CH). 
31PNMR (162 MHz, Chloroform-d) δ 29.72 (ESI) calculated for 
C32H22AuFN2P
+:681.1165. Found: 681.1225.Error: -8.84 ppm 
 IR (diamond, cm-1): 3056.99 (aromatic C-H), 2224.67 (CN), 1633.95 (aromatic C=C) 
1437.28 (PPh3).  
IV.4. General Procedure for the Synthesis of Compounds 62, 63a, 64a, 65b and 66b. 
AgClO4 (4.2 mg, 0.020 mmol, 1 eq.) and Ph3PAuCl (10.0 mg, 0.020 mmol, 1 eq.) were 
dissolved in methanol (0.5 mL) yielding a white precipitate instantly. The mixture was 
stirred for 30 minutes. The completion of the reaction was monitored by 31P NMR (162 
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MHz, Chloroform-d) δ 27.5 ppm. A solution of corresponding pyrazole (0.020 mmol, 1 
eq.) in CH2Cl2 (0.5 ml) was added to the previous solution and stirred for a further 30 
minutes. The mixture was filtered over a glass microfiber filter placed in a syringe and 
into an NMR Schlenk flask, under nitrogen. The solution was dried under reduced 
pressure and CDCl3 (0.5 mL) was added.
 31P, 1H and13C NMR analyses were recorded. 
The material was concentrated under reduced pressure to obtain the title complex as a 
solid. 
Triphenylphosphine(5-amino-4-(pyridin-2-yl)-1H-pyrazole)gold(I) perchlorate  62 
 
Brown solid (11.9 mg, 83 %). 
 MP: 165.6-168.2 oC 
1H NMR (600 MHz, Chloroform-d) δ 8.49 (d, J = 4.7 Hz, 1H), 7.85 (s, 1H), 7.64 (td, J 
= 7.8, 1.9 Hz, 2H), 7.42-7.62 (m, 14H), 7.39 (d, J = 7.8 Hz, 2H), 7.06 (dd, J = 7.5, 4.9Hz, 
1H), 6.39 (s, 2H). 
 13C NMR (151 MHz, Chloroform-d) δ 154.7 (4-C), 148.6 (3-C), 136.5 (8-CH), 134.3 
(6-CH), 134.2 (14-C, 20-C, 26-C), 132.5 (1-CH), 132.4(9-CH, 13-CH, 15-CH, 19-CH, 
21-CH, 25-CH), 129.6(10-CH 12-CH, 16-CH, 18-CH, 22-CH,24-CH), 128.0(11-CH, 17-
CH,23-CH), 127.1 (7-CH), 120.1 (5-CH), 118.4 (2-C). 
 31P NMR (162 MHz, Chloroform-d) δ 30.0 
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 HRMS (ESI) Calculated for C8H8N4AuPh3P
+: 619.1320. Found 619.1320. Error: 0.12 
ppm. 
 IR (diamond, cm-1): 3073.97 (NH2), 2923.29 (CH), 1621.74 (C=C), 1514.68 (benzene 
ring). 
Triphenylphosphine(5-Amino-4-(4-bromophenyl)-pyrazole) gold(I) perchlorate  
63a 
 
Light brown solid (15.0 mg, 94 %). 
 MP: 142.4-144.6oC. 
 1H NMR (600 MHz, Chloroform-d) δ 12.21 (broad s, 1H), 7.52–7.62 (m, 21H), 7.24 
(s, 1H). 
 13C NMR (151 MHz, Chloroform-d) δ 134.3 (3-C), 134.2(15-C, 21-C, 27-C), 132.5 (1-
CH), 132.5 (4-CH), 132.4 ((10-CH, 14-CH, 16-CH, 20-CH, 22-CH, 26-CH), 129.8 (5-
CH), 129.8 (9-CH), 129.6 (11-CH, 13-CH, 17-CH, 19-CH, 23-CH,25-CH), 128.3 (12-
CH, 18-CH,24-CH), 127.4 (7-C), 127.0 (6-CH, 8-CH), 120.9(2-C). 
31P NMR (162 MHz, Chloroform-d) δ 31.0. 
 HRMS (ESI) calculated for C9H8BrN3AuPh3P
+:696.0473. Found: 696.0469. Error: -
5.22 ppm. 









Grey solid (14.3 mg, 88 %).  
MP: 148.0-149.6oC. 
 1H NMR (600 MHz, Chloroform-d) δ 11.86 (broad s, 2H), 7.51–7.62 (m, 16H), 7.45 
(d, J = 8.7 Hz, 1H), 7.16 (d, J = 8.3 Hz, 2H), 3.72 (q, J = 7.0 Hz, 1H), 2.32 (s, 3H). 
 13C NMR (151 MHz, Chloroform-d) δ 134.4 (1-C), 134.2(16-C, 22-C, 28-C), 132.5 (4-
C), 132.4(11-CH, 15-CH, 17-CH, 21-CH, 23-CH, 27-CH), 130.5 (5-CH, 9-CH), 130.4 
(7-C), 129.7 (6-CH, 8-CH), 129.6(12-CH 14-CH, 18-CH, 20-CH, 24-CH,26-CH), 
127.6(13-CH, 19-CH, 25-CH),121.2 (2-C), 13.8 (10-CH3) 
. 31P NMR (162 MHz, Chloroform-d) δ 31.50   
HRMS (ESI) Calculated for C10H10BrN3AuPh3P
+:710.0630. Found: 710. 0634. Error: -
2.01 ppm 
 IR (diamond, cm-1): 3316.13 (NH2), 2924.07 (CH), 1598.28 (benzene ring). 
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Yellow solid. (13.5 mg, 95%). 
 MP: 126.3-127.4 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 7.82 (s, 1H), 7.45 – 7.63 (m, 16H), 5.86 (s, 2H), 
4.44 (t, J = 5.0 Hz, 2H), 4.10 (t, J = 5.1 Hz, 2H). 
 13C NMR (151 MHz, Chloroform-d) δ 152.9 (3-C), 134.1(1-CH), 134.0 (12-C, 18-C, 
24-C), 132.8(7-CH, 11-CH, 13-CH, 17-CH, 19-CH, 23-CH), 129.9 (8-CH 10-CH, 14-
CH, 16-CH, 20-CH,22-CH)  , 129.8(9-CH, 15-CH, 21-CH), 109.9 (4-C), 78.0 (2-C), 60.5 
(5-CH2), 52.7 (6-CH2)  
 31P NMR (162 MHz, Chloroform-d) δ 29.70 
 HRMS (ESI) Calculated for C6H8N4OAuPh3P
+:611.1270. Found: 611.1253. Error: 2.76 
ppm. 
 IR (diamond, cm-1): 3339.28 (NH2), 3214.86 (OH) 2924.76 (CH), 2224.58 (CN), 





    
 
Triphenylphosphine(3-Amino-4-bromo-2-methylpyrazol) gold(I) perchlorate  66b 
 
Dark brown solid (12.8 mg, 87%). 
 MP: 172.2-174.3 oC. 
 1H NMR (600 MHz, Chloroform-d) δ 7.60 – 7.66 (m, 3H), 7.47 – 7.60 (m, 12H), 7.35 
(s, 1H), 4.97 (s, 2H), 3.98 (s, 3H) 
 13C NMR (151 MHz, Chloroform-d) δ 157.2 (3-C), 134.0 (10-C, 16-C, 22-C), 133.9 
(1-CH), 132.9 (5-CH, 9-CH, 11-CH, 15-CH, 17-CH, 21-CH), 129.8(6-CH 8-CH, 12-
CH, 14-CH, 18-CH,20-CH), 127.0(7-CH, 13-CH, 19-CH) , 78.5 (2-C), 36.8 (4-CH3). 
 31P NMR (162 MHz, Chloroform-d) δ 30.0. 
 HRMS (ESI) Calculated for C4H6BrN3AuPh3P
+:634.0317. Found: 634.0310 Error: 
0.95 ppm 
 IR (diamond, cm-1): 3337.43 (NH2), 2925.08 (CH), 1645.83 (C=C), 1579.65 (benzene 
ring) 
IV.5. General Procedure for the Synthesis of Compounds 67-75 
AgClO4 (4.2 mg, 0.020 mmol, 1 eq.) were dissolved in methanol (0.5 mL) yielding a 
white precipitate. A solution of corresponding acridine/pyrazole (0.020 mmol, 1 eq.) in 
CH2Cl2 (0.5 ml) was added to the solution and stirred for 30 minutes. The mixture was 
filtered over a glass microfiber filter placed in a syringe and into an NMR Schlenk flask, 
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under nitrogen. The solution was dried under reduced pressure and CDCl3 (0.5 mL) was 
added. 1H and13C NMR analyses were recorded. The material was concentrated under 




Yellowish green solid (5.4 mg 78 %) 
MP: 221.3-223.3 oC 
1H NMR (600 MHz, Chloroform-d) δ 8.30 – 8.35 (m, 2H), 8.28 (d, J = 8.7 Hz, 1H), 
8.23 (d, J = 9.2 Hz, 1H), 7.89 (t, J = 7.7 Hz, 1H), 7.76 – 7.82 (m, 2H). 
13C NMR (151 MHz, Chloroform-d) δ 148.3 (13-C), 146.5 (11-C), 135.6 (2-C), 132.4 
(3-CH), 132.0(12-C), 131.2 (6-CH), 130.5 (4-CH), 129.7 (5-CH), 126.3 (10-C), 126.2 
(8-CH), 125.1 (7-CH), 123.5 (1-CH), 114.7 (9-C), 114.2 (14-C). 
HRMS (ESI) Calculated for C14H7AgClN2:344.9343. Found: 344.9338.Error: 1.59 ppm 












Yellowish green solid (5.9 mg, 75 %) 
MP: 166.1-168.1 oC 
1H NMR (600 MHz, Chloroform-d) δ 8.42 (s, 1H), 8.27 (d, J = 8.6 Hz, 1H), 8.21 (d, J 
= 8.7 Hz, 1H), 8.08 (d, J = 9.1 Hz, 1H), 7.86 (d, J = 8.7 Hz, 2H), 7.75 (t, J = 7.6 Hz, 1H). 
13C NMR (151 MHz, Chloroform-d) δ 148.3 (13-C), 146.5 (11-C), 134.7 (3-CH), 131.8 
(6-CH), 131.2 (12-C), 130.4 (4-CH), 129.7 (5-CH), 126.9 (8-CH), 126.6 (7-CH), 126.1 
(10-C), 125.1 (1-CH), 124.0 (2-C), 114.6 (9-C), 114.0 (14-C). 
HRMS (ESI) Calculated for C14H7AgBrN2:388.8838. Found: 388.8826.Error: 0.38 ppm 




Yellowish brown solid (5.4 mg, 72 %) 
MP: 224.7-226.7 oC 
1H NMR (600 MHz, Chloroform-d) δ 7.90 (d, J = 8.5 Hz, 2H), 7.77 (s, 1H), 7.54 (d, J 
= 9.4 Hz, 1H), 7.34 – 7.16 (m, 1H), 7.05 (s, 1H), 3.89 (s, 3H). 
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13C NMR (151 MHz, Chloroform-d) δ 162.0 (6-C), 150.2 (13-C), 146.7 (11-C), 134.1 
(2-C), 132.4 (3-CH), 131.2 (12-C), 126.1 (8-CH), 125.5  (4-CH), 124.9 (10-C), 123.7 (1-
CH), 122.9 (7-CH), 114.7 (9-C), 114.2 (14-C), 105.8 (5-CH), 55.9 (15-CH3). 
HRMS (ESI) Calculated for C15H9AgClON2:376.5700. Found: 374.9449.Error:-3.67 
ppm 
IR (diamond, cm-1): 2930.50 (CH sat), 2228.50 (CN), 1627.74 (aromatic C=C), 1295.94 
(C-O). 
[Ag(7-chloro-2, 3, 4-trimethoxyacridine-9-carbonitrile)ClO4] 70 
 
 
Brown solid (7.5 mg, 86 %) 
MP: 210.2-212.2 oC 
1H NMR (600 MHz, Chloroform-d) δ 8.30 (d, J = 9.1 Hz, 1H), 8.25 (s, 1H), 7.74 – 7.69 
(m, 1H), 7.25 (s, 1H), 4.24 (s, 3H), 4.13 (d, J = 13.1 Hz, 6H). 
13C NMR (151 MHz, Chloroform-d) δ 156.6 (2-C), 146.8 (13-C), 145.8 (4-C), 144.0 
(11-C), 141.8 (7-C), 135.1 (6-CH), 132.2 (3-C), 131.0 (12-C), 125.9 (5-CH), 125.4 (10-
C), 123.0 (8-CH), 115.2 (9-C)7, 111.1 (14-C), 96.7 (1-CH), 62.5 (17-CH3), 61.7 (16-
CH3), 56.6 (15-CH3). 




    
 
IR (diamond, cm-1): 2942.90 (saturated CH) 2243.60 (CN), 1608.60 (aromatic C=C). 
[Ag(7-bromo-2, 3, 4-trimethoxyacridine-9-carbonitrile)ClO4] 71 
 
Brown solid (8.0 mg, 83 %) 
MP: 217.8-219.8 oC 
1H NMR (600 MHz, Chloroform-d) δ 
 8.45 (d, J = 2.0 Hz, 1H), 8.22 (d, J = 9.1 Hz, 1H), 7.85 (dd, J = 9.0, 2.1 Hz, 1H), 7.26 (s, 
1H), 4.24 (s, 3H), 4.14 (d, J = 13.6 Hz, 6H). 
13C NMR (151 MHz, Chloroform-d) δ 156.6 (2-C), 146.7 (13-C), 144.2 (4-C), 142.0 
(6-CH), 133.4 (3-C), 132.2 (12-C), 126.4 (5-CH), 126.3 (10-C), 125.4 (8-CH), 123.5 (7-
C), 115.3 (9-C), 111.0 (14-C), 96.7 (1-CH), 62.5 (17-CH3), 61.6 (16-CH3), 56.5 (15-CH3). 
HRMS (ESI) Calculated for C17H13AgBrO3N2:478.9155. Found: 478.9183.Error:-8.81 
ppm 
IR (diamond, cm-1): 









Greenish brown solid (4.7 mg 88 %) 
MP: 142.2-144.2 oC 
1H NMR (600 MHz, Chloroform-d) δ 8.50 (s, 1H), 7.76 (d, J = 4.9 Hz, 2H), 7.61 (m, J 
= 7.8, 1.9 Hz, 1H), 7.41 (d, J = 8.1 Hz, 2H), 7.01 (dd, J = 7.4, 5.1 Hz, 2H). 
13C NMR (151 MHz, Chloroform-d) δ 168.7(4-C), 148.6 (8-CH), 144.5 (6-CH), 136.2 
(1-CH), 119.4 (7-CH), 118.7 (5-CH), 73.6 (2-C). 
HRMS (ESI) Calculated for C8H8AgN4:266.9794. Found: 266.9799.Error: -1.81 ppm 





Dark green solid (6.4 mg, 93 %) 
MP: 156.8-157-8 oC 
1H NMR (600 MHz, Chloroform-d) δ 7.47-7.53 (m, 4H), 7.34 (d, J = 8.1 Hz, 3H), 
7.26(s, 1H). 
13C NMR (151 MHz, Chloroform-d) δ 132.0 (3-C), 131.8 (1-CH), 128.3 (4-C), 128.3 
(5-CH, 9-CH), 119.9 (7-C), 108.1 (6-CH, 8-CH), 103.6 (2-C). 
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HRMS (ESI) Calculated for C9H8AgBrN3:343.8947. Found: 343.8948.Error: -0.40 ppm 





Dark green solid (6.5 mg, 91 %) 
MP: 154.9-156.9 oC 
1H NMR (600 MHz, Chloroform-d) δ 7.50 – 7.55 (m, 2H), 7.19 – 7.23 (m, J = 1.3 Hz, 
4H).4.28 (broad s, 1H) 2.25 (s, 3H) 
13C NMR (151 MHz, Chloroform-d) δ 151.9 (3-C), 137.9 (1-C), 131.9 (5-C), 131.9 (6-
CH, 10-CH), 130.1 (8-C), 120.0 (7-CH, 9-CH), 105.5 (2-C), 10.8 (4-CH3). 
HRMS (ESI) Calculated for C10H10AgBrN3:357.9104. Found: 359.9098.Error: -4.47 
ppm 








    
 
[Ag (3-Amino-4-bromo-2-methylpyrazol)ClO4] 75 
 
Dark green solid (5.1 mg, 90 %) 
MP: 130.2-132.2 oC 
1H NMR (600 MHz, Chloroform-d) δ 7.23 (s, 3H), 3.52 – 3.60 (s, 3H) 
13C NMR (151 MHz, Chloroform-d) δ 142.4 (3-C), 137.6 (1-CH), 77.9(2-C), 35.4 (4-
CH3). 
HRMS (ESI) Calculated for C4H6AgBrN3:281.8791 Found: 283.8783.Error: -0.64 ppm 
IR (diamond, cm-1): 3340.25 (NH2), 2923.52 (CH), 1626.60 (C=C), 1570.27 (benzene 
ring). 
IV.6. Uv-Vis and fluorescence 
1X10-3 M stock solution of acridine ligand, acridine gold complexes and the standard 
were prepared with absolute ethanol (99 %) in 50 mL volumetric flasks and placed in the 
sonic bath for 5 minutes in other to obtain a homogeneous solution. Then, 1X10-4 M, 
1X10-5 M, 1X10-6 M, 1X10-7 M, 1X10-8 M, 1X10-9 M of each solution were prepared in 
10 mL volumetric flask from the stock solutions by serial dilution. The UV-vis specra of 
the solutions were measured by Thermo Spectronic UV 300 UV-visible spectrometer to 
find the concentration of each sample that gave a maximum absorption closed to 0.5 
Absorbance at 365nm.  The linear mode of each sample were taken in other to ensure that 
Beer Lambert law was obeyed. The fluorescence data of each sample were taken by a 




    
 
IV.7. Cell viability assays 
The biological activity of the complexes were assessed after dilution in 
DMSO/H2O (10% v/v) and addition to HepG2 cells. Assays were performed in 96-
well plates using the Promega CellTiter-Blue assay as an endpoint method with a 
2-hour incubation with the assay reagent. This assay measures cell viability and is 
based upon the ability of living cells to convert a redox dye (resazurin) into a 
fluorescent product (resorufin). Each well received 90 μL of cell suspension at a 
density of 22,500 cells per well and was cultured overnight (at 37 °C/5% CO2 
humidified air) before 10 μL of the test sample was added. The experiments were 
set up in triplicate. The mock control wells received 90 μL of cell suspension and 
10 μL of the appropriate buffer (DMSO/H2O). Wells that contained just 100 μL of 
cell culture medium served as background fluorescence controls. Fluorescent 
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